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ABSTRACT

DEVELOPING THE YEAST DISAGGREGASE HSP104 AS A TREATMENT FOR
POLYGLUTAMINE DISEASE IN DROSOPHILA
Mimi Cushman-Nick
Dr. Nancy M. Bonini
Dr. James Shorter
There is currently no cure for neurodegenerative disease or the underlying burden of protein
aggregation that is associated with symptom development. A novel approach to combat this
accumulation of misfolded protein species is surprisingly found in a protein disaggregase in yeast,
the heat shock protein Hsp104. To investigate whether Hsp104 can be introduced into an animal
system and harnessed to attack disease-associated protein inclusions, we created a transgenic
Drosophila model expressing Hsp104 and investigated whether this would mitigate toxicity and
alter the load of protein accumulations. We found that Hsp104 indeed suppressed toxicity of a
disease-associated protein fragment containing an expanded polyglutamine tract. However, we
found that Hsp104 worsened toxicity of the full-length pathogenic polyglutamine protein, and this
coincided with increased accumulation of amyloid inclusions. This aberrant activity of Hsp104
depended on intact domains in the non-polyglutamine stretches of the protein, and this negative
interaction could be prevented by mutation to these neighboring domains. These results indicate
that knowing the precise protein state of a disease environment is critical in evaluating potential
therapeutics. Moreover, we sequentially activated Hsp104 after the onset of protein aggregation
and start of tissue degeneration, to find that Hsp104, but not Hsp70, significantly suppressed
progressive degeneration.

Thus, the unique ability of Hsp104 to tackle pre-existing amyloid

conformers may offer a novel opportunity to reverse disease progression once underway.
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DEVELOPING THE YEAST DISAGGREGASE HSP104 AS A TREATMENT FOR
POLYGLUTAMINE DISEASE IN DROSOPHILA
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CHAPTER 1 : INTRODUCTION

HARNESSING THE MOLECULAR DISAGGREGASE HSP104 TO COMBAT THE
AMYLOID ACCUMULATION THAT UNDERLIES NEURODEGENERATIVE DISEASE

2

Protein aggregation underlies neurodegenerative disease
Proper protein folding is essential to life. In order for a protein to perform its function, it
must obtain its native state, but this is an extremely difficult task within the cell. The
cytosol is crowded (exceeding 200 mg/ml), with other molecules restricting protein
movement as well as bombarding the nascent chain with potentially hazardous
interactions (Ellis, 2001, 2007). Moreover, because of aberrantly exposed hydrophobic
sequences, misfolded protein is prone to accumulate into insoluble aggregates, thus
compounding loss of function of the protein with potentially toxic gain of function due to
accrual of these large, disruptive aggregates (Powers et al., 2009). This problem is
amplified in post-mitotic tissue, such as within the neurons of the central nervous
system, where these species accumulate with time (Terman and Brunk, 2006).

The collection of neurodegenerative diseases is comprised of distinct disorders,
presenting with striking differences among the symptomatic impairments and affected
systems (Taylor et al., 2002, Forman et al., 2004). For example, Alzheimer’s disease
(AD) causes cell loss in the cortex and hippocampus, with patients displaying dementia
with loss of intellect and memory, while Parkinson’s disease (PD) presents with
degeneration in the substantia nigra and is characterized by loss of motor control (Fahn,
2003, Thies and Bleiler, 2011).

These and other neurodegenerative diseases are

devastating to patients and their families, and also create a massive emotional and
financial burden for society (Thies and Bleiler, 2011). As the population rapidly ages, the
prevalence of these diseases is increasing with no imminent cure (Fearnley and Lees,
1991, Duncan, 2011, Lopez, 2011, Thies and Bleiler, 2011).
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To combat this escalating problem, it would be ideal to target processes that are
common to all neurodegenerative disease. Interestingly, a remarkable feature of these
disparate diseases is that many are characterized by underlying protein aggregation
pathology (Forman et al., 2004, Chiti and Dobson, 2006).

AD patients develop

extracellular plaques of amyloid-β peptide (Aβ) and intracellular tangles of tau, and PD
has marked accumulation of α-synuclein (α-syn) in Lewy body inclusions (Forman et al.,
2004, Jellinger, 2012). Not only do these pathological hallmarks define each disease,
but the formation of these protein accumulations is associated with development of
symptoms (Hardy and Selkoe, 2002, Ferrer et al., 2011, Chetelat et al., 2012, Masdeu et
al., 2012).

Interestingly, in some cases, symptomatically distinct disorders may have a common
pathogenic mechanism. For example, Huntington’s disease (HD), which has marked
degeneration of the basal ganglia, and Spinocerebellar Ataxia Type 3/ Machado-Joseph
disease (SCA3/MJD), which affects the hindbrain, share the mechanism by which
degeneration is initiated (Zoghbi and Orr, 2000, Michalik and Van Broeckhoven, 2003,
Orr and Zoghbi, 2007).

The pathogenic proteins associated with these diseases,

huntingtin (htt) and Ataxin-3/ Machado Joseph disease protein (MJD), respectively, each
contain a polyglutamine (PolyQ) tract within the protein that, when the repeat length
exceeds a threshold, causes protein accumulation and disease (Norremolle et al., 1993,
Kawaguchi et al., 1994).

In addition, this pathogenic PolyQ expansion has been
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identified in other unrelated proteins that are collectively known as PolyQ diseases
(Zoghbi and Orr, 2000).

Despite markedly different primary sequences, Aβ, tau, α-syn, the PolyQ proteins, and
other proteins implicated in neurodegenerative disease form protein accumulations by
adopting a stereotypical fold called ‘amyloid’ (Kirschner et al., 1986, Forman et al.,
2004). Amyloid is defined by the formation of β-sheet folds perpendicular to a fibril axis;
Typically, these fibrils are 5-15 nm in width and up to several micrometers in length
(Toyama and Weissman, 2011). Because of the stable intermolecular contacts created
by the extensive hydrogen bonds of the cross-β fold, the amyloid conformation is
extremely stable and difficult to eradicate (Westermark et al., 2005, Chiti and Dobson,
2006). Indeed, amyloid fibrils are resistant to denaturation by detergents, boiling, and
proteases (Westermark et al., 2005). Once an amyloid fibril is formed, the conformation
is self-templating; individual proteins adopt the existing fold upon joining the fibril (Nelson
and Eisenberg, 2006, Jucker and Walker, 2011). As such, certain fibrils with contacts
that are susceptible to fragmentation may expose many templating ends, thus allowing
the amyloid conformation to become transmissible, which is termed a ‘prion’
(proteinaceous infectious particle).

An example of this is the prion protein (PrP) in

Creutzfeldt-Jakob disease (CJD), a variant of which is known as “mad cow” disease
(Prusiner, 1982, Prusiner et al., 1983, Cushman et al., 2010).

Also problematic are the soluble oligomers that form prior to fibrils, which also possess a
generic conformation, distinct from fibers, which is shared by many amyloidogenic
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proteins (Kayed et al., 2003). These oligomers may be even more cytotoxic than the
fibrils themselves, and there are some lines of evidence to suggest that the
sequestration of protein into fiber inclusions at the expense of oligomers may actually be
protective (Dobson, 2003, Kayed et al., 2003, Douglas et al., 2008, Wolfe and Cyr,
2011). These soluble oligomers may go on to promote polymerization of amyloid fibers
(Shorter and Lindquist, 2004), or, like fibers, the soluble oligomeric assemblies can be
persistent and SDS-stable (Walsh et al., 2002).

The existence of these amyloid

precursors must be kept in mind when considering protein-aggregation disease and
developing therapeutic interventions.

Antagonizing amyloid fibrils and their soluble precursors are an attractive therapeutic
target

because

these

common

neurodegenerative diseases.

protein

conformations

underlie

so

many

However, because of the extreme stability of amyloid

intermolecular contacts, the most promising current avenue of treatment is to prevent the
contacts from forming prior to extensive protein aggregation and development of disease
symptoms (Chiti and Dobson, 2006, Masdeu et al., 2012, Vanitallie, 2013).

While

preventing amyloidogenesis is obviously desirable, it is likely impractical because
symptoms often occur only after protein accumulation has advanced and become a
heavy burden for the tissue (Hardy and Selkoe, 2002, Caughey and Lansbury, 2003).
For example, accumulation of amyloid deposits precedes mild cognitive impairment,
which is itself a precursor and predictor of AD (Masdeu et al., 2012). Therefore, while
preventative treatments may have some effect in deterring amyloid accumulation and
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accompanying symptoms, a treatment is needed to reverse existing amyloidogenic
conformers to truly combat the protein pathology associated with disease.

Molecular chaperones: a natural defense against protein misfolding
Because life requires proper protein folding, evolution has provided defenses against
aberrant misfolding: molecular chaperones, which facilitate folding and prevent
misfolding; protein disaggregases, which restore protein monomers from the aggregated
state; and protein degradation machinery to eliminate proteins recalcitrant to rescue.

Molecular chaperones comprise a variety of proteins that modulate protein homeostasis,
and are essential in assisting nascent proteins to access their native fold within the
crowded cellular environment (Hartl and Hayer-Hartl, 2002, Bukau et al., 2006).

In

addition to facilitating proper protein folding, chaperones are critical in preventing
misfolding, which may lead to protein aggregation (Hartl and Hayer-Hartl, 2002,
Broadley and Hartl, 2009). Because these chaperones are pivotal in counteracting the
misfolded or unfolded protein conformations induced by stress, such as following heat
shock, many are also known as heat shock proteins (HSPs) (Morimoto, 2008). HSPs
range in size from small HSPs (15-30 kDa) to the Hsp100 family (100+ kDa) and offer a
variety of functional approaches to antagonize aberrant protein conformations: small
HSPs block protein aggregation; Hsp60s (chaperonins) act as a folding chamber, thus
competing with misfolding; Hsp70s facilitate access of proper tertiary structure and
therefore suppress incorrect folding events; Hsp90s have modulatory and stabilizing
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activity; and Hsp100s reverse protein misfolding and aggregation (Muchowski and
Wacker, 2005, Broadley and Hartl, 2009, Garrido et al., 2012).

Hsp70 has been of particular interest in countering protein aggregation.

A form of

Hsp70 is found in most cellular compartments, and the chaperone acts to stabilize
substrates and promote proper folding (Bukau and Horwich, 1998, Mayer and Bukau,
2005). The Hsp70 protein contains a C-terminal substrate-binding domain that interacts
with the protein substrate and an N-terminal ATP binding site that hydrolyzes ATP to
produce conformational shifts (Zhuravleva et al., 2012). Hsp70 recognizes hydrophobic
patches in nascent or transiently misfolded proteins and binds to the exposed sequence,
which in turn induces ATP hydrolysis to clamp the chaperone closed around the
substrate (Fig 1-1) (Hartl and Hayer-Hartl, 2002, Mayer and Bukau, 2005, Bukau et al.,
2006, Broadley and Hartl, 2009).
This function is known as holdase
activity, and repeated cycles of
clamping may allow the substrate
protein

to

conformation

access
upon

its

native
release

(Slepenkov and Witt, 2002, Mayer
and Bukau, 2005).

The baseline Figure 1-1 Hsp70 promotes proper folding
As a nascent chain (green strand) is produced,
ATPase rate of Hsp70 is quite slow, the Hsp70 chaperone (red oval) binds to
exposed regions to prevent aberrant misfolding
and requires regulation by co-factors and aggregation, thus allowing the protein to
achieve its proper fold.
such as nucleotide-exchange factors

8

or coordinating chaperone Hsp40 to stimulate ATP hydrolysis (Ha and McKay, 1994,
Russell et al., 1998, Laufen et al., 1999, Bukau et al., 2006). The Hsp70 system is
critical for routine protein homeostasis and perturbation of Hsp70 function can itself be
associated with disease (Senderek et al., 2005, Kakkar et al., 2012).

Hsp104, in contrast, is an HSP that, rather than preventing protein misfolding, actually
reverses pre-existing protein aggregates. The disaggregase is a member of the AAA+
(ATPases Associated with diverse cellular Activities) family and forms a functional unit
by assembling into a ring-shaped homohexamer (Wendler et al., 2007). Each monomer
contains two nucleotide-binding domains (NBDs) that each couple to a substrate-binding
loop with a conserved GYVG motif (KYKG in NBD1) responsible for engaging substrate
(Lum et al., 2004, Lum et al., 2008).

ATP hydrolysis in each NBD confers large

structural shifts to translocate substrates bound to the substrate-binding loops through
the central pore of the ring (Wendler et al., 2007, Wendler et al., 2009).

This

translocation mechanically pries substrate monomers from protein accumulations (Fig 12). The dissolution of stress-induced denatured protein aggregates confers protection
and up to 10,000-fold increase in survival following heat shock (Sanchez and Lindquist,
1990, Sanchez et al., 1992, Parsell et al., 1994, Glover and Lindquist, 1998). These
non-amyloid aggregates require the administration of coordinating chaperones Hsp70
and Hsp40; the Hsp104 and its coordinating chaperone system is able to tackle
substrates resistant to Hsp70/Hsp40 alone (Glover and Lindquist, 1998).
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Moreover, Hsp104 can also disassemble highly stable amyloid fibrils. The disaggregase
employs different patterns of inter-subunit coordination for distinct substrates, with more
subunits being recruited for the more obstinate amyloid substrates (DeSantis et al.,
2012). This remarkable activity allows Hsp104
to

extract

protein

monomers

from

sequestration in amyloid fibrils in order to
maintain the beneficial prion states observed
in yeast (Fig 1-2) (Chernoff et al., 1995,
Shorter and Lindquist, 2004).
phenotypic

observations

In addition to
that

Hsp104

solubilizes amyloid fibrils in yeast, the effects
have been reconstituted in a pure-protein
system that demonstrates that Hsp104 is
sufficient to reverse pre-formed amyloid fibrils

Figure 1-2
Hsp104
aggregated proteins

resolubilizes

The Hsp104 hexamer (teal) is pictured
with substrate-contacted loops (yellow
(Shorter and Lindquist, 2004, 2006, Lo Bianco
Y) extending into the central channel.
These
channel
loops
bind
to
et al., 2008, DeSantis et al., 2012). Further,
monomers
within
a
disordered
aggregate or an amyloid fibril and
Hsp104
also
eliminates
amyloidogenic
translocate it through the pore to
resolubilize an individual protein.
oligomers, the soluble multimeric associations
that serve as obligate intermediates preceding fibril formation (Shorter and Lindquist,
2004, 2006, Lo Bianco et al., 2008, DeSantis et al., 2012). Thus, Hsp104 has potent
activity against the common structures required for amyloidogenesis, disassembling both
fibril and oligomeric conformations that are shared by amyloidogenic proteins.
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Unlike Hsp70, Hsp104 has no known homologue or othologue in metazoan systems.
The bacterial Hsp104 homologue ClpB is also able to provide thermotolerance and
reverse disordered aggregates, but neither ClpB nor the mammalian Hsp110 share the
remarkable ability to dismantle amyloid (Shorter, 2011, DeSantis et al., 2012). Thus, the
anti-amyloid function is unique to Hsp104 and, as such, might be harnessed by other
systems if introduced exogenously.

HSPs in treating neurodegenerative disease
Because of the shared structural elements common to amyloid fibrils and pre-amyloid
oligomers, molecular chaperones and HSPs might be able to target a mechanism
common to many neurodegenerative diseases. Targeting the more universal features of
the amyloidogenesis pathway would be desirable because the precise properties of each
amyloid fibril will be distinct on the molecular level, depending on the primary sequence
of the disease-associated protein.

Further complicating the issue, identical primary

sequences can form distinct intermolecular contacts to produce different strains of fibril
with distinct properties (Tanaka et al., 2004, Toyama and Weissman, 2011).

To

eliminate the diverse amyloid species associated with human disease, the prevention
and even reversal of the stable cross-β conformation would be an enormous
achievement. Additionally, antagonizing pre-amyloid oligomers may be very important in
attacking protein conformational disease because soluble oligomers have been
suggested to be more toxic than insoluble fibrils.

While amyloid plaques/inclusions

might offer some protection by sequestering the toxic soluble species, these amyloid
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accumulations may also serve as a reservoir to release toxic oligomers (Koffie et al.,
2009, Jin et al., 2011, Shahnawaz and Soto, 2012). Thus, a complete therapy would
target both structures, and would interact broadly with diverse amyloidogenic proteins.

Indeed, the molecular chaperone Hsp70 has been of great interest in application to
protein aggregation disease because of its ability to mitigate endogenous protein
misfolding, and has been shown to be a potent suppressor of neurodegenerative
disease associated with protein aggregation (Muchowski and Wacker, 2005). In cell
culture, Hsp70 suppressed toxicity of Aβ, tau, and PolyQ proteins (Jana et al., 2000,
Magrane et al., 2004, Shimura et al., 2004). Additionally, the Hsp70 chaperone has
been effective in dramatically suppressing degeneration in Drosophila models of PD and
SCA3/MJD (Warrick et al., 1999, Auluck et al., 2002).

In mouse models of PolyQ

disease, Hsp70 had minimal efficacy against mouse models of PolyQ diseases HD and
SCA7 (Hansson et al., 2003, Helmlinger et al., 2004), but Hsp70 suppressed PolyQ
pathology and severity of disease in a SCA1 model (Cummings et al., 2001).

A

summary of the studies examining Hsp70 in disease models is presented in Table 1-1.
Thus, initial studies indicate that Hsp70 may be a promising therapy in preventing
neurodegenerative disease, but due to the nature of its function to avert protein
misfolding, the outlook for treating existing disease is unclear.

Table 1-1 Summary of disease models testing Hsp70

Reference

Animal
system

Disease
model
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Effect of Hsp70 on disease

Cummings et
al., 1998

Cell culture
HeLa

SCA1
(PolyQ)

Decrease protein aggregation

Warrick et
al., 1999

Drosophila

SCA3/MJD
(PolyQ)

Suppressed cell loss without preventing
inclusion formation

Jana et al.,
2000

Cell culture:
Neuro2a

HD
(PolyQ)

Suppressed aggregates and cell death

Cummings et
al., 2001

Mouse

SCA1
(PolyQ)

Improved motility, reduced pathology but
not inclusions

Auluck et al.,
2002

Drosophila

PD

Prevented dopaminergic cell loss

Hansson et
al., 2003

Mouse

HD
(PolyQ)

No effect on inclusions, brain tissue loss,
or behavioral phenotypes

Helmlinger et
al., 2004

Mouse

SCA7
(PolyQ)

No effect on neuronal toxicity or
aggregation

Magrane et
al., 2004

Cell culture:
N1 primary rat
neurons

AD: Aβ

Prevented cell death

Shimura et
al., 2004

Cell culture:
Cos7 cells

AD: Tau

Prevented cell death

Because of the unique capacity of Hsp104 to reverse pre-formed amyloid fibrils and preamyloid oligomers, the disaggregase has also been tested in several models of
amyloidogenic disease. In general, Hsp104 was well tolerated in animal systems and
even conferred thermotolerance to mammalian cells (Dandoy-Dron et al., 2006).
However, Hsp104 has had variable efficacy in preventing disease. On one end of the
spectrum, mice transgenic for Hsp104 had no added protection against PrP infection,
and at the other end, Hsp104 strongly suppressed α-syn aggregation and prevented
neurodegeneration in a lentiviral rat model of PD (Dandoy-Dron et al., 2006, Lo Bianco
et al., 2008). However, the majority of these studies have focused on PolyQ disease.
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Hsp104 mitigated formation of PolyQ-GFP aggregates in C. elegans, and this corrected
a growth defect (Satyal et al., 2000). Hsp104 reduced aggregation of htt in a transgenic
mouse model, and offered a slight extension of lifespan, although behavioral
impairments were not corrected (Vacher et al., 2005). In a lentiviral rat model, Hsp104
altered the distribution of htt inclusions and prevented brain pathology (Perrin et al.,
2007). A summary of the studies examining Hsp104 in vivo is presented in Table 1-2.
Thus, Hsp104 shows promise in a variety of disease settings and model organisms, but
because the experimental paradigms require concomitant expression, its potential in
treating pre-existing disease has not been fully evaluated.

Table 1-2 Summary of in vivo models expressing Hsp104

Effect of
Hsp104 on
protein
aggregation

Effect of
Hsp104 on
disease
phenotype

Reference

Animal system

Disease
protein
expressed

Satyal et al.,
2000

C. elegans

GFP-Q82

Reduced
aggregate
formation

Corrected
growth rate
defect

Carmichael
et al., 2000

Mammalian cell
transfection
(PC12 and Cos7
cell lines)

EGFP-HttExon1-Q74

Reduced
proportion of
cells with
aggregates

Reduced cell
death and
nuclear
fragmentation

Mosser et al.,
2004

Human cell
tranfection
(PEER cell line)

n/a

n/a

Increased
survival
following heat
shock

Htt[n171]-Q82

Reduced
number of
aggregates,
not size or
shape

Did not correct
motor defect,
but did extend
lifespan

Vacher et al.,
2005

Mouse
(transgenic)
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Dandoy-Dron
et al., 2006

Mammalian cell
transfection
(CAD and HeLa
cell lines)

n/a

n/a

Mouse
(transgenic)

PrP
(ME7 strain
infection)

No difference
in PrPSc
accumulation

E16 rat striatal
neuron culture

Htt[n171]-Q82

Redirected into
non-nuclear
inclusions

Perrin et al.,
2007

Lo Bianco et
al, 2008

Rat
(lentiviral)

Htt[n171]-Q82

Rat
(lentiviral)

α-syn-A30P

Redistributed
into more,
smaller
inclusions
Reduced
formation of
phosphorylated
inclusions

Increased
survival
following heat
shock
No difference
in disease
incubation time
Prevented loss
of neurons
Prevented
striatal
pathology
Reduced
dopaminergic
cell loss

Can chaperones reverse neurodegenerative disease?
As previously highlighted, prevention of disease is potentially the most effective course
of action, but patients often present with disease only after pathology has developed and
the amyloid burden is high.

While Hsp70 has shown some efficacy in preventing

disease, the ability to affect disease progression once the pathology has begun to
accumulate remains unknown.

Although the technology exists to temporally control

gene expression, all studies of Hsp70 as a modulator of disease have focused on
concomitant co-expression or activation of the chaperone prior to disease initiation.
Geldanamycin, a drug that boosts expression of endogenous Hsp70, was found to
prevent neurodegeneration in mice when administered before a toxic insult of MPTP (1methyl-4-phenyl-1,2,3,6-tetrahydropyridine) to chemically induce PD (Shen et al., 2005).
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However, the authors report that geldanamycin treatment was required before induction
of the disease phenotype in order to have any beneficial effect (Shen et al., 2005). It
should also be noted that the MPTP model of PD does not result in α-syn aggregation,
so these results may imply an indirect mechanism. However, a protein-induced cell
culture model of PD found similar results, determining that geldanamycin was required at
least 24 hours prior to transfection with α-syn to prevent formation of pathological
inclusions (McLean et al., 2004). In Drosophila, pharmacological induction of Hsp70
was found to suppress both PD and PolyQ disease, but, again, these were administered
prior to disease onset (Auluck and Bonini, 2002, Wang et al., 2013). A summary of the
studies sequentially expressing Hsp70 is presented in Table 1-3. Despite the existence
of these experimental paradigms, sequential activation of chaperone expression
following disease onset has not been examined.

Table 1-3 Summary of models testing sequential activation of Hsp70

Reference

Animal
system

Hsp70
selectively
activated by:

Disease
model

Effect of Hsp70 on
disease

Auluck and
Bonini, 2002

Drosophila

Geldanamycin

PD

Increased survival of
dopaminergic neurons

McLean et
al., 2004

Cell culture:
H4 cells

Geldanamycin

PD

Pretreatment prevented
aggregation and
toxicity

Shen et al.,
2005

Mouse

Geldanamycin

MPTP
induction
of PD
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Prevented
dopaminergic cell loss
Note: no aggregates

Wang et al.,
2013

Drosophila

HIP small
molecule

SBMA
(PolyQ)

Suppressed pupae
toxicity, promoted
protein degradation

The potential to physically remodel the protein aggregation associated with
neurodegenerative disease calls Hsp104 into focus. In a pure protein system, Hsp70
prevents fibrillization of PolyQ but cannot reverse it; Hsp104 strikingly reverses it
(Muchowski et al., 2000, DeSantis et al., 2012). Therefore, in vivo activation of Hsp70
will likely be required prior to disease onset to have a strong modulatory effect, but
Hsp104 might have the potential to tackle existing aggregates and halt disease
progression that is already under way.

This thesis seeks to examine the therapeutic potential of Hsp104 in a novel model
system with the creation of transgenic Drosophila lines.

Here we show that, in

Drosophila, Hsp70 is better at preventing onset of MJD/SCA3 toxicity, but that induction
of Hsp104, but not Hsp70, has the remarkable ability to suppress disease progression
once it has begun (Chapter 2). However, despite no previous reports of deleterious
effects following Hsp104 expression in animal systems, we encountered toxicity of
Hsp104 when expressed at high levels in Drosophila. This effect is explored further in
Appendix I.
minimize

By lowering the protein expression level of Hsp104, we were able to

this

effect

and

evaluate

the

efficacy

of

Hsp104

in

combatting

neurodegenerative disease. A number of disease lines were screened (Appendix I), and
an interesting interaction was observed between Hsp104 and the PolyQ protein MJD.
The detailed analysis of Hsp104-mediated modulation of MJD amyloid formation and
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toxicity is defined in Chapter 2.

Additionally, an evaluation of Hsp70 and Hsp104

activated after onset of neurodegeneration is presented for the first time, with our results
showing that Hsp104 halts the progression of pre-existing disease. The implications of
Hsp104 as a post-onset treatment for protein aggregation disease are discussed in
Chapter 3.
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HSP104 SUPPRESSES POLYGLUTAMINE-INDUCED DEGENERATION POST
ONSET IN A DROSOPHILA MJD/SCA3 MODEL.
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INTRODUCTION

Many neurodegenerative diseases, such as Alzheimerʼs Disease, Parkinsonʼs Disease
(PD), prion disease, and the collection of polyglutamine (PolyQ) disorders, including
Huntingtonʼs Disease (HD) and the Spinal Cerebellar Ataxias (SCAs), are characterized
by the formation of protein inclusions in the nervous system (Forman et al., 2004, Chiti
and Dobson, 2006, Cushman et al., 2010). Moreover, despite vastly different primary
sequences, many of the proteins implicated in these diseases adopt the stereotypical
amyloid conformation in the aggregated state (Forman et al., 2004). Amyloid is defined
by a highly stable cross-β conformation, in which proteins polymerize via intermolecular
contacts of β-strands that align orthogonal to the fiber axis. Amyloid is typically a stable
structure that is resistant to denaturation by heat, detergents (up to 2% sodium dodecyl
sulfate (SDS)), and proteases (Westermark et al., 2005, Chiti and Dobson, 2006).

Despite the extraordinary structural stability of amyloid, a protein disaggregase from
yeast, Hsp104, can rapidly solubilize amyloid. Hsp104 is a hexameric AAA+ (ATPases
Associated with diverse cellular Activities) protein that couples ATP hydrolysis to
translocation of substrate through a central pore, thus prying individual monomers from
the amyloid fiber (Wendler et al., 2007, Tessarz et al., 2008, Wendler et al., 2009,
DeSantis et al., 2012). In yeast, Hsp104 is a heat shock protein (HSP), promoting
survival following stresses by resolubilizing denatured protein aggregates and restoring
proteins to native form and function (Sanchez and Lindquist, 1990, Parsell et al., 1994).
Hsp104 also maintains beneficial prion states by controlling the disassembly and
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dissemination of amyloid aggregates (Shorter and Lindquist, 2004, 2006, Alberti et al.,
2009).

Curiously, Hsp104 has no homologue in metazoa. Indeed, until recently it was unclear
whether

the

metazoan

proteostasis

network

possessed

any

coupled

protein

disaggregase and reactivation machinery. It is now clear that Hsp110, Hsp70, and
Hsp40 collaborate to promote the dissolution and reactivation of disordered aggregates
(Shorter, 2011, Rampelt et al., 2012), and can even slowly depolymerize amyloid fibrils
from their ends (Duennwald et al., 2012). However, these disaggregase activities are
slow and ineffective compared to Hsp104 (Shorter, 2011, Duennwald et al., 2012). In
particular, amyloid depolymerization by Hsp110, Hsp70, and Hsp40 is many orders of
magnitude slower (weeks versus minutes) than amyloid dissolution by Hsp104
(Duennwald et al., 2012). Importantly, Hsp104 can synergize with metazoan Hsp110,
Hsp70, and Hsp40 to promote dissolution of amyloid and nonamyloid aggregates
(Shorter, 2011, Duennwald et al., 2012). Thus, introduction of Hsp104 into an animal
system may provide an unprecedented opportunity to directly and rapidly target the
intractable protein aggregates that underlie amyloid diseases (Shorter, 2008, Vashist et
al., 2010).

Spinocerebellar Ataxia Type 3 or Machado-Joseph Disease (MJD/SCA3) is the most
prevalent dominantly inherited ataxia (Bettencourt and Lima, 2011, Paulson, 2012). The
genetic basis of MJD/SCA3 is an expansion of the polyglutamine (PolyQ) tract of ataxin-
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3 (also known as Machado-Joseph Disease protein; MJD). When the PolyQ tract
surpasses 50 consecutive Qs it is associated with the formation of amyloid aggregates
and development of disease (Takiyama et al., 1993, Paulson et al., 1997). The normal
physiological function of MJD is as a deubiquitylase (DUB) that catalyzes the cleavage of
polyubiquitin (poly-ub) chains to promote proteostasis. It has a chain-editing function,
preferentially cleaving certain poly-ub linkages to increase the presence of poly-ub
chains that signal for degradation via the ubiquitin-proteasome system (UPS) (Winborn
et al., 2008, Kuhlbrodt et al., 2011). MJD has DUB activity in the N-terminal Josephin
domain, plus two ubiquitin-interacting motifs (UIMs) that present poly-ub chains to the
Josephin domain, as well as the C-terminal PolyQ tract that is associated with disease
(Masino et al., 2003). The PolyQ domain is known to form amyloid fibers, and
interestingly, MJD aggregation occurs in a two-step process in vitro, with the Josephin
domain forming SDS-soluble linear polymers that then convert into SDS-insoluble PolyQdriven amyloid fibers (Masino et al., 2004, Ellisdon et al., 2006, Ellisdon et al., 2007). As
such, Hsp104 may be well suited to combating MJD protein aggregation because it
antagonizes non-amyloid aggregates, pre-amyloid conformers, and amyloid fibers
(Shorter and Lindquist, 2006, Lo Bianco et al., 2008, Shorter and Lindquist, 2008,
DeSantis et al., 2012).

Hsp104 has been introduced to combat protein-aggregation disease in metazoan
systems with various levels of success (Satyal et al., 2000, Vacher et al., 2005, DandoyDron et al., 2006, Perrin et al., 2007, Lo Bianco et al., 2008). In C. elegans, Hsp104
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prevented aggregation and toxicity of GFP-tagged PolyQ (Satyal et al., 2000). In a
lentiviral rat model, co-expression of Hsp104 with a PolyQ fragment implicated in HD
resulted in the accumulation of more but smaller aggregates and rescue of striatal
dysfunction (Perrin et al., 2007). In mouse, animals transgenic for both an HD fragment
and Hsp104 showed limited suppression of PolyQ inclusion formation but prolonged
lifespan by ~20% (Vacher et al., 2005). While these studies suggest promise for Hsp104
as a therapeutic against disease-associated protein aggregation, none has provided
mechanistic insight into how Hsp104 interacts with amyloidogenic proteins in an animal
system. Further, studies to date have looked only at prevention of aggregation by
concomitant co-expression of Hsp104. There has not been an evaluation of the potential
of Hsp104 to modulate disease phenotypes in vivo after aggregates have already formed
and degeneration has begun; a situation likely to mimic an actual therapy. Therefore, we
created novel Hsp104 Drosophila lines because of the well-characterized models of
disease and the access to powerful genetic tools, such as the technology to temporally
control

the

expression

of

Hsp104

after

disease-associated

aggregation

and

degeneration has begun.

Our studies reveal surprisingly distinct interactions of Hsp104 with the full-length versus
a truncated version of the MJD protein, and that Hsp104 indeed possesses the ability to
suppress the progression of degeneration when activated subsequent to onset of
expression of the disease protein. These data indicate that protein context is central in
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Hsp104 interactions, and that Hsp104 displays in vivo the ability to halt the progression
of pre-established disease.

RESULTS

Hsp104 mitigates toxicity of truncated MJD, but enhances toxicity of the fulllength MJD

The disaggregase Hsp104 efficiently antagonizes protein aggregates in yeast, and while
homologues are present in bacteria, plants, fungi, chromista, and protozoa, no functional
homologue has been found in metazoa (Mosser et al., 2004, Vashist et al., 2010). We
stably introduced Hsp104 into Drosophila to evaluate its ability to prevent and potentially
reverse aggregation of disease-associated human proteins, readily available in various
fly models of disease. To achieve strong expression of the Hsp104 protein in the fruit fly,
we codon-optimized the transgene for Drosophila, and added a fly-optimal Kozak
sequence (ACAAA) before the start codon (Trinh et al., 2008). The Hsp104 transgene
was then expressed in Drosophila using the GAL4/UAS system (Brand and Perrimon,
1993). Because we achieved high expression of Hsp104, expression by the gmr-GAL4
driver in the eye had a mild disruptive effect (Fig 2-1A), which has also been observed
for another AAA+ protein, p97 (Ritson et al., 2010). As the gmr-GAL4 driver line has
multiple copies of the glass gene element for driving GAL4 expression, we instead used
a driver line with reduced expression (Fig 2-1B) bearing only a single glass element,
1×gr-GAL4. Using this driver, the effect of Hsp104 was minimized (Fig 2-1A and Fig 2-
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2A). Thus, we used the 1×gr-GAL4 driver line for our experiments evaluating the impact
of Hsp104 on protein-aggregation disease in vivo.
Figure 2-1 Tuning
Hsp104 expression
level for the fly eye.
(A) Expression of
UAS-Hsp104 using
gmr-GAL4 caused
disruption of internal
retinal structure by
d7. A less strong
driver, 1×gr-GAL4
minimized this effect
and prevented
disruption to cellular
organization within the retina. Arrows indicate the width of the retina to highlight changes in tissue
integrity.
(B) Immunoblots demonstrated that 1×gr-GAL4 drives lower Hsp104 expression than gmr-GAL4
at d7. Actin served as a loading control. Quantitation of immunoblots determined that 1×gr-GAL4
levels of Hsp104 were ~35% that of gmr-GAL4. Hsp104 levels were normalized to actin (n=3
(mean ± SEM)).

Hsp104 dissolves PolyQ amyloid in vitro (DeSantis et al., 2012, Duennwald et al., 2012)
and has been expressed in various PolyQ animal models, with results ranging from
minimal beneficial effect to strong abrogation of PolyQ aggregation (Satyal et al., 2000,
Vacher et al., 2005, Perrin et al., 2007). However, a detailed analysis of the underlying
protein interactions is lacking in vivo. We sought to dissect the ability of Hsp104 to
antagonize PolyQ aggregation and toxicity using MJD as a model protein. Pathogenic
MJD with expanded PolyQ has been previously established in fly models of MJD/SCA3,
and induces progressive neurodegeneration with the formation of nuclear inclusions
(Warrick et al., 1998, Warrick et al., 2005). We also examined a truncated C-terminal
fragment of MJD that is predominantly comprised of the PolyQ tract because

25

fragmentation of the protein may be associated with MJD/SCA3 pathogenesis (Warrick
et al., 1998, Haacke et al., 2007, Jung et al., 2009).

We examined interactions of Hsp104 with the pathogenic, full-length MJD containing an
expanded glutamine tract (MJDnQ78) and the truncated C-terminal region of the protein
containing the expanded glutamine tract (MJDtrQ78) (Warrick et al., 1998). Hsp104 had
no effect on non-pathogenic forms of MJD containing non-expanded PolyQ tracts (Fig 22B), confirming that the interaction is PolyQ length-dependent. With expanded PolyQ
domains, the pathogenic MJDtrQ78 and MJDnQ78 both caused degeneration of the
external eye and disruption to internal retinal structure (Fig 2-2C, D). Unexpectedly, we
found that Hsp104 had opposite effects on these two forms of MJD that have an identical
PolyQ expansion: Hsp104 mitigated MJDtrQ78 degeneration (Fig 2-2C), yet enhanced
degeneration associated with the full-length MJDnQ78 (Fig 2-2D). This effect is in
contrast to human Hsp70, a molecular chaperone that suppresses PolyQ disease in
multiple systems (Cummings et al., 1998, Warrick et al., 1999, Chan et al., 2000,
Muchowski et al., 2000). Despite more severe degeneration due to stronger expression
by the gmr-GAL4 driver, Hsp70 suppressed the toxicity of both MJDtrQ78 and MJDnQ78
(Fig 2-2E).
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Figure 2-2 Hsp104 mitigates
toxicity of Truncated MJD but
enhances toxicity of Fulllength MJD.
(A) With the 1×gr-GAL4 driver at
d7, Hsp104 alone had minimal
disruption to external eye and
internal retinal structure. Arrows
indicate the width of the retina to
highlight changes
in
tissue
integrity.
(B) With the 1×gr-GAL4 driver at
d7, Hsp104 had no effect on MJD
with non-expanded PolyQ tract.
Non-pathogenic truncated protein
MJDtrQ27
and
full-length
MJDnQ27 had no toxicity alone,
and Hsp104 did not alter this lack
of toxicity. The slight disruption to
the retina in Hsp104-containing
flies is consistent with Hsp104
alone effect. Arrows indicate the
width of the retina to highlight
changes in tissue integrity.
(C) With the 1×gr-GAL4 driver at
d7, MJDtrQ78 showed moderate
toxicity, and co-expression of
Hsp104 mitigated the disrupted
eye pigmentation and prevented
disorganization of internal retinal structure. Arrows indicate the width of the retina to highlight
changes in tissue integrity.
(D) With the 1×gr-GAL4 driver at d7, Hsp104 enhanced toxicity of MJDnQ78, causing loss of
pigmentation and dramatic tissue degeneration within the retina. Arrows indicate the width of the
retina to highlight changes in tissue integrity.
(E) With the gmr-GAL4 driver at d7, both MJDtrQ78 and MJDnQ78 displayed severe toxicity, with
loss of pigmentation and necrotic patches on the eye (note that severity of degeneration is
increased due to the use of the stronger gmr-GAL4 driver). Co-expression of Hsp70 strongly
suppressed the toxicity of both full length and truncated pathogenic MJD proteins. Arrows indicate
the width of the retina to highlight changes in tissue integrity.

The opposite effects of Hsp104 on MJDtrQ78 and MJDnQ78 correspond to distinct
modulation of underlying protein accumulations

To probe the mechanism underlying the dichotomous results found for the Hsp104
interaction with MJDtrQ78 and MJDnQ78, an in-depth investigation of the protein
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aggregates was performed. To slow protein aggregation such that we could analyze
underlying protein accumulations in detail, we expressed the transgenes in the eye with
an

adult-onset

driver

rhodopsin1(rh1)-GAL4.

Analysis

of

the

PolyQ

protein

accumulations showed that Hsp104 altered the kinetics of inclusion formation for both
MJD protein isoforms. By cryosectioning and subsequent immunohistochemistry (IHC),
MJDtrQ78 formed compact inclusions that increased in size over time (Fig 2-3A, top
row). Quantification of inclusion size over time (Fig 2-3A, gray bars in graph) reveals
distinct inclusion size populations (small <2.5 µm, medium 2.5-5 µm, large >5 µm in
optical diameter), demonstrating that inclusions became larger and more numerous with
time. Consistent with previous studies, co-expression of Hsp70 delayed the kinetics and
significantly reduced MJDtrQ78 protein aggregation (Fig 2-3A, bottom row; green bars in
graph, p=0.03). By contrast, Hsp104 initially delayed inclusion formation (p=0.004, but
then significantly enhanced the formation of small inclusions (p=0.04), eventually
reaching accumulation levels similar to that with MJDtrQ78 alone (Fig 2-3A, center row;
red bars in graph, n.s. p=0.5).

To examine protein accumulation by biochemical methods, we used SDD-AGE (SemiDenaturing Detergent–Agarose Gel Electrophoresis), a protein agarose gel technique
that can resolve amyloid aggregates (Halfmann and Lindquist, 2008). This technique is
useful for resolving high molecular weight polymer assemblies that maintain stable
contacts in 2% SDS (a feature of highly stable amyloid). SDD-AGE revealed that the
truncated MJDtrQ78 protein formed SDS-resistant amyloid structures that accrue with
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time (Fig 2-3C). Unlike Hsp70, which significantly suppressed amyloid formation
(p=0.003), Hsp104 did not change the overall kinetics of MJDtrQ78 amyloid formation or
the overall level of aggregation (Fig 2-3C). Confirming that insoluble amyloid material
was increased, the reduction of SDS-soluble levels of protein by immunoblot matched
the concomitant increase in amyloid formation observed by SDD-AGE (Fig 2-3C). Thus,
Hsp104 rescues MJDtrQ78 toxicity, but the relationship to MJDtrQ78 aggregation is
complex. IHC revealed that Hsp104 initially delays MJDtrQ78 inclusion formation, but
then significantly enhances the formation of small inclusions (Fig 2-3A). However, when
amyloidogenesis was tracked by SDD-AGE, Hsp104 affected neither the rate nor the
extent of amyloid formation (Fig 2-3C). This finding indicates that to rescue toxicity
Hsp104 might reduce formation of soluble and toxic oligomeric MJDtrQ78 species that
are populated during amyloidogenesis, just as it does with the yeast prion proteins
Sup35 and Ure2 (Shorter and Lindquist, 2004, 2006).
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Figure
2-3
Hsp104
delays
aggregation
of truncated
MJD,
but
enhances
aggregation
of full-length
MJD.
(A and B) With
the rh1-GAL4
driver
at
indicated time
points,
cryosections
and
IHC
demonstrate accumulations
of
MJDtrQ78 and
MJDnQ78 (red)
over
time,
using anti-HA
and anti-myc
antibodies,
respectively.
Sections were
co-stained with
anti-Hsp104 or
anti-Hsp70
(green)
as
indicated, and
nuclei
were
labeled
by
Hoechst (blue).
Hsp104
delayed but did
not suppress
aggregation of
MJDtrQ78, but
Hsp104 enhanced
accumulation
formation
of
MJDnQ78.
Hsp70 suppressed aggregation of both MJD proteins. The size of the aggregates was quantified
using ImageJ, with delineations for large inclusions (>5 µm across), medium inclusions (2.5–5
µm), or small inclusions (<2.5 µm) (n=3 (mean ± SEM)). Scale bar = 20 µm. *p<0.05, **p=0.0010.01, ***p<0.001; Statistics indicate comparison to the disease protein alone for total number of
inclusions at each timepoint (black asterisks). Additional statistical comparisons for inclusion size
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divisions are indicated by color, e.g., dark red asterisk indicates significant change in large
inclusions.
(C and D) With the rh1-GAL4 driver at indicated time points, SDD-AGE and immunoblot analysis
show the progression of amyloid formation of MJDtrQ78 and MJDnQ78 proteins over time.
Hsp104 did not greatly affect the aggregation profile of MJDtrQ78 but enhanced formation of
SDS-insoluble amyloid aggregates of MJDnQ78. Hsp70 suppressed aggregation of both MJD
proteins. The formation of large, SDS-insoluble aggregates by SDD-AGE corresponded with the
disappearance of SDS-soluble soluble protein from immunoblots. MJDtrQ78 and MJDnQ78 were
detected using anti-HA and anti-myc, respectively, with anti-tubulin as a loading control. Band
density for both amyloid smears (SDD-AGE) and soluble bands (Western blot) were quantified
using ImageJ (n=3 (mean ± SEM)). *p<0.05, **p=0.001-0.01, ***p<0.001; Statistics indicate
comparison to the disease protein alone at each timepoint.

Next, we assessed MJDnQ78 misfolding. In contrast to the truncated MJDtrQ78 isoform,
the pathogenic full-length MJDnQ78 initially formed amorphous inclusions that did not
become more numerous after day 1 (Fig 2-3B, top row; gray bars in graph). These
MJDnQ78 amorphous aggregates appeared early by IHC, and insoluble amyloid
aggregates developed later as observed by SDD-AGE (Fig 2-3B and D). Thus, the early
MJDnQ78 aggregates are non-amyloid in nature but later convert into the insoluble
amyloid structure, closely resembling the two-step aggregation kinetics observed in vitro
(Masino et al., 2004, Ellisdon et al., 2006, Ellisdon et al., 2007). As with MJDtrQ78, coexpression of Hsp70 delayed the kinetics of aggregation and significantly suppressed
inclusion formation (Fig 2-3B, bottom row; green bars in graph, p=0.02). However, in
marked contrast, co-expression of Hsp104 significantly increased the formation of large
aggregates at early time points (p=0.002), and then significantly increased the number of
small inclusions over time (Fig 2-3B, center row; red bars in graph, p<0.001). Consistent
with IHC results, SDD-AGE analysis demonstrated that Hsp104 significantly promoted
the early formation of insoluble MJDnQ78 amyloid aggregates (Fig 2-3D, p<0.001),
whereas Hsp70 delayed kinetics of amyloid formation (Fig 2-3D, p=0.01). Hsp70, but not
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Hsp104, stably colocalized with both MJDtrQ78 and MJDnQ78 inclusions (Fig 2-3A and
B; see Fig 4 for channel breakdown). The striking contrast between the effects of
Hsp104 and Hsp70 on inclusion formation
reinforces

their

functional

differences

(Sanchez et al., 1993).

Figure 2-4
Hsp70, but not Hsp104,
colocalizes with both MJDtrQ78 and
MJDnQ78 inclusions.
(A) Split channels from the MJDtrQ78 treatment
set at the Day 7 time point (from Fig. 3A). Note
that Hsp104 (green, middle row) had minimal
overlap with MJDtrQ78 inclusions (red, middle
row), but some colocalization was observed. In
contrast, Hsp70 (green, bottom row) strongly
colocalized with MJDtrQ78 inclusions (red,
bottom row).
(B) Split channels from the MJDnQ78 treatment
set at the Day 7 time point (from Fig. 3B).
Hsp104 (green, middle row) had no observable
colocalization with MJDnQ78 inclusions (red,
middle row), while Hsp70 (green, bottom row)
did colocalize with MJDnQ78 inclusions (red,
bottom row).

Domains neighboring the expanded PolyQ tract hinder protective Hsp104
activities

While it is known that in select conditions, Hsp104 promotes amyloid formation of
specific yeast prions (Shorter and Lindquist, 2004, 2006, 2008), we did not anticipate
that Hsp104 would have opposite actions on two constructs of the same PolyQ protein.
Thus, we assessed which domains of the full-length MJD protein prevented rescue by
Hsp104 by employing a series of expression-matched MJD variants with disruptions to
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specific motifs (summarized in Fig 2-7A). Because the PolyQ domains are pure CAG
repeats, they are subject to instability. Given this, the repeat lengths have been matched
as closely as possible with matching protein expression levels (see (Warrick et al.,
2005)). Because of the reduced expression level by the 1×gr-GAL4 driver used for these
experiments, MJDnQ84 (the pathogenic protein for this set of expression matched
proteins) now showed mild degeneration. However, as before, analysis of retinal integrity
demonstrated that the toxicity of MJDnQ84 was enhanced upon co-expression of
Hsp104 (Fig 2-5A). In contrast, an MJD variant in which both UIMs were mutated and
unable to engage poly-ub, MJD-Q80-UIM*, exhibited mild toxicity that was suppressed
by Hsp104 (Fig 2-5A). Thus, the ability of the UIM domains to engage poly-ub hinders
protective Hsp104 activity.

We also examined variants lacking DUB activity through mutation of the active site in the
Josephin domain, MJD-Q88-C14A, which causes more severe toxicity than MJDnQ84
due to the loss of the physiological UPS function (Warrick et al., 2005). This occurs
because DUB activity of MJD can suppress its own PolyQ toxicity; the C14A mutation is
innocuous when MJD has a normal length, non-expanded Q repeat (Fig 2-6A) (Warrick
et al., 2005). Co-expression of Hsp104 did not affect the severe MJD-Q88-C14A toxicity
(Fig 2-5A). However, when the active site mutation was combined with the UIM
mutations, in MJD-Q80-C14A-UIM*, Hsp104 now suppressed toxicity (Fig 2-5A). This
result reiterates that functional UIMs hinder rescue by Hsp104. We further examined a
separate splice variant lacking DUB activity through an exon deletion that includes the
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active site, MJD-Q79-Δexon2 (missing amino acids 9-63) (Fig 2-6B) (Bettencourt et al.,
2010, Harris et al., 2010), which, like MJD-Q88-C14A, conferred severe toxicity. Coexpression of Hsp104 with MJD-Q79-Δexon2 strongly suppressed degeneration (Fig 25A). Thus, Hsp104 mitigated MJD toxicity when the exon containing the active site was
deleted (MJD-Q79-Δexon2) but had no effect when the active site was inactivated by a
single point mutation (MJD-Q88-C14A). Taken together, these data indicate that
functional UIMs and an intact Josephin domain both prohibit Hsp104 from rescuing fulllength MJDnQ84 toxicity.

To uncover additional mechanistic insight into the interactions with Hsp104, we
examined inclusion formation and kinetics with adult-onset rh1-GAL4 expression. By
IHC, the MJD variants formed accumulations in a manner roughly consistent with
severity of eye degeneration (Fig 2-5B, top row; gray bars in graph). Those variants with
mutated UIMs, MJD-Q80-UIM* and MJD-Q80-C14A-UIM*, showed significantly reduced
levels of aggregate formation with Hsp104 (Fig 2-5B, bottom row; red bars in graph,
p=0.003 for both). SDD-AGE analysis revealed that Hsp104 significantly enhanced the
conversion of soluble protein to SDS-resistant polymers for variants with intact UIMs:
MJDnQ84 and MJD-Q88-C14A (Fig 2-5C, p=0.002 and p=0.005, respectively).
Moreover, Hsp104 significantly reduced the formation of amyloid material by MJD-Q80C14A-UIM* (Fig 2-5C, p=0.01). The MJD-Q79-Δexon2 protein was not detectable by
immunoblot (but was confirmed by genotyping, Fig 2-6C, D), precluding aggregate
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analysis of this variant. These findings underscore the role of active ubiquitin binding in
obstructing productive remodeling by Hsp104.

Figure 2-5 A
portion of the
Josephin
domain
and
the UbiquitinInteracting
Motifs prevent
Hsp104
from
rescuing fulllength
MJD
pathogenicity.
(A) With the
1×gr-GAL4
driver at d7,
external
eye
and
internal
retinal structure
showed
suppression of
toxicity
by
Hsp104
for
MJD
variants
with
mutated
UIMs
(MJDQ80-UIM* and
MJD-Q80C14A-UIM*).
Hsp104
strongly
suppressed the
external
eye
degeneration
and loss of
internal retinal
structure
of
MJD lacking a region spanning the Josephin domain (amino acids 9-63 (Δ exon 2)). The
MJDnQ84 and MJD-Q80-UIM* crosses were performed at 29ºC to enhance the severity of
degeneration. Arrows indicate the width of the retina to highlight changes in tissue integrity.
(B) With the rh1-GAL4 driver at d3, Hsp104 suppressed inclusion formation in MJD variants with
UIM mutations, as seen by IHC (d3). Accumulations of the MJD variant proteins were detected by
anti-myc (red) and nuclei are labeled by Hoechst stain (blue). Scale bar = 20 µm. Size of
inclusions was quantified using ImageJ, with delineations for large inclusions (> 5 µm across),

35

medium inclusions (2.5–5 µm), or small inclusions (< 2.5 µm) (n=3 (mean ± SEM)). Scale bar =
20 µm. **p=0.001-0.01.
(C) With the rh1-GAL4 driver at d3, SDD-AGE and Western immunoblot showed that by d3,
Hsp104 enhanced aggregation of MJD variants with wild-type UIMs, but reduced formation of
amyloid of MJD variants with UIM mutations. MJD variants were detected using anti-myc with
anti-tubulin as a loading control. Band density for both amyloid smears (SDD-AGE) and soluble
bands (Western blot) were quantified using ImageJ (n=3 (mean ± SEM)). **p=0.001-0.01.

Figure 2-6 Characterization of DUB-deficient
MJD variants.
(A) Driven by 1xgr-GAL4
at d7, MJD with nonexpanded Q has no
toxicity. Loss of DUB
activity through point
mutation,
MJD-Q27C14A, or through exon
deletion,
MJD-Q27Δexon2, did not confer
toxicity.
(B) The structure of the
Josephin domain, from
PDB file 1YZB. The
amino acids lost in the
exon 2 deletion are
highlighted in gray and
the catalytic residue
mutated in the C14A
variant is highlighted in
red.
(C) Genomic DNA from Drosophila was amplified for the UAS insert and was resolved on an
agarose gel. We confirmed that MJD-Q79-Δexon2 was missing the appropriate size of DNA
contained within exon 2.
(D) Sequencing of the Josephin domain confirmed that MJD-Q79-Δexon2 lacked the bases
encoding amino acids 9-63, but was otherwise identical to MJDnQ78.

A summary of the effect of Hsp104 on MJD variants is presented in Fig 2-7B. In the two
cases in which Hsp104 enhanced aggregation (MJDnQ84, MJD-Q88-C14A), the MJD
protein has both functional UIMs and an intact Josephin domain. By contrast, protein
variants whose toxicity and underlying protein accumulations were suppressed by
Hsp104 (MJD-Q80-UIM*, MJD-Q80-C14A-UIM*, MJD-Q70-Δexon2) each lack UIM
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binding or a portion of the Josephin domain. This supports a model in which an inflexible
or “closed” loop is formed, possibly through associations with a poly-ub chain, between
the

functional

UIMs and the
intact Josephin
domain (Fig 27B, red circle).
Our hypothesis

Figure 2-7 Model of MJD domain contribution to the interaction with
Hsp104.
is that Hsp104 (A) Schematic of MJD variants with functional deficiencies.
(B) Model of MJD protein conformation as it affects accessibility to Hsp104
is
able
to treatment. Hsp104 worsens the pathogenicity and enhances aggregation of
MJD variants with functional UIMs and an intact Josephin domain. A closed
loop may be formed between these domains, potentially through mutual
effectively
association with a poly-ub chain, which inhibits productive remodeling by
Hsp104. MJD variants with a more flexible conformation are receptive to
remodel a more successful remodeling by Hsp104.

flexible or “open” conformation of select protein variants (e.g., MJD-Q80-UIM*, MJDQ80-C14A-UIM*, MJD-Q70-Δexon2, or the truncated MJDtrQ78), but that the
inflexible/closed conformation of other proteins (e.g., MJDnQ78, MJDnQ84, or MJDQ88-C14A) obstructs protective Hsp104 activities.

Active remodeling by Hsp104 is required for modulation of protein pathogenicity

To verify the critical role of active remodeling by Hsp104, we created an ATPase-Dead
and substrate-binding defective Hsp104 transgenic fly. We introduced four mutations
(Y257A:E285Q:Y662A:E687Q) into Hsp104 to ensure that Hsp104 could not engage
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substrate or hydrolyze ATP, creating the mutant known as Double Pore Loop Double
Walker B (Hsp104DPLDWB), which is structurally identical to wild-type but functionally
inactive (DeSantis et al., 2012). Unlike wild-type Hsp104, which caused mild retinal
disruption by the gmr-GAL4 driver, similar expression levels of Hsp104DPLDWB were
innocuous (Fig 2-8A, B). Moreover, Hsp104DPLDWB did not modulate the toxicity of either
MJDtrQ78 or MJDnQ78 (Fig 2-8A), underscoring the importance of substrate
translocation for Hsp104 to mitigate MJDtrQ78 or worsen MJDnQ78-associated
degeneration. Thus, ATPase activity and substrate binding are required in vivo for
modulatory effects of Hsp104.

Figure 2-8 ATPase activity
and substrate binding are
required for Hsp104 to
modulate disease.
(A) With the gmr-GAL4 driver
at d7, expression of the
inactive
mutant
UASDPLDWB
Hsp104
, which is unable
to bind substrate or hydrolyze
ATP, caused no effect on its
own when expressed by gmrGAL4.
Additionally,
the
DPLDWB
inactive Hsp104
did not
modulate the toxicity of
MJDtrQ78 or MJDnQ78. Eye
images and retinal sections
showed
moderate
degeneration upon expression
of MJDtrQ78 or MJDnQ78, but
unlike wild-type Hsp104 (see
DPDLWB
Fig. 2), Hsp104
did not
mitigate the degeneration caused by MJDtrQ78 nor did it enhance the toxicity of MJDnQ78.
Arrows indicate the width of the retina to highlight changes in tissue integrity.
DPLDWB
(B) Western immunoblot demonstrated that WT Hsp104 and Hsp104
had similar
expression levels. Tubulin served as a loading control. Quantification of Western immunoblots
DPLDWB
confirmed that protein expression levels were similar, but that Hsp104
was expressed at
levels slightly higher than WT Hsp104. Hsp104 signal was normalized to tubulin (n=3 (mean ±
SEM)).
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Hsp104 suppresses progression of pre-existing degenerative disease in vivo

Hsp104 is unique in its capacity to reverse pre-existing amyloids in yeast and in vitro.
However, the potential of Hsp104 to affect pre-existing protein-aggregation disease in a
metazoan, i.e., a genuine in vivo treatment situation, has never been addressed. To do
so, we constructed fly lines containing three elements: (1) the toxic MJDtrQ78 protein
driven directly by a gmr element such that the disease-associated protein was
constitutively expressed in the eye; (2) a drug-inducible gmr-GAL4 driver known as
“GeneSwitch” (gmr-GS) to activate GAL4 expression only in the presence of the drug
RU486 (mifepristone) (Osterwalder et al., 2001, Roman and Davis, 2002); and (3) the
UAS-HSP treatment molecule (here, Hsp104 or Hsp70), such that the HSP will be
expressed conditionally only when RU486 is present in the fly food (Fig 2-9A). This
system allows the activation of HSP expression sequential to disease-associated protein
onset. In this manner, we could test the ability of exogenous HSPs to mitigate the toxicity
of the pathogenic PolyQ protein after the pathogenic protein was already accumulating in
aggregated forms and causing degeneration. We hypothesized that, due to its
disaggregation rather than chaperone activity, Hsp104 may have the potential to
markedly mitigate degeneration associated with pre-existing PolyQ protein aggregates.
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Figure 2-9 Establishing the
GeneSwitch paradigm.
(A)
Western
immunoblot
demonstrated that the gmr-GSGAL4 line specifically drove
Hsp104 expression in the
presence of RU486 (gmr-GS
ON), but there was no
expression of Hsp104 in the
absence of the drug (gmr-GS
OFF) at d7. The level of
expression by gmr-GS was
lower than with the other eyespecific drivers gmr-GAL4 and
1×gr-GAL4. Tubulin served as
a
loading
control.
Quantification
of
Western
immunoblots confirmed that
gmr-GS expressed at a lower
level than the other drivers,
with the amount of Hsp104
expressed by gmr-GS reaching about 33% of that expressed by 1×gr-GAL4. Hsp104 levels were
normalized to tubulin (n=3 (mean ± SEM)).
(B) Paraffin sections demonstrate that the retinal tissue loss associated with gmr-MJDtrQ78 is
apparent at d0, and progresses through d7. In comparison, control flies (7d) display no such loss
2
of retinal integrity. For each example shown here, a 7,000 µm rectangular selection (used for
quantification in Fig. 2-10) of a retinal section from three independent animals is presented. Each
region was converted to a black and white image to show the area covered by tissue and
quantitated by ImageJ analysis (see Methods). For the analysis in Fig. 2-10, regions from 6
independent animals were used for quantitation; all experiments were repeated at least three
times with similar results.

We established that retinal degeneration associated with gmr-MJDtrQ78 had begun at
the time of adult fly emergence (d0) and progressed in severity to d7 (Fig 2-9B, Fig 210). We then activated Hsp104 or Hsp70 expression at an early time point (d1), or a
later time point (d3), and examined the pathogenic impact of the MJDtrQ78 protein at d7
by retinal section. When activated at d1, Hsp104 was able to significantly mitigate retinal
degeneration associated with MJDtrQ78 (p=0.001), while Hsp70 did not have a
significant effect (Fig 2-10A, n.s. p=0.06). These data show that Hsp104 is significantly
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more effective than Hsp70 at mitigating toxicity once disease progression has begun (Fig
2-10A, p=0.01). Importantly, inactive Hsp104DPLDWB had no effect (Fig 2-10A). Hsp104
significantly improved tissue structure even when expression was induced at a later time
point of d3 when degeneration was even more severe (Fig 2-10B, p=0.003). Moreover,
while MJDtrQ78 treated with Hsp70 continued to degenerate with time, induction of
Hsp104 arrested disease progression (Fig 2-10A, d7 vs d1; Fig 2-10B, d7 vs d3). We
also examined the underlying protein aggregates by SDD-AGE and Western
immunoblot. We observed that gmr-MJDtrQ78 had high levels of amyloid, and this was
lessened with time (potentially due to tissue loss) (Fig 2-11). When turned on at d1,
Hsp104 did not reverse MJDtrQ78 amyloid formation, but rather significantly increased
the amyloid present by d7 (p=0.02), while Hsp70 had no effect (Fig 2-11A). Neither
molecule significantly altered amyloid load when turned on at d3 (Fig 2-11B). These
results imply that Hsp104 is not acting as a MJDtrQ78-amyloid disaggregase, but rather
is mitigating toxicity in a distinct manner, which is also consistent with our results for
MJDtrQ78 (see Fig 2-2, 2-3). Intriguingly, representative densitometry traces for the
amyloid smears for each treatment condition turned on at d1 suggest that the peak of
MJDtrQ78 amyloid species shift downward to indicate smaller amyloid accumulations by
d3 following Hsp104 activation (Fig 2-11C). No shift in the densitometry trace is
observed for the control or Hsp70 treatment (Fig 2-11C), suggesting that Hsp104 is
indeed altering the character of amyloid species although not eliminating these fibrils
completely. In summary, this novel system of temporally controlled HSP expression
demonstrates that although concomitant expression of Hsp70 is more successful than
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Hsp104 at preventing degeneration (see Fig 2-2), inducible expression of Hsp104 is
more effective than Hsp70 at suppressing disease progression once protein aggregation
and degeneration are already established (Fig 2-10).

Figure
2-10
Progressive
MJDtrQ78
pathogenicity can
be suppressed by
expression
of
Hsp104
after
onset
of
degeneration.
(A) External eye
and internal retinal
sections demonstrate the effect of
sequential onset of
chaperone treatment. The adult
animals emerged
from the pupal
case
with
a
disrupted eye (d0);
chaperone activity
was initiated at d1.
Disruption caused
by MJDtrQ78 was
significantly suppressed
by
activation
of
DPLDWB
Hsp104 at d1. In contrast, Hsp70 or the inactive Hsp104
did not significantly impact the
progression of pathology. To quantify degeneration within the retina, the percentage of a standard
area covered by tissue was measured by ImageJ (n=6 (mean ± SD)) (see also Fig 2-9). *p<0.05,
**p=0.001-0.01.
(B) The progression of toxicity of MJDtrQ78 was also significantly altered by sequential activation
of Hsp104 later in the degenerative process, on d3. Quantification of tissue as above (n=6 (mean
± SD)). **p=0.001-0.01.
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Figure 2-11 Hsp104
does not mitigate
disease
progression by clearing
MJDtrQ78 amyloid
fibrils.
(A and B) SDD-AGE
and
immunoblot
analysis
show
the
progression of amyloid
formation
of
gmrMJDtrQ78 over time.
Drug
activation
of
disaggregase
or
chaperone at the early
time point of d1 (A)
shows that induced
Hsp104
expression
significantly increased
amyloid load by d7.
Hsp70
had
no
significant impact on
amyloid
levels.
Activation
of
the
molecules at later time
point
d3
(B)
demonstrated
that
neither Hsp104 nor
Hsp70
affected
amyloid
load.
MJDtrQ78
was
detected using anti-HA
antibody with antitubulin as a loading
control. Band density
for
both
amyloid
smears (SDD-AGE) and soluble bands (Western blot) were quantified using ImageJ (n=3 (mean
± SEM)). *p<0.05; Statistics indicate comparison to the disease protein alone at each timepoint.
(C) Representative densitometry traces of the SDD-AGE amyloid immunoblots, as in A, show the
distribution of amyloid species resolved by size. After HSP activation at d1, the distribution of
MJDtrQ78 amyloid accumulations exposed to Hsp104 shifts downward by d3 (red trace),
compared to the control (black) and Hsp70 (green) profiles. The densitometry analysis was
performed in ImageJ and the effect was reproducible among three independent replicates.
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DISCUSSION

Here, we reveal key novel insights into the efficacy and interactions of Hsp104 with the
pathogenic PolyQ protein MJD. Our studies reveal the surprising finding that Hsp104
interacts differentially with different forms of the MJD protein. Hsp104 is a potent
suppressor of toxicity of the truncated protein, but an enhancer of toxicity of the fulllength protein. These differences are determined by specific domains of MJD that are
not directly implicated in aggregation. Our findings have also uncovered a heretofore
unrecognized and important application of Hsp104 in vivo, which is its ability to mitigate
the course of protein-aggregation disease even after it has already initiated. Indeed, our
studies show that Hsp104 is able to mitigate disease progression once it has begun,
unlike the classical metazoan chaperone Hsp70. These studies provide new insight into
the in vivo effects of Hsp104 in the context of a therapeutic agent.

Hsp104 has opposite effects on two constructs of the same disease protein

Our detailed investigations of the effects of Hsp104 on the MJD protein led to the
unexpected result that Hsp104 has opposite effects on the toxicity of different versions of
the MJD protein (MJDtrQ78 and MJDnQ78), despite the fact that these proteins contain
the same pathogenic PolyQ stretch. These disparate actions indicate that Hsp104 might
be a useful probe to understand the nature of aggregates and the toxicity imposed by
them. Hsp70 suppressed both MJDtrQ78 aggregation and toxicity (Fig 2-2E, 2-3C). By
contrast, Hsp104 mitigated toxicity of MJDtrQ78 without suppressing the extent of
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MJDtrQ78 aggregation (Fig 2-2C, 2-3C). This result suggests that MJDtrQ78
aggregation per se need not be deleterious. Uncoupling of aggregation and toxicity has
also been observed in other settings. For example, numerous genetic suppressors of
FUS and TDP-43 toxicity, which are connected with amyotrophic lateral sclerosis and
frontotemporal dementia, rescue toxicity without affecting FUS or TDP-43 aggregation in
yeast (Ju et al., 2011, Sun et al., 2011, Armakola et al., 2012). We suggest that Hsp104
likely mitigates toxicity of MJDtrQ78 accumulations via subtle biochemical changes
rather than gross changes in aggregation levels.

What might these biochemical changes be? Hsp104 can disrupt toxic soluble oligomers
of various proteins, including Sup35, which may help explain why Sup35 prion formation
is not intrinsically toxic to yeast (Shorter and Lindquist, 2004, 2005, 2006, Lo Bianco et
al., 2008, DeSantis et al., 2012). Thus, Hsp104 might eliminate toxic soluble oligomers
formed by MJDtrQ78 just as it does for Sup35 and alpha-synuclein. Furthermore, the
amyloid-remodeling activity of Hsp104 can selectively amplify some amyloid strains (i.e.
different cross-β structures formed by the same polypeptide) at the expense of others
(DeSantis and Shorter, 2012). Given that PolyQ can access both toxic and benign
amyloid strains (Nekooki-Machida et al., 2009), it is plausible that the presence of
Hsp104 might amplify benign amyloid strains of MJDtrQ78 at the expense of toxic
strains (Nekooki-Machida et al., 2009, DeSantis and Shorter, 2012). Indeed, we
observed that Hsp104 activity visibly altered the distribution of MJDtrQ78 amyloid
species (Fig 2-11C), suggesting that Hsp104 may be selectively eliminating certain fibril
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strains. Finally, to promote toxicity amyloid structures typically sequester large
metastable proteins with unstructured regions, which occupy key nodes in functional
networks linked to transcription, translation, chromatin organization, cell structure, and
proteostasis (Olzscha et al., 2011, Vabulas and Hartl, 2011). Hsp104 might disaggregate
and rescue these proteins sequestered by MJDtrQ78 amyloid or promote the formation
of MJDtrQ78 amyloid strains that do not deplete such an essential constellation of
proteins. Further studies are needed to distinguish these non-mutually exclusive
possibilities.

In other settings, it has been suggested that chaperone-initiated formation of large,
insoluble amyloid aggregates can actually be protective by sequestering potentially toxic
pre-fibrillar conformers (Dobson, 2003, Douglas et al., 2008, Wolfe and Cyr, 2011). Our
results, however, indicate that, at least for Hsp104-driven enhancement of MJDnQ78,
increased and accelerated aggregation is more toxic than MJDnQ78 aggregation that
occurs in the absence of Hsp104. Our findings illustrate the complex relationship
between aggregation and toxicity, which likely extends to other neurodegenerative
disease models (Wolfe and Cyr, 2011). Moreover, our studies suggest that cautious
interpretation is required when translating findings from cell culture experiments to
neurodegeneration in animal models (Carmichael et al., 2000, Vacher et al., 2005).
Although Hsp104 is not found in the metazoan proteostasis network, our observations
could help inform how to manipulate existing components of the metazoan proteostasis
network for therapeutic purposes. Thus, components that suppress MJDnQ78
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aggregation are likely beneficial, whereas MJDtrQ78 toxicity can be mitigated without
having to suppress MJDtrQ78 aggregation.

Moreover, our findings demonstrate that an agent with a mitigating effect on the
truncated version of the MJD protein may act in a different manner against the full-length
MJD protein. Thus, what is good for one may not be beneficial to the other. In
MJD/SCA3, as well as other neurodegenerative diseases, fragmentation of the disease
protein may initiate aggregation and this process is critical for disease progression
(Wellington et al., 1998, Graham et al., 2006, Haacke et al., 2007, Jung et al., 2009).
Therefore, agents that effectively eliminate one specific sub-population of toxic protein
accumulation but enhances another toxic sub-population may not be therapeutically
viable in the complicated mixed populations that occur in disease. Our results highlight
the complexity in developing therapeutic agents for neurodegenerative disorders.

Protein context is critical in evaluating disease-associated proteins

Although Hsp104 enhances MJDnQ78 amyloidogenesis and toxicity, we found that
elimination of functional domains not implicated in PolyQ aggregation facilitated the
ability of Hsp104 to suppress MJD-associated degeneration. Elimination of UIM
functionality or removal of a component of the Josephin domain (exon 2) restored the
remodeling capacity of Hsp104. This suggests that MJDnQ78 pathogenicity is not
intrinsically intractable, but is capable of being suppressed by Hsp104 if other domains
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of the protein are inactivated (e.g., the UIMs). Alternatively, potentiated or MJDnQ78optimized Hsp104 variants might be developed that are able to overcome these
hindrances via increased unfolding power (Vashist et al., 2010, DeSantis et al., 2012).

Our studies underscore the importance of protein context in studying protein-misfolding
diseases. Within the protein itself, neighboring domains not thought to be involved in
aggregation may be impacting accumulation kinetics and the biochemical properties of
inclusions, as well as accessibility of the aggregation domain to potential disaggregase
therapeutics. That Hsp104 efficiently mitigates toxicity of MJD variants with ubiquitinbinding defects also demonstrates that, in addition to protein context, the cellular context
of the protein is critical to consider; for example, the interaction between poly-ub chains
and MJD may hinder Hsp104.

Previous studies in vitro have characterized aggregation of the full-length, pathogenic
MJD protein as a two-step process in which the protein assembles first into SDS-soluble
fibrillar polymers associating via the Josephin domain, and then converts to SDSinsoluble amyloid fibers driven by the PolyQ domain (Masino et al., 2004, Ellisdon et al.,
2006, Ellisdon et al., 2007, Masino et al., 2011). We propose that this two-step process
occurs in vivo as well. Indeed, it is consistent with our observation that full-length
MJDnQ78 forms amorphous accumulations that appear visually by IHC before they can
be observed as SDS-insoluble amyloid aggregates by SDD-AGE (see Fig 2-3B and D).
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We suspect that full-length MJD initially forms SDS-soluble, Josephin-driven nonamyloid accumulations that initiate Hsp104 remodeling.

The initial formation of non-amyloid polymers is also compatible with our model of
Hsp104 interacting differentially with the “open” and “closed” conformations of the protein
discussed above (see Fig 2-7B). We hypothesize that a poly-ub chain creates the closed
loop by mutually interacting with the UIMs and the flexible helical hairpin encoded by
exon 2 in the Josephin domain (Fig 2-6B), as this arm is thought to be important for
interacting with substrates (Nicastro et al., 2005). Further experiments are required to
confirm a poly-ub-mediated interaction between the two domains. According to our
model, Hsp104 is able to efficiently translocate and release proteins that are more
flexible (e.g., MJD-Q80-UIM*), resulting in fewer aggregates (see Fig 2-5B). But due to
an inflexible conformation imposed by the UIMs and the Josephin domain, Hsp104 is
unable to efficiently remodel proteins containing the closed loop (e.g., MJDnQ84). This
incomplete or slow translocation may expose or “prime” the PolyQ region to drive the
formation SDS-insoluble amyloid inclusions (see Fig 2-3D, Fig 2-5C).

Our model suggests that the UIMs and the Josephin domain act together to obstruct
Hsp104 remodeling, but we cannot rule out a separate function of the Josephin domain
outside of poly-ub interactions. For example, removal of 55 amino acids might
destabilize the Josephin domain such that it gets proteolytically cleaved and Hsp104
would then encounter a protein similar to MJDtrQ78 and rescue toxicity. Alternatively,
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because the MJD-Q79-Δexon2 protein could not be detected by biochemical methods,
we cannot exclude the possibility that the deletion within the Josephin domain disrupts
the proposed process of Josephin-domain-driven polymerization. In this case, toxicity of
this variant may be dependent on highly soluble, possibly oligomeric species, which are
effectively targeted by Hsp104.

These findings indicate that there is an opportunity to tailor therapies that are optimized
for a specific disease scenario. In the case of full-length MJD, if inefficient translocation
by Hsp104 does indeed drive the switch from less toxic SDS-soluble aggregates to
highly toxic SDS-insoluble amyloid inclusions, then the development of substrateoptimized Hsp104 mutants (or Hsp104 mutants with altered ATPase rates or unfolding
power) may increase efficiency of such interactions and enable Hsp104 to rescue
disease phenotypes. Moreover, if UIM binding to poly-ub chains is impairing access of
Hsp104 to MJD, this suggests that co-administering an agent to modulate function of a
neighboring domain may affect the access of a treatment to the aggregation-prone
domain. Indeed, increasing global DUB activity coupled with Hsp104 induction could
overcome antagonism due to poly-ub chains.

Implications for Hsp104 as a therapeutic agent

Chaperone treatment, and examination of Hsp70 in particular, has been an exciting
avenue of research in the battle to combat and contain neurodegenerative disease
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(Muchowski and Wacker, 2005, Broadley and Hartl, 2009). However, all studies
investigating Hsp70 as a modulator of disease have looked only at the chaperone
transgenically co-expressed or activated prior to the disease insult. In a study seeking to
activate existing Hsp70 rather than introducing exogenic expression, researchers sought
to evaluate the chaperone in a mouse model of PD by boosting endogenous Hsp70
expression by treating animals with geldanamycin (Shen et al., 2005). While this
procedure has the potential to test true reversal of disease course, the authors found
that beneficial effects were only observed if upregulation of Hsp70 was initiated prior to
pharmacological induction of the PD phenotype (Shen et al., 2005). In fact, in a cell
culture PD model, geldanamycin was required at least 24 hours prior to disease protein
transfection to provide any protection against inclusion formation (McLean et al., 2004).
In addition, pharmacologic activation of Hsp70 has been shown to suppress both PD
and PolyQ disease in Drosophila (Auluck and Bonini, 2002, Wang et al., 2012), but
again, these manipulations were performed prior to disease onset. Despite the existing
pharmacological paradigms, and other genetic tools available, such as the tetracyclineinducible system in mouse, no group has evaluated specific chaperone or disaggregase
expression induced subsequent to expression of a disease-associated protein.

An inducible system is particularly well suited for Hsp104 because of its unique ability to
rapidly dismantle pre-existing amyloid aggregates. Since metazoan chaperones can only
very slowly depolymerize amyloid (Duennwald et al., 2012), Hsp104 may be more
effective in an environment with pre-existing aggregation than a chaperone such as
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Hsp70, which is more adapted to prevent the initial aggregation. Here, we address the
value of temporally controlled induction of disaggregase function after the initiation of
PolyQ protein aggregation and the beginning of disease progression. To our knowledge,
previous research has been performed with concomitant expression of a therapeutic
gene, and thus does not distinguish prevention of disease from halting the progression of
the disease state. Neurodegenerative diseases are not detected until later in life, and
symptoms may not be apparent until pathological damage has accumulated beyond a
tolerable point (Davies et al., 1997, Naslund et al., 2000, Braak et al., 2003). Thus, an
agent that can rapidly impact the existing trajectory would be more valuable than one
that can only prevent the development of the disease.

Our experimental paradigm offers the exciting possibility to address the efficacy of
Hsp104 (or other molecules) in a more genuine therapeutic setting. Indeed, we found
that turning on Hsp104 was able to significantly suppress disease-associated
degeneration. Interestingly, however, Hsp104 did not disaggregate MJDtrQ78 amyloid in
these experiments (Fig 2-11A, B). Thus, Hsp104 might mitigate disease progression in
this setting by: (a) eradicating toxic soluble MJDtrQ78 oligomers, (b) amplifying benign
amyloid forms of MJDtrQ78 at the expense of toxic MJDtrQ78 amyloid, (c) by
disaggregating and rescuing essential metastable proteins sequestered by MJDtrQ78
aggregates. Our observation that activation of Hsp104 shifted the MJDtrQ78 amyloid
smears resolved by SDD-AGE toward smaller species without eliminating the total
amyloid population (Fig 2-11C) suggests that Hsp104 may indeed have strain selectivity.
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Further studies are required to define precisely how Hsp104 mitigates disease
progression. Our data show that Hsp70 induction after MJD-associated degeneration
has already initiated was unable to significantly mitigate disease progression.
Optimization of Hsp70 expression, or administration of the suite of chaperones (for
example, Hsp70 with Hsp110 and Hsp40), may improve the outcome, but our findings
are consistent with other reports that Hsp70 must be administered before disease
initiation to have a positive effect (McLean et al., 2004, Shen et al., 2005). Our
observation that even a later-onset induced expression of Hsp104 is able to significantly
suppress progressive PolyQ degeneration suggests that it is possible to mitigate disease
phenotypes even after aggregates have begun accumulating and marked pathological
degeneration is underway.

Naturally, several barriers must be surmounted to translate Hsp104 into a therapeutic
agent for human neurodegenerative disease (Shorter, 2008, Vashist et al., 2010). Not
least is the issue that gene therapy might be required to introduce Hsp104 (or any other
genetic modifier) as a therapeutic agent. Gene therapy has yielded encouraging
preclinical results for several disorders including congenital blindness (Hacein-Bey-Abina
et al., 2002, Bainbridge et al., 2008, Maguire et al., 2008). However, technical and safety
issues restrict facile translation to the clinic. Indeed, gene therapy for neurodegenerative
diseases remains in early developmental stages and considerable caution is essential at
this time. However, initial studies have generated cautious optimism that gene therapy in
the adult brain might be safe for various neurodegenerative disorders, including
Parkinson’s disease (Feigin et al., 2007, Kaplitt et al., 2007, Stoessl, 2007, San
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Sebastian et al., 2013, Simonato et al., 2013). Thus, even though we await several key
advances before any Hsp104 gene therapy (or any other gene therapy) becomes truly
viable it is, nonetheless, important to develop solutions to protein misfolding and to test
these solutions both in vitro and in the most appropriate animal models. Moreover, the
fact that Hsp104 is well tolerated by mammalian systems is encouraging (Carmichael et
al., 2000, Mosser et al., 2004, Vacher et al., 2005, Dandoy-Dron et al., 2006, Perrin et
al., 2007, Lo Bianco et al., 2008). Ultimately, we envision that only transient expression
of Hsp104 (or a substrate-optimized variant) would be required to provide therapeutic
benefit. In this way, long-term expression of an exogenous agent and potential off-target
side effects would be minimized. Alternatively, methods could be developed to deliver
pure Hsp104 (or a substrate-optimized variant) to targeted areas in a single or multiple
doses, and thereby avoid issues connected with long-term expression. These various
issues and others highlight the complexities of designing therapeutics to treat human
neurodegenerative disease.

Finally, the concept of using a yeast protein as the basis for a therapeutic agent might at
first glance seem implausible. However, it must also have seemed equally implausible to
use a lethal protein toxin from the bacterium, Clostridium botulinum, as a therapeutic
agent. Despite being a deadly toxin, botulinum toxin variants have found key clinical
applications due to their highly potent and selective ability to cleave SNARE proteins and
prevent secretion (Schiavo et al., 1992). Importantly, they are used to treat a variety of
neuromuscular disorders including: blepharospasm, strabismus, muscle spasms, upper
motor neuron syndrome, cervical dystonia and chronic migraine (Bentivoglio and
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Albanese, 1999, Hallett, 1999, Osborne et al., 2007, Elia et al., 2009, Esquenazi et al.,
2009, Yeh et al., 2011). Indeed, the massive clinical success of botulinum toxin variants
suggests it is critical to identify potentially therapeutic biological activities that originate in
the microbial world and utilize and develop them to treat human disease.

MATERIALS AND METHODS

Drosophila transgenic lines and crosses
Transgenic flies expressing UAS-Hsp104 and UAS-Hsp104DPLDWB were generated by
standard techniques using the pUAST vector (Brand and Perrimon, 1993). In order to
boost expression of the transgene, pUAST-Hsp104 was codon-optimized for expression
in Drosophila and a Kozak sequence (ACAAA) was added prior to the start codon (Trinh
et al., 2008).

The full sequence of codon-optimized Hsp104 is:
ATGAACGATCAGACCCAGTTCACCGAGCGCGCCCTGACCATCCTGACCCTGGCCCA
GAAGCTGGCCAGCGATCACCAGCACCCCCAGCTGCAGCCCATCCACATCCTGGCC
GCCTTCATCGAGACCCCCGAGGATGGCAGCGTGCCCTACCTGCAGAACCTGATCG
AGAAGGGCCGCTACGATTACGATCTGTTCAAGAAGGTGGTGAACCGCAACCTGGTG
CGCATCCCCCAGCAGCAGCCAGCCCCAGCCGAGATCACCCCAAGCTACGCCCTGG
GCAAGGTGCTGCAGGATGCCGCCAAGATCCAGAAGCAGCAGAAGGATAGCTTCAT
CGCCCAGGATCACATCCTGTTCGCCCTGTTCAACGATAGCAGCATCCAGCAAATCTT
CAAGGAGGCCCAGGTGGATATCGAGGCCATCAAGCAGCAGGCCCTGGAGCTGCGC
GGAAACACCCGCATCGATAGCCGCGGAGCCGATACCAACACCCCCCTGGAGTACC
TGAGCAAGTACGCCATCGATATGACCGAGCAGGCCCGCCAGGGAAAGCTGGACCC
AGTGATCGGACGCGAGGAGGAGATCCGCAGCACCATCCGCGTGCTGGCCCGCCG
CATCAAGAGCAACCCATGCCTGATCGGAGAGCCAGGAATCGGCAAGACCGCCATC
ATCGAGGGAGTGGCCCAGCGCATCATCGATGATGATGTGCCAACCATCCTGCAGG
GAGCCAAGCTGTTCAGCCTGGATCTGGCCGCCCTGACCGCCGGCGCCAAGTACAA
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GGGCGATTTCGAGGAGCGCTTCAAGGGCGTGCTGAAGGAGATCGAGGAGAGCAAG
ACCCTGATCGTGCTGTTCATCGATGAGATCCACATGCTGATGGGCAACGGCAAGGA
TGATGCCGCCAACATCCTGAAGCCAGCCCTGAGCCGCGGACAGCTGAAGGTCATC
GGAGCCACCACCAACAACGAGTACCGCAGCATCGTGGAGAAGGATGGAGCCTTCG
AGCGCCGCTTCCAGAAGATCGAGGTGGCCGAGCCAAGCGTGCGCCAGACCGTGGC
CATCCTGCGCGGACTGCAGCCCAAGTACGAGATCCACCACGGCGTGCGCATCCTG
GATAGCGCCCTGGTGACCGCCGCCCAGCTGGCCAAGCGCTACCTGCCATACCGCC
GCCTGCCAGATAGCGCCCTGGATCTGGTGGATATCAGCTGCGCCGGAGTGGCCGT
GGCCCGCGATAGCAAGCCAGAGGAGCTGGATAGCAAGGAGCGCCAGCTGCAGCTG
ATCCAGGTGGAGATCAAGGCCCTGGAGCGCGATGAGGATGCCGATAGCACCACCA
AGGATCGCCTGAAGCTGGCCCGCCAGAAGGAGGCCAGCCTGCAGGAGGAGCTGG
AGCCACTGCGCCAGCGCTACAACGAGGAGAAGCACGGCCACGAGGAGCTGACCCA
GGCTAAGAAAAAGCTGGATGAGCTGGAGAACAAGGCCCTGGATGCCGAGCGCCGC
TACGATACCGCCACCGCCGCCGATCTGCGCTACTTCGCCATCCCCGATATCAAGAA
GCAGATCGAGAAGCTGGAGGATCAGGTGGCCGAGGAGGAGCGCCGCGCCGGCGC
CAACAGCATGATCCAGAACGTGGTGGATAGCGATACCATCAGCGAGACCGCCGCC
CGCCTGACCGGCATCCCCGTGAAGAAGCTGAGCGAGAGCGAGAACGAGAAGCTGA
TCCACATGGAGCGCGATCTGAGCAGCGAGGTGGTGGGCCAGATGGATGCCATCAA
GGCCGTGAGCAACGCCGTGCGCCTGAGCCGCAGCGGACTGGCCAACCCACGCCA
GCCAGCCAGCTTCCTGTTCCTGGGCCTGAGCGGCAGCGGCAAGACCGAGCTGGCC
AAGAAGGTGGCCGGCTTCCTGTTCAACGATGAGGATATGATGATCCGCGTGGATTG
CAGCGAGCTGAGCGAGAAGTACGCCGTGAGCAAGCTGCTGGGCACCACCGCCGG
CTACGTGGGCTACGATGAGGGCGGCTTCCTGACCAACCAGCTGCAGTACAAGCCC
TACAGCGTGCTGCTGTTCGATGAGGTGGAGAAGGCCCACCCCGATGTGCTGACCG
TGATGCTGCAGATGCTGGATGATGGCCGCATCACCAGCGGCCAGGGCAAGACCAT
CGATTGCAGCAACTGCATCGTGATCATGACCAGCAACCTGGGCGCCGAGTTCATCA
ACAGCCAGCAGGGCAGCAAGATCCAGGAGAGCACCAAGAACCTGGTCATGGGCGC
CGTGCGCCAGCACTTCCGCCCCGAGTTCCTGAACCGCATCAGCAGCATCGTGATCT
TCAACAAGCTGAGCCGCAAGGCCATCCACAAGATCGTGGATATCCGCCTGAAGGAG
ATTGAGGAGCGCTTCGAGCAGAACGATAAGCACTACAAGCTGAACCTGACCCAGGA
GGCCAAGGATTTCCTGGCCAAGTACGGCTACAGCGATGATATGGGCGCCCGCCCC
CTGAACCGCCTGATCCAGAACGAGATCCTGAACAAGCTGGCCCTGCGCATCCTGAA
GAACGAGATCAAGGATAAGGAGACCGTGAACGTGGTGCTGAAGAAGGGCAAGAGC
CGCGATGAGAACGTGCCAGAGGAGGCCGAGGAGTGCCTGGAGGTGCTGCCAAACC
ACGAGGCCACCATCGGAGCCGATACCCTGGGCGATGATGATAACGAGGATAGCAT
GGAGATCGATGATGATCTGGATTAA

Multiple insertion lines were characterized for each transgene. To create the 1×gr-GAL4
driver line, the pGMR (glass multimer reporter) vector (Hay et al., 1994) was digested by
XhoI/Acc651 to remove the insert containing five glass-binding sites. Complementary
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oligonucleotides (5ʼ-TCGAACCCAGTGGAAACCCTTGAAATGCCTTTAACTCGAGACG
G-3ʼ

and

5ʼ-GTACCCGTCTCGAGTTAAAGGCATTTCAAGGGTTTCCACTGGGT-

3ʼ), with a single copy of the 31 bp glass-binding site from the Rh1 proximal enhancer,
were duplexed and ligated into the vector, producing p1×GR (1 copy of glass
reporter). This plasmid was then modified to introduce the GAL4 coding sequence,
excised from pGaTN (Brand and Perrimon, 1993) with HindIII, to create p1×gr-GAL4.
MJD lines are from (Warrick et al., 2005). Experiments were performed at 25ºC except
for a select few
conducted at 29ºC
as

indicated.

results
confirmed

All
were
with

multiple

UAS-

Hsp104

insertion

lines (Fig 2-12).

Figure
2-12
Confirmation
of
Hsp104 interaction
with key MJD lines.
Key
genetic
interactions
were
confirmed with the
1xgr-Gal4 driver and
two
independent
Hsp104
transgenic
lines with similar expression levels, 2.1 (3) and 4.1 (X). Both Hsp104 lines suppressed toxicity of
truncated MJD (MJDtrQ78 and MJDtrQ92) and MJD-Q79Δexon2, worsened toxicity of MJDnQ78,
and had no effect on MJD-Q88.C14A. Images from 1xgr-Gal4 and 1xgr-Gal4; Hsp104 2.1 rows
are also used in previous figures.
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Evaluation of eye degeneration
Eye images were obtained on day 7 of adulthood using a Leica Z-16 apo zoom
microscope. To view internal retinal structure, heads were embedded in paraffin
according to standard protocols, sectioned at 8 µm, and autofluorescence was viewed
with a Leica fluorescence microscope. To quantify tissue loss, a standard area (3×15
rectangle; 7,000 µm2) (see also Fig 2-9) was selected within the paraffin retinal section
and the percentage of area covered by tissue was measured in ImageJ. Statistical
analysis was performed using one-way ANOVA and unpaired t-test.

Cryosections and immunohistochemistry
Heads were frozen in Tissue Freezing Medium (Electron Microscopy Sciences) and
sectioned at 12 µm by cryotome, and the tissue sections were then fixed with 4%
paraformaldehyde. Immunohistochemistry was performed according to standard
procedures using primary antibodies anti-HA 5B1D10 (1:100, Invitrogen 32-6700) or
anti-myc 9E10 (1:100, Santa Cruz sc-40) (both mouse) alongside either anti-Hsp104
(1:100, Enzo Life Sciences ADI-SPA-1040) or anti-Hsp70 (1:100, Enzo Life Sciences
ADI-SPA-812) (both rabbit). Hsp70 staining was confirmed with human-specific antiHsp70 (1:100, Santa Cruz sc-24) (mouse) alongside anti-HA Y11 (1:100, Santa Cruz sc805) or anti-myc A14 (1:100, Santa Cruz sc-789) (both rabbit). Rabbit primary antibodies
were preadsorbed at 1:25 with fixed, dissected wild-type larvae. Secondary antibodies
were Alexa Fluor 594 Goat-anti-Mouse IgG (1:100, Life Technologies A-11032), Alexa
Fluor 488 Goat-anti-Rabbit IgG (1:100, Life Technologies A-11008), Alexa Fluor 594
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Goat-anti-Rabbit IgG (1:100, Life Technologies A-11037), and Alexa Fluor 488 Goatanti-Mouse IgG (1:100, Life Technologies A-11029). Sections were co-stained with
Hoechst nuclear dye (1:1000, Molecular Probes 33342) and viewed with a Leica
fluorescence microscope. A 75 µm × 75 µm square (5625 µm2) area was selected;
particle analysis was performed with ImageJ and statistics performed with one-way
ANOVA and unpaired t-test.

Immunoblots and SDD-AGE
For Hsp104 expression level characterization, heads were ground with a pestle in
NuPage LDS Sample Buffer, boiled for 3 min, run on NuPage 4-12% Bis-Tris gel, and
semi-dry transferred onto nitrocellulose membrane. Antibodies used were anti-Hsp104
(1:2000, Enzo Life Sciences ADI-SPA-1040) and anti-actin (1:2000, Abcam ab8227) with
secondary antibody Goat-anti-Rabbit-HRP (1:5000, Chemicon AP307P). For MJD
aggregation analysis through SDD-AGE (Semi-Denaturing Detergent Agarose Gel
Electrophoresis) and accompanying Western immunoblots, heads were ground in lysis
buffer (100 mM Tris pH 7.5, 50 mM NaCl, 10 mM β-Mercaptoethanol, and Roche
complete mini EDTA-free protease inhibitor cocktail tablets) (Halfmann and Lindquist,
2008) and an aliquot was taken for evaluation of soluble material by Western
immunoblot, as above. To the remaining sample, 4X Sample Buffer (2X TAE, 20%
glycerol, 8% SDS, bromophenol blue) was added to final concentration 1X. The samples
were run on a 1.5% agarose gel with 0.1% SDS in a running buffer of 1X TAE (40 mM
Tris, 20 mM Acetic acid, 1 mM EDTA, pH 8.3) containing 0.1% SDS, and then
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transferred overnight onto nitrocellulose membrane using downward capillary transfer
(Halfmann and Lindquist, 2008). Antibodies used were anti-HA-conj-HRP 3F10 (1:500,
Roche 12013819001), anti-myc 9E10 (1:500, Santa Cruz sc-40) followed by Goat-antiMouse-HRP (1:2000, Jackson ImmunoResearch 115-035-146), and anti-tubulin-conjHRP (1:1000, Cell Signaling 11H10). All immunoblots were imaged using a FujiFilm
LAS-3000 imaging system and quantification was performed in ImageJ and statistically
analyzed by one-way ANOVA and unpaired t-test.

Gene switch protocol
A 4.0 mg/ml stock solution of RU486 (Sigma M8046) was prepared in 100% ethanol, and
then 50 µl (200 µg) was added to pre-prepared food vials containing ~12 ml of food and
gently shaken overnight (Shen et al., 2009). For control conditions, 50 µl of 100%
ethanol was added to vials. Adult flies were aged in food treated with either RU486 or
ethanol for the time periods indicated.

ADDENDUM
To begin, clarification of the term “amyloid” is required. In this manuscript, the term is
used to describe accumulated protein material that is resistant to 2% SDS and therefore
resolves as a high molecular weight smear by SDD-AGE.

However, to define this

aggregated material as amyloid rigorously by biochemical and other criteria, further
techniques are needed to confirm the presence of the cross-β conformation.

The

diagnostic amyloid-binding dyes Congo Red (CR) and Thioflavin-S (ThS) would be
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useful in making this distinction. Amyloid material stained with CR shows apple-green
birefringence under polarized light, while ThS increases fluorescence when bound to
amyloid in tissue (Kelenyi, 1967, Klunk et al., 1989, LeVine, 1993). Additionally, tissue
containing amyloid material exhibits inherent birefringence (Sipe and Cohen, 2000). The
technique of X-ray diffraction is also instructive, as amyloid fibrils give a characteristic
diffraction pattern consistent with β-sheets running perpendicular to the fibril axis (Sunde
et al., 1997).

Visual examination of the tissue by EM may also be informative, as

amyloid fibrils appear as a non-branching linear structure (Cohen and Calkins, 1959).
Moreover, even without the detection equipment required to analyze the previous
techniques, sequential extraction of the protein inclusions can inform on the stability of
the aggregates.

Thus, following solubilization in 2% SDS used in our SDD-AGE

experiments, further treatment of the eye tissue in increasing concentrations of formic
acid could be used to determine the properties of existing amyloid species by these
additional criteria (Rostagno and Ghiso, 2009). Thus, our usage of the term applies
specifically to the properties of the protein material in response to SDS; additional
characterization as outlined above is needed to extend these initial findings to confirm
that the protein inclusions are truly amyloid in nature.

Next, because we used the general eye-specific 1xgr-Gal4 driver to evaluate eye toxicity
in the retina and the photoreceptor-specific driver rh1-Gal4 to examine protein
aggregation in the adult in a subset of retinal cells, we wanted to confirm that the finding
regarding the distinct interactions of Hsp104 with MJDtrQ78 and MJDnQ78 were
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applicable to both situations. As such, we determined toxicity with the rh1-Gal4 system
to accompany the protein aggregation data (see Fig 2-3), and evaluated protein
aggregation in the 1xgr-Gal4 system to accompany the existing toxicity results (see Fig
2-2).

First, we evaluated toxicity of the disease proteins to the photoreceptor cells using the
rh1-Gal4 driver. Using the pseudopupil assay to shine light through the flyʼs eye, one
can quantify the loss of rhabdomere structure because intact photoreceptor cells
illuminate as red while disrupted cells do not. The photoreceptors cluster into
stereotypical ommatidial patterns containing seven photoreceptors in each ommatidium.
As such, 100% of ommatidia examined for control flies contain seven photoreceptors per
cluster, indicating that there is no toxicity in this condition (Fig 2-13A). Consistent with
our 1xgr-Gal4 results, Hsp70 displayed no toxicity when expressed with rh1-Gal4 (Fig 213A). Similarly, Hsp104 on its own had no toxicity to the photoreceptor cells (Fig 2-13A);
this is in contrast to our observations of Hsp104 toxicity upon expression with gmr-Gal4
or 1xgr-Gal4 (Fig 2-1A). Because rh1-Gal4 is an adult-onset driver, we interpret this to
reflect that developing cells are more sensitive to disruption by expression of Hsp104.

Expression of the disease protein MJDtrQ78 was very toxic to photoreceptor cells, with a
mean number of 4.52 ± 0.28 photoreceptor cells per ommatidium (Fig 2-13B).

Co-

expression of Hsp104, with a mean of 3.90 ± 0.20, did not significantly impact toxicity
(Fig 2-13B, p=0.09).

MJDnQ78 was less toxic, with a mean of 6.72 ± 0.07
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photoreceptors per ommatidium (Fig 2-13C).

Hsp104 co-expression significantly

enhanced toxicity, with now only 2.60 ± 0.17 photoreceptors per ommatidium (Fig 2-13C,
p<0.001). Hsp70 significantly suppressed toxicity of both disease proteins (Fig 2-13B,
p<0.001, Fig 2-1C, p=0.002). These results generally reflected the trends in toxicity we
observed for the 1xgr-Gal4 driver, although we did not confirm the trend of Hsp104mediated suppression of MJDtrQ78 toxicity.

Figure 2-13 MJD toxicity to
photoreceptor neurons
The pseudopupil assay, performed
by expressing disease protiens
with the rh1-Gal4 driver and
examining at d18, quantifies the
number of intact photoreceptor
neurons in each ommatidial
cluster. (A) Control flies and those
expressing Hsp104 or Hsp70
alone had no loss of photoreceptor
rhabdomeres, indicating that these
proteins have no toxicity.
(B)
MJDtrQ78 showed strong toxicity
and Hsp104 co-expression did not
significantly alter photoreceptor
loss. However, Hsp70 strongly
suppressed MJDtrQ78 toxicity. (C)
MJDnQ78 had milder toxicity, but
Hsp104 co-expression significantly
enhanced
degeneration
of
photoreceptor cells. Again, Hsp70
suppressed toxicity. The number
of
photoreceptors
in
each
ommatidial cluster was evaluated
by ANOVA (n=10 (mean ± SEM)).
**p=0.001-0.01,
***p<0.001;
Statistics compare HSP coexpression conditions to disease
protein alone.
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Next, we also performed the complementary investigation, evaluating protein
aggregation in the 1xgr-Gal4 system. Due to technical limitations, it was not possible to
perform IHC on these retinas, so we conducted SDD-AGE and Western immunoblot
analysis. Our results show that Hsp104 does not alter the overall kinetics of MJDtrQ78
amyloid aggregation (Fig 2-14A).
MJDtrQ78

We observed that Hsp104 increased the total

amyloid

load,

but

hypothesized

that

this may be due to
increased

tissue

integrity.

To

address

this,

normalized

to

we
the

rhodopsin signal as
an indicator of total
amount

of

eye

tissue and saw that
there

was

significant
between

no

change
untreated

and Hsp104-treated
MJDtrQ78

amyloid

Figure 2-14 Aggregate analysis using 1xgr-Gal4
With the rh1-GAL4 driver at indicated time points, SDD-AGE and
Western immunoblot analysis show the progression of amyloid formation
of MJDtrQ78 (A) and MJDnQ78 (B) proteins over time. Hsp104 did not
greatly affect the aggregation profile of MJDtrQ78 but enhanced
formation of SDS-insoluble amyloid aggregates of MJDnQ78. The
formation of large, SDS-insoluble aggregates by SDD-AGE
corresponded with the disappearance of SDS-soluble soluble protein
from immunoblots. MJDtrQ78 and MJDnQ78 were detected using antiHA and anti-myc, respectively, with anti-rhodopsin as a tissue level
control and anti-tubulin as a loading control. Band density for both
amyloid smears (SDD-AGE) and soluble bands (Western blot) were
quantified using ImageJ; presented both as raw values and as adjusted
to rhodopsin signal to normalize for tissue level (n=3 (mean ± SEM)).
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accumulation (Fig 2-14A).

This is consistent with our conclusions presented in the

Chapter 2, but rh1-Gal4 evaluation of aggregation allows more sensitive observations
using IHC.

Our results also show that Hsp104 co-expression greatly increases the rate and extent
of MJDnQ78 amyloid aggregation (Fig 2-14B).

Again, analysis of rhodopsin levels

confirms that eye tissue is lost in the Hsp104 condition; however the adjusted MJDnQ78
amyloid load is still greatly increased upon Hsp104 co-expression (Fig 2-14B). This is
consistent with the aggregation pattern as analyzed using the rh1-Gal4 driver.

In

summary, these data confirm that the conclusions (presented in Chapter 2) drawn from
1xgr-Gal4-driven eye tissue toxicity and rh1-Gal4-driven protein accumulation analysis
appear appropriate.
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CHAPTER 3 : CONCLUSIONS

CONCLUSIONS AND IMPLICATIONS OF HSP104 AS A THERAPEUTIC AGENT.
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Hsp104 is influenced by the flanking sequence surrounding the PolyQ domain
We have established that Hsp104 and MJD have a profound genetic interaction in
Drosophila, and that the resulting impact of Hsp104 treatment on the severity of MJDdriven degeneration may be either ameliorative or detrimental. Surprisingly, it was not
the aggregation-prone PolyQ domain that determined the outcome of Hsp104 treatment,
but, rather, successful remodeling by Hsp104 was dictated by the surrounding domains
within the MJD protein.

An expansion in the PolyQ region was required for the

development of MJD toxicity, but Hsp104 could either mitigate or exacerbate MJDassociated degeneration, depending on protein context.

It is well established that PolyQ flanking sequence is able to influence PolyQ
aggregation rate (Wetzel, 2012).

For exon 1 of Htt, inclusion of the polyproline

sequence C-terminal to the PolyQ domain slows amyloid growth and prevents β-sheet
formation (Richardson and Richardson, 1989, Bhattacharyya et al., 2006, Lakhani et al.,
2010, Dlugosz and Trylska, 2011). Conversely, the N-terminal region forms α-helical
conformations that associate into tetramers, which may nucleate PolyQ-mediated
amyloidogenesis (Thakur et al., 2009, Atwal et al., 2011, Jayaraman et al., 2012, Wetzel,
2012). Despite the changes to kinetics conferred by these complex flanking sequences,
the resulting Htt-exon1 amyloid core has similar biochemical properties to a pure PolyQ
sequence of same repeat length that is minimally flanked by lysines, K2QNK2 (Thakur et
al., 2009, Sivanandam et al., 2011).

Therefore, we did not anticipate that flanking

sequence would impact an agent that disrupts the PolyQ aggregation core.
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To examine the role of flanking sequence in our studies of the MJD protein, we must
consider the distinct modulatory outcomes resulting from Hsp104 coexpression. The
truncated C-terminal MJD fragment comprised mainly of the expanded PolyQ region
(MJDtrQ78) caused severe eye toxicity, and co-expression of Hsp104 ameliorated the
associated retinal degeneration (Fig 2-2). Hsp104 therefore suppressed toxicity, but did
not do so by altering the amount of SDS-resistant aggregates formed by MJDtrQ78 (Fig
2-3). In contrast, the full-length MJD protein with expanded PolyQ (MJDnQ78) also
conferred toxicity to the fly eye, but co-expression of Hsp104 strikingly increased the
severity of the retinal degeneration (Fig 2-2), which corresponded to a dramatic
acceleration in the formation of MJDnQ78 amyloid-like inclusions (Fig 2-3). Our results
reveal that the presence or absence of the N-terminal Josephin domain and UIMs
dramatically impacted the interaction between MJD and Hsp104.

Because these

specific experiments were performed with concomitant expression, it is not possible to
conclude whether Hsp104 is altering early oligomerization stages or differentially
approaching the PolyQ aggregation core.

Hsp104 efficacy depends on precise protein context
It was unexpected that two variants of the same protein that contain identical
aggregation domains would have such distinct outcomes following Hsp104 treatment.
We therefore studied a collection of MJD variants with various functional and structural
deficiencies to the domains neighboring the PolyQ domain to determine which portions
of the full-length MJD protein caused Hsp104 to not only fail to suppress toxicity but to
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enhance it. Because this set of variants contains domains inactivated through point
mutations, the role of each domain’s function can be separated from its contribution as a
flanking sequence.

Because MJD has deubiquitylase (DUB) activity in the N-terminal Josephin domain and
this is known to contribute to proteostasis, elimination of DUB function confers a more
severe toxicity than is caused by pathogenic MJD with intact DUB activity (Warrick et al.,
2005). We examined two separate MJD variants that lack DUB function, through either
point mutation or exon deletion. The severe degeneration caused by the MJD variant
with mutation of the catalytic residue, MJD-Q88-C14A, was not suppressed by coexpression of Hsp104. However, the toxicity of MJD with a deletion of exon 2 (a.a. 963), MJD-Q79-Δexon2, which is missing the catalytic residue as well as a large
structural component of the Josephin domain, was strongly suppressed by Hsp104 (Fig
2-5).

The distinct outcomes of Hsp104 treatment on DUB-deficient MJD variants inactivated
by either C14A or Δexon2 modifications indicate that some feature contained within exon
2 is hindering proper Hsp104 function.

The α-helices α1, α2, and α3 are a large

structural component of the Josephin domain and are noticeably absent in the Δexon2
construct (Fig 3-1, gray). Thus, these helices could be inhibiting Hsp104 due to the
structural stability conferred by these α-helices. We think this is unlikely due to Hsp104’s
ability to remodel an abundance of diverse substrates, but it is possible that the
presence of these highly stable structures could slow down the Hsp104 enzymatic
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activity so the remodeling kinetics
favor

increased

polymerization
resolubilization.

amyloid-like
rather

than

We think it more

likely that Hsp104 is impeded by an
interaction

between

the

flexible

helical hairpin formed by α2 and α3 Figure 3-1 Structure of Josephin domain
Crystal structure of the Josephin domain, 1YZB in
The catalytic residue responsible for DUB
activity is C14, highlighted in red, with the necessary
coordinating amino acids in blue. The amino acids
contained in exon 2 (a.a. 9-63) are designated by gray.
Notice that the Δexon2 MJD lacks α-helices α1, α2,
and α3, which make a large structural component of
the Josephin domain. The poly-ub entry sites to the
catalytic active site are located along α4 and are
highlighted in magenta. It is thought that poly-ub
chains line up along the α2 and α3 coils to gain access
to the entry sites

of MJD and a poly-ub chain, which PDB.
may coordinate along this finger-like
protrusion to enter the active site
(Fig 3-1, magenta) (Nicastro et al.,
2005). Thus, without this structural
component to associate with poly-

ub chains, the MJD-Q79-Δexon2 would be more flexible and therefore amenable to
Hsp104 remodeling, but MJD-Q88.C14A, with its Josephin domain tethered by a poly-ub
chain, would not.

It is also worth noting that the initial Josephin-driven oligomerization steps may be
disrupted upon deletion of the structural component encoded by exon 2 of MJD. It is
difficult to interpret the results of this variant because the protein was undetectable by
antibody; we do not know if inclusions were formed at all. Immunohistochemistry with αHsp70/Hsc70 to visualize the endogenous Hsp70 that colocalizes with aggregates
demonstrated that neither MJD-Q79-Δexon2 nor MJD-Q79-Δexon2 co-expressed with
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Hsp104 contained accumulations (data not shown). It is possible that non-aggregated,
monomeric protein is itself a toxic species (Zoghbi and Orr, 2000, Wetzel, 2012), and if
the MJD protein cannot oligomerize via the Josephin domain, this may be conferring the
observed toxicity. The PolyQ domains contained within soluble monomers is known to
collapse in on itself in solution (Crick et al., 2006), so if this is occurring for MJD,
remodeling by Hsp104 might be able alleviate the protein toxicity without the
involvement of large protein aggregates. This is purely speculative at this point, but in
vitro experiments could be helpful in determining the oligomerization capacity of MJDQ79-Δexon2 and therefore refine our model of its interaction with Hsp104.

The Ubiquitin-Interacting Motifs (UIMs) are also important for the DUB function of MJD,
as they bind the poly-ub chain and direct it toward the Josephin domain active site.
Consistent with our hypothesis of poly-ub involvement, we additionally found the UIMs to
be critical in modulating MJD disease suppression by Hsp104. Pathogenic MJD with
mutations to the ubiquitin-binding residues of the UIMs, MJD-Q80-UIM*, conferred mild
toxicity, and co-expression of Hsp104 did not worsen the degeneration, as it did for
expression-matched full-length MJD with competent UIMs, MJDnQ84 (Fig 2-5). More
strikingly, the combination of the Josephin active site mutation C14A to abolish DUB
activity combined with UIM mutations, MJD-Q80-C14A-UIM*, caused much stronger
degeneration, and co-expression of Hsp104 provided a strong suppression of toxicity.
Hsp104 was not able to suppress toxicity of MJD with the Josephin mutation alone,
MJD-Q88-C14A (Fig 2-5). We also observed that Hsp104 again promoted aggregation
of MJD variants with intact UIMs, but solubilized SDS-resistant aggregates of MJD
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variants with mutated UIMs (Fig 2-5).

Thus, we conclude that regardless of DUB

functionality, active UIMs that are capable of binding poly-ub chains block the
accessibility of MJD to Hsp104 remodeling.

Other features of MJD were determined to be unrelated to the negative interaction
between MJD and Hsp104 (see Table I-4). We therefore constructed a model in which
the Josephin domain and the UIMs are both required to induce the adverse outcome of
Hsp104 treatment (Fig 3-2). We propose that an interaction between the two domains,
potentially mediated through mutual binding of a poly-ub chain, creates a structural
hindrance that Hsp104 is unable to effectively process, thus driving an enhancement of
protein aggregation and associated toxicity.

Figure 3-2 Model of Hsp104
effect on MJD variants
We have created a model of
how the MJD protein may look
based on the organization of
domains:
Josephin domain
(gray), UIMs (blue), and PolyQ
(purple), with a poly-ub chain
(green) added to demonstrate
functional binding of the UIMs.
With these representations, it
is easy to see the formation of
a
structural
connection
between the Josephin domain
and the UIMs, potentially
mediated by reciprocal binding of a poly-ub chain. This connection is designated with red circles
to highlight the closed loop formed between the domains. We hypothesize that Hsp104 is unable
to process MJD due to this connection and thus worsens aggregation and toxicity. In contrast,
this inflexible conformation is not present if the UIMs are mutated (UIM*) or if a portion of the
Josephin domain is removed (Δexon2), thus facilitating productive interactions with Hsp104.
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How does Hsp104 drive aggregation of Full-length MJD?
To expand upon the actual mechanism by which the closed loop formed by intact MJD
domains obstructs Hsp104 remodeling, we have incorporated other biochemical data
about MJD amyloidogenesis into a more detailed mechanistic model. Previous in vitro
experiments have established that MJD forms aggregates in a two-step process, first
forming
linear

SDS-soluble
polymers

associating
Josephin

via
domain

by
the
and

then converting to SDSinsoluble amyloid fibrils Figure 3-3 Model of two-step aggregation of MJD
Summary of in vitro studies demonstrating that MJD aggregates in

driven by the expanded a two-step process. MJD first forms SDS-soluble linear polymers

by associating via the Josephin domain and then converts to SDS-

PolyQ domain (Fig 3-3) insoluble amyloid fibrils driven by the expanded PolyQ domain.
(Masino et al., 2004, Ellisdon et al., 2006, Ellisdon et al., 2007). We therefore propose
that these SDS-soluble Josephin-driven polymers are also formed by MJD in vivo and
initiate remodeling by Hsp104. This fits well with our observations regarding aggregation
kinetics in vivo, with amorphous, SDS-soluble MJDnQ78 accumulations appearing by
IHC before the SDS-insoluble amyloid-like material by SDD-AGE (Fig 2-3). In fact, this
Josephin association may actually initiate Hsp104 remodeling, as the disaggregase does
not remodel natively folded substrates (Doyle et al., 2007).

We speculate that MJD is affected by Hsp104 translocation differently depending on the
presence of the connection between the Josephin domain and the UIMs.
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When a

structural inflexibility is formed by this “closed loop” in intact MJD, Hsp104 is unable to
fully translocate the protein and, in the process, exposes the PolyQ domain to accelerate
the formation of toxic PolyQ-driven amyloid-like inclusions (Fig 3-4 A). This would be
akin to the in vitro finding that addition of a pure PolyQ fragment recruits full-length MJD
to bypass Josephin-driven aggregation and immediately join the PolyQ-driven amyloid
fibril (Haacke et al., 2006). In contrast, we propose that when the closed loop is absent
in the UIM* or Δexon2 variants, the MJD protein is successfully translocated and
aggregates are resolved (Fig 3-4 B).

Figure 3-4 Model of differential interaction
between Hsp104 and MJD
A. The closed loop between the Josephin
domain and the UIMs in intact MJD hinders
Hsp104 remodeling. We propose that MJD
starts as Josephin-driven aggregates in vivo, as
observed in vitro, which initiates Hsp104
remodeling. The structural constraint between
the Josephin domain and the UIMs prevents (or
slows) successful Hsp104 translocation, which
exposes the PolyQ domain to allow rapid
accumulation of amyloid-like accumulations,
causing severe toxicity.
B. MJD variants lacking the closed loop are
successfully remodeled by Hsp104. Again, we
propose that MJD starts as Josephin-driven
aggregates, but because there is no association
between the Josephin domain and the UIMs, the
MJD protein is efficiently translocated by
Hsp104. This results in fewer aggregates, which
correspond to reduced toxicity.

We have therefore constructed specific molecular models to describe the protein-protein
interactions between Hsp104 and MJD using results from genetic interactions in
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Drosophila. While this model is consistent with our observations (see Chapter 2), we
have not directly tested it experimentally. Pure protein disaggregation assays with MJD
variants containing the UIM mutations would be an ideal approach to probe this
interaction. Specifically, it will be important to determine whether Hsp104 has distinct
modes of action on MJDtrQ78 versus MJDnQ78 with purified components in vitro.
Hsp104 has been shown to disaggregate pre-formed amyloid fibrils of a pure PolyQ
repeat (DeSantis et al., 2012), so we anticipate that Hsp104 will effectively eliminate
MJDtrQ78 fibrils with its minimal flaking sequence. However, we suspect that outside of
its cellular context, Hsp104 will not drive aggregation of MJDnQ78 in vitro due to the
absence of poly-ub chains. The addition of purified poly-ub chains to the reaction would
allow us to investigate whether the formation of a closed loop through mutual poly-ub
binding between specified domains of MJD is indeed driving Hsp104-mediated
aggregation; introduction of UIM mutations would preclude this negative interaction.

Further research is required to extend these findings to other disease proteims. Note
that co-expression of Hsp104 suppressed the toxicity of truncated MJD without
eliminating the amount of SDS-insoluble aggregates (see Fig 2-2, 2-3).

Moreover,

activation of Hsp104 subsequent to the appearance of MJDtrQ78 aggregates actually
increased aggregate accumulation (see Fig 2-11), which was associated with greater
tissue survival (see Fig 2-10). The reason for this ameliorative effect is unknown, but
may be due to interactions with soluble oligomers, among other possibilities (see
Chapter 2 for full discussion). Critically, this result demonstrates that increased load of
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amyloid-like accumulations is not always deleterious, and that subtle biochemical
changes can be sufficient to eliminate toxicity of aggregation-prone proteins.

Implications of modulating protein inclusions
It is generally thought that reducing the burden of amyloidogenic conformers might
prevent the cascade of pathological insults that occur in protein-aggregation disease
(Hardy and Selkoe, 2002). Indeed, in a mouse model of AD, the rapid occurrence of
large protein aggregates was toxic to neighboring cells (Meyer-Luehmann et al., 2008),
indicating that this is a critical mediator of pathogenicity. It is therefore intuitive that
reversing large inclusions may alleviate pressure on cells. Moreover, merely turning off
expression of PolyQ-htt using the tet-inducible system in mice has reversed the nuclear
and cytoplasmic aggregates, and this also alleviated behavioral symptoms (Yamamoto
et al., 2000).

Therefore, eradicating amyloid-like accumulations might offer greater

benefit than simply preventing further addition to the aggregate, suggesting that the
disaggregase activity of Hsp104 may be more powerful than the chaperoning activity of
Hsp70. Critically, in targeting these aggregated species, any therapeutic must prevent
the release of soluble, toxic oligomers from the fibrillar aggregate (Koffie et al., 2009).
Therefore, an agent capable of dismantling both fibrils and oligomers would be ideal,
again bringing focus onto Hsp104.

Our staging experiments determined that Hsp104 prevented tissue degeneration when
expressed subsequent to onset of expression of MJDtrQ78, effectively halting tissue loss
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while actually promoting accumulation of SDS-insoluble protein accumulations. It will be
critical to understand the source of toxic species in vivo, because in this case, Hsp104 is
not acting as a disaggregase.

We have considered alternate modes of action by

Hsp104, such as interactions with soluble oligomers, but our results highlight that
elimination of amyloid-like inclusions is not required to alleviate protein-associated
toxicity. Further detailed characterization of the mechanism by which Hsp104 prevents
tissue degeneration would be insightful for further development of Hsp104 as a
treatment tool.

Moreover, additional limitations of Hsp104 must be considered.

Hsp104 has been

shown to spontaneously promote oligomerization of a yeast prion, and low levels of
Hsp104 generally stimulate amyloid fibril formation (Shorter and Lindquist, 2004, 2006).
This occurs because high levels of Hsp104 efficiently resolubilize amyloid fibrils, but low
levels break fibrils into smaller pieces. This activity is critical in the physiological function
of Hsp104 in maintaining yeast prion states, as it promotes heritability of the fibril into
daughter cells (Wegrzyn et al., 2001, Shorter and Lindquist, 2006). However, exposing
more replicative ends might have catastrophic consequences in a disease state, and
could seed unimpeded growth of protein inclusions. Additionally, consistent with the
model of our results in Drosophila (Chapter 2), inefficient or incomplete translocation of
substrates might expose previously shielded aggregation domains and thus stimulate
the protein aggregation cascade and accompanying toxicity. A better understanding of
mechanism will be critical in evaluating the interaction between Hsp104 and protein
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inclusions in vivo and to evaluating its full and complete potential as a disruption agent to
protein aggregation disease.

Evaluating Hsp104 as a treatment for protein aggregation disease
As discussed, Hsp104 presents limitiations in treating protein aggregation disease in
vivo at this time; however, with further development, the potential issues surrounding
Hsp104 treatment might be suppressed or minimized by optimizing the chaperone for a
disease environment. The chaperonin GroEL has been optimized by alterations to the
folding chamber to maximize refolding of particular substrates (Tang et al., 2006).
Similar tailoring of Hsp104 may allow it to preferentially contact particular diseaseassociated substrates and avoid nonspecific remodeling of benign proteins. Changes
among subunit collaboration or to the ATPase rate of Hsp104 may also eliminate
unintended negative interactions with obstinate substrates by increasing the unfolding
power.

However, such an alteration might increase overall remodeling activity, and

therefore enhance off-target effects; these modifications would likely need to be paired
with substrate-optimization. Further, the complication of amyloid fibril strains may pose
a problem in a disease setting; certain fibril strains are more difficult to eradicate and,
moreover, certain strains are associated with stronger toxicity (Tanaka et al., 2006,
Nekooki-Machida et al., 2009, DeSantis and Shorter, 2012).

Promisingly, Hsp104

coordinates subunits to tackle even difficult strain conformations (DeSantis et al., 2012),
and identifying features of Hsp104 that result in optimized activity against these stubborn
strains in screens of Hsp104 mutant libraries is ongoing.
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A critical feature of Hsp104 function in yeast is that the remodeled substrate is able to
regain its native conformation and resume physiological activity (Patino et al., 1996,
Shorter and Lindquist, 2004). However, it is less clear that this is a desirable outcome in
neurodegenerative disease. For example, in AD, tau is a microtubule-binding protein, so
recovering protein monomers from an amyloid inclusion might restore lost function. On
the other hand, the Aβ peptide, which also accumulates in amyloid aggregates in AD, is
an aberrant cleavage product with no known function, so elimination of the peptide may
be preferable to release of monomer, which rapidly reassociates with existing
assemblies (Cohen et al., 2013).

A variant of Hsp104, known as HAP, physically

couples to the bacterial proteolytic chamber ClpP such that any substrates translocated
by HAP are fed directly into ClpP and degraded (Tessarz et al., 2008). Thus, an Hsp104
variant optimized for tau might restore functional tau protein while an Aβ-optimized HAP
variant might eliminate Aβ altogether. Moreover, administration of the HAP/ClpP system
in vivo might prevent unintended deleterious effects of Hsp104 treatment (e.g.,
promoting MJDnQ78 aggregation) by eliminating amyloid accumulations without
stimulating

any

off-target

translocation by Hsp104.

seeding

or

inadvertent

protein

misfolding

following

Thus, we envision that disease-specific treatments with

Hsp104 are possible, and may in fact be preferable to the broad remodeling activity for
which Hsp104 is known.

Our results underscore that understanding the exact nature of the disease state will be
critical in designing therapies.

For example, truncation of MJD is thought to initiate
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pathogenesis in SCA3/MJD because it exposes the templating PolyQ region to drive
amyloid formation (Haacke et al., 2006, Haacke et al., 2007). In this case, application of
Hsp104 may be very useful in the initiating phases of SCA3/MJD in which Truncated
MJD prevails, as Hsp104 was found to suppress early MJDtrQ78 aggregation and
impede toxicity, but Hsp104 application would be detrimental when Full-length MJD is
recruited to the aggregates. This may not be insurmountable, as addition of a co-agent
to disrupt poly-ub binding could potentially unleash Hsp104 remodeling power, as
observed for the UIM* variants. Because of the complicated set of interactions within the
cell and the diverse composition of aggregates in vivo, Hsp104 may need to be modified
before it is able to tackle all components of the disease environment effectively.

Our results indicate that Hsp104 expression should be controlled in an animal system.
Previous studies have expressed Hsp104 in a variety of metazoan systems with no
deleterious effects (Satyal et al., 2000, Vacher et al., 2005, Dandoy-Dron et al., 2006,
Perrin et al., 2007, Lo Bianco et al., 2008), and moreover, Hsp104 was seen to confer
beneficial stress resistance to mammalian cells (Dandoy-Dron et al., 2006). Therefore, it
has been perplexing that Hsp104 was not evolutionarily conserved to metazoans, and
our result that sustained high levels of Hsp104 can cause cytotoxicity may provide a
reason for this loss. In yeast, Hsp104 levels are tightly regulated; Hsp104 is not detected
under normal growth conditions, but expression is rapidly induced upon heat stress
(Sanchez and Lindquist, 1990), which is consistent with the notion that high basal levels
are not desirable. In fact, even the inducible Hsp70 that is endogenous to Drosophila is
tightly controlled when not needed, and forced high expression causes a growth defect
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to Drosophila cells (Feder et al., 1992). Therefore, careful control of expression, rather
than indiscriminate upregulation, may be required to harness Hsp104 as a therapeutic.

The administration of a foreign protein such as Hsp104 as a treatment to humans
currently depends on gene therapy, a technique that still requires much optimization.
Further, there are additional complexities as noted surrounding Hsp104 action, which
must be addressed to present the protein as a potential therapeutic option. We have
presented ideas to circumvent some of these problems. However, our results, which
were unpredicted, suggest that introduction of Hsp104 into the complex disease
environment requires caution. We observed that Hsp104 suppressed the toxic effects of
MJDtrQ78 when expressed concomitantly and in staged experiments, but we also
discovered that Hsp104 was capable of enhancing degeneration induced by MJDnQ78.
Further, the mechanism by which Hsp104 is alleviating toxicity is still unknown.
Regardless, Hsp104 remains a powerful tool to examine the biological and biochemical
effects of disrupting existing aggregates in animal models.

Conclusions
The use of molecular chaperones and heat shock proteins may be a valuable approach
to combating protein aggregation diseases and intractable amyloid disorders. In such
diseases, patient presentation of symptoms often indicates advanced pathology.
Therefore, a molecule such as Hsp104 that can target existing protein assemblies may
be better suited to tackling pre-existing disease-associated protein aggregation than a
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fold-promoting chaperone such as Hsp70 (Chapter 2). Because of the nature of the
disease environment, true reversal of the pathological amyloid-like inclusions might have
multi-fold benefits: relief of mechanical burden on the cells, elimination of a reservoir
able to release soluble oligomers, termination of the capture and conversion of native
monomers, and containment of pathology to existing regions, to name a few. Therefore,
because of its ability to remodel pre-existing amyloidogenic conformers, Hsp104
emerges as a unique potential treatment that warrants further characterization.

Because of the issues surrounding protein resolubilization, concomitant expression of a
therapeutic molecule is not sufficient to evaluate the potential medicinal application of
molecular chaperones and heat shock proteins. Prevention of disease by a treatment
that coincides with pathogenicity is distinct from disease reversal by a treatment
occurring after pathogenesis is underway. While prevention of disease is likely the most
effective way to preserve nervous system structure and function, it is not feasible without
advances in biomarker identification and improved diagnostic capabilities.

Current

limitations in identifying disease onset prior to symptom onset require an intervention to
modulate existing disease pathology. In animal models, gene expression technology
that allows staged activation of specific molecules should be utilized to understand how
controlled expression affects disease progression once it is underway. Our results in
Drosophila demonstrate for the first time that Hsp104 can indeed halt SCA3/MJDassociated tissue degeneration once it has begun.

This serves as a first step in

evaluating molecular modulators of disease in a true therapeutic setting, but the capacity
to modulate pre-existing disease must be tested in other model systems and for other
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protein aggregation diseases. In particular, the existence of the tetracycline-inducible
system in the mouse calls for detailed analysis of Hsp104 as a disease modulator in a
mammalian system. Coupled with the identification of Hsp104 features that enhance
anti-amyloid activity, such studies may provide unique, tailored therapies for the distinct
diseases of the nervous system.
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APPENDIX I : ADDITIONAL FLY RESULTS

EXPRESSING HSP104 IN THE FLY
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In order to test the capacity of Hsp104 to modulate protein aggregation disease in vivo,
we created an Hsp104 transgenic fly.

We unexpectedly observed that Hsp104

expressed on its own had toxicity in the fly eye. We therefore wanted to explore and
characterize this effect, presented in Part 1. After tuning Hsp104 expression for the fly,
we conducted two genetic screens to see if Hsp104 had any impact on degeneration
caused by proteins associated with human neurodegenerative disease. Although the
most intriguing interaction with MJD is defined in Chapter 2, we document the full results
of the genetic screens here, in Part 2. Finally, to gain further understanding of how
Hsp104 functions in an animal system, we created two mutant Hsp104 transgenic lines.
An inactive Hsp104, DPLDWB, and an increased activity mutant, A503V, are described
and characterized in Part 3.
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PART 1. Creating an Hsp104 fly
Background
Previous attempts to create an Hsp104 transgenic fly were unsuccessful, with
expression levels too low to detect. Therefore, we modified the Hsp104 gene before
creating the plasmid. First, we added a Kozak sequence prior to the AUG start codon to
enhance translation of the mRNA.

We selected the sequence ACAAA for optimal

expression in Drosophila (Trinh et al., 2008).

Next, we used GenScript to have the gene codon-optimized for expression in
Drosophila. Between species, there are differences in the relative abundancy of tRNAs
that each correspond to a codon. For example, the synonymous codons ACG, ACA,
ACT, and ACC all
encode the amino
acid Threonine, but
the tRNA associated
Figure I-1 Codon optimization of Hsp104

with ACT is most The relative frequency specific to Drosophila for each codon is plotted
common

in

against the relative position of the codon. A higher frequency (more

yeast white) indicates that the codon corresponds to a tRNA that is more

readily available in the fly. Before optimization, the Codon Adaptation

and ACC tRNA is Index (CAI) was 0.56, suggesting that the sequence was only half of its
more

available

potential optimum efficiency. After optimization, the CAI of the gene
in was boosted to 0.98, which suggests it will be more efficiently translated
in the fly.

Drosophila. Therefore, a gene such as Hsp104 that is adapted for expression in yeast
might be limited by available tRNAs in Drosophila.

Accordingly, exchanging a rare

codon for one more common in Drosophila can enhance translation speed and
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efficiency. Our initial Hsp104 sequence had a Codon Adaptation Index (CAI) of 0.56,
indicating that the sequence has only 56% similarity to the most efficient sequence for
the fly. After optimization, the CAI jumped to 0.98, demonstrating that almost every
codon was maximally available (Fig I-1).

Not all sites could be optimized to the

maximum frequency in order to prevent introduction of restriction cleavage sites.

We had the optimized gene synthesized by GenScript, with the ACAAA Kozak sequence
prior to the start codon (the full sequence is listed in Chapter 2). We used restriction
sites XhoI and XbaI to insert the gene into the pUAST vector for injection into the fly,
which was performed by Genetic Services.

Multiple independent Hsp104 lines were obtained. The transgenes were mapped and
balanced:
Table I-1 WT Hsp104 lines

Line:
1.1
2.1
4.1
5.1
6.1
7.1

Chromosome:
X
3
X
X
3 (/Sb)

Description
Possibly two transgenes [not used]
Weak
Weak
Strong
Strong; cannot go homozygous
Floating transgene [not used]

To characterize expression level, the Hsp104 gene was expressed in the eye by the
gmr-Gal4 driver and analyzed by Western blot (Fig I-3). In the course of characterizing
these lines, we unexpectedly discovered that Hsp104 expression disrupts the fly eye.
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High expression of Hsp104 may be harmful
To determine relative levels of Hsp104 among the lines, the gene was expressed in the
eye by the gmr-Gal4 driver. In doing so, we discovered that Hsp104 expression caused
a slight eye disruption to the
weak lines, 2.1 and 4.1, and
noticeable degeneration to the
strong lines, 5.1 and 6.1 (Fig I2A).

Paraffin

confirmed

sections

dramatic

toxicity

through loss of retinal integrity
caused by Hsp104 expression
by

gmr-Gal4

Because

(Fig

I-2A).

gmr-Gal4

has

multiple copies of the glass
element

driving

Gal4
Figure I-2 Hsp104 causes eye degeneration

expression,

we

used

a A. Hsp104 driven by gmr-Gal4 is toxic. The weak Hsp104

reduced driver with only one
copy of the glass element,
1xgr-Gal4.

This

driver

reduced the impact of Hsp104
on eye morphology, with the

lines, 2.1 and 4.1, displayed slight disruption to the external
eye and structural impairments to the retina. The strong
lines, 5.1 and 6.1, had visible degeneration with necrotic
patches on the eye and severely disorganized retinal
structure.
B. Hsp104 driven by the reduced driver 1xgr-Gal4 is less
disruptive to the eye. Strong Hsp104 lines, 5.1 and 6.1, had
much improved retinal organization. The weak lines, 2.1 and
4.1, had only minimal impact on the eye, with normal cellular
organization within the retina and no disruption visible in the
external eye.

strong lines, 5.1 and 6.1, impairing retinal structure but with minimal effect contributed by
the weak lines, 2.1 and 4.1 (Fig I-2B). As such, using the 1xgr-Gal4 driver with a weak
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line of Hsp104 were used to evaluate the efficacy of Hsp104 in mitigating disease (see
Chapter 2).

Figure I-3 Hsp104 expression level corresponds with severity of degeneration
Western immunoblots were performed for each Hsp104 line driven by either gmr-Gal4 or 1xgrGal4. Quantification was performed in ImageJ and each Hsp104 band was normalized to actin as
a loading control. n=3, Mean±SEM. The eye image and retinal section for each genotype
presented in Fig I-2 was arranged to correspond with increasing expression level. In this manner,
it became very apparent that the correspondence between higher Hsp104 expression level and
increased severity of eye defect.

Because lowering Hsp104 expression with the reduced driver minimized the effect of
Hsp104 on the eye, we wanted to thoroughly associate protein expression level with
degree of disorganization in the retina.

Quantitative Western immunoblots were
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performed to compare Hsp104 expression level among the different lines with both 1xgrGal4 and gmr-Gal4 drivers (Fig I-3A). To evaluate the impact of increased expression
level, the eye images and retinal sections from Fig I-2 were arranged in order of
increasing Hsp104 signal intensity.

It is very apparent that high expression level

corresponded with increased severity of degeneration (Fig I-3B). Thus, our attempts to
boost expression by codon-optimizing the gene and adding a Kozak sequence may have
been too successful; the high levels of expression must be dialed back using the
reduced 1xgr-Gal4 driver to minimize the toxic effect of Hsp104.

We were not anticipating any disruption caused by Hsp104.

Previous studies have

examined Hsp104 expression in various model systems, including C. elegans, mouse,
and rat (Satyal et al., 2000, Vacher et al., 2005, Dandoy-Dron et al., 2006, Perrin et al.,
2007, Lo Bianco et al., 2008).

Moreover, Hsp104 expression actually conferred

beneficial protective effects in mammalian cell culture (Dandoy-Dron et al., 2006).
Therefore, we had no indication that Hsp104 may be toxic in an animal system. Further,
we also examined an inactive Hsp104 that is unable to hydrolyze ATP and is incapable
of binding substrate, Hsp104 DPLDWB. This inactive Hsp104 had no negative impact
on the retina (see Chapter 2 and Fig I-9), confirming that the toxic effect is dependent on
Hsp104 activity. We were unsure why we observed an activity-dependent deleterious
effect of Hsp104 expression while others have not.
expression levels we achieved?

Is this toxicity due to the high

Is this effect specific to the fly, or even more

specifically, the fly eye?
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To address this, we crossed a strong line, Hsp104 6.1, a weak line, Hsp104 2.1, and an
inactive Hsp104 line, DPLDWB 2.1, to several driver lines to induce expression in
multiple systems. Amongst all drivers, a similar pattern emerged that Hsp104 6.1 was
harmful and the effect of weak-expressing Hsp104 line, 2.1, was milder in degree,
suggesting that the damage is dose-dependent.

Moreover, the inactive Hsp104

DPLDWB had no effect on any system (Table I-2), confirming the necessity of active
remodeling in conferring toxicity.

Strikingly, Hsp104 6.1 was lethal when expressed

ubiquitously (da-Gal4), pan-neuronally (elav-Gal4), or in all muscle cells (24B-Gal4).
Ubiquitous expression of the weaker Hsp104 2.1 was also lethal, but lethality was not
complete when expressed in muscle cells (Table I-2).

Interestingly, Hsp104 2.1

expressed pan-neuronally had no obvious toxicity; the flies eclosed, survived, and
produced progeny (Table I-2). This result indicates that further experiments could be
performed using the elav-Gal4 neuronal driver, such as performing Kaplan-Meier
survival curves to evaluate efficacy of Hsp104 as a therapeutic for disease toxicity.

Table I-2 Toxicity of Hsp104 in multiple systems

Effect of:
Driver name:

Expression
System:

gmr-GAL4

WT Hsp104 2.1
(Weak)

WT Hsp104 6.1
(Strong)

DPLDWB
Hsp104 2.1

eye

Mild
degeneration

Severe
degeneration

No effect

da-GAL4

ubiquitous

Lethal
(pupae)

Lethal
(larvae)

No effect

elav-GAL4

pan-neuronal

No effect

Lethal
(early larvae)

No effect
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24B-GAL4

Semi-lethal
(~10% escape)

pan-muscle

Lethal
(larvae/pupae)

No effect

Hsp104 expression results in aggregation of protein
We wanted to begin to characterize the mechanism of Hsp104 in causing degeneration
on its own. Because of Hsp104’s unique disaggregase activity, we hypothesized that
Hsp104 may be indiscriminately remodeling endogenous proteins or protein complexes,
thus disrupting the normal homeostasis of the eye. To investigate this, we examined
whether Hsp104 caused general protein
aggregation

by

using

immunohistochemistry (IHC) to probe for
the existence of protein accumulations with
an

antibody

Drosophila

against

endogenous

Hsp70/Hsc70,

which

colocalizes with aggregates.

Figure I-4 Hsp104 drives aggregation
A. Retinal sections probed by IHC reveal protein
aggregates in tissue expressing Hsp104. An
antibody against endogenous Hsp70/Hsc70 was
used because it colocalizes with protein
aggregates (red) and tissue was counterstained
with Hoechst to identify nuclei (blue). Hsp104
expression by gmr-Gal4 or by 1xgr-Gal4
resulted in protein aggregation. Hsp104
expressed by gmr-GS does not result in
aggregated protein.
B. Western immunoblot demonstrates relative
protein expression levels of Hsp104. The gmrGS driver expresses at a much lower level than
1xgr-Gal4, which is itself lower than gmr-Gal4.
This immunoblot is also pictured in Fig 2-9.
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As anticipated, protein aggregates were not observed in eyes containing just the gmrGal4 driver with no transgene expressed (Fig I-4, top panel). Expression of Hsp104 2.1
driven by gmr-Gal4, however, did result in protein aggregation.

In addition to

compromised retinal depth, consistent with that seen by paraffin sections (Fig I-2A), a
number of protein accumulations were observed throughout the eye tissue (Fig I-4,
second panel).

The reduced 1xgr-Gal4 driver expressing Hsp104 also showed the

development of protein accumulations, to a lesser extent (Fig I-4, third panel).
Therefore, the impaired retinal integrity caused by Hsp104 corresponds to the formation
of protein aggregates.

The mechanism by which Hsp104 causes protein aggregation remains speculation, but
this finding may indicate that Hsp104 is remodeling crucial proteins or protein complexes
to result in misfolding and accumulation of these endogenous proteins. If this is indeed
the mode of action, facilitating protein clearance pathways may counteract the effect.

The damaging Hsp104 effect may be developmental
We have established that expression of Hsp104 by gmr-Gal4 and 1xgr-Gal4 caused
toxicity to the eye and this corresponded with the appearance of aggregated protein.
However, we did not observe these features when examining other drivers that are
adult-onset.

Therefore, we hypothesized that the Hsp104 effect may be specific to

developing cells, which are potentially more sensitive to perturbation.
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We examined a modified gmr-Gal4 driver that is activated only in the presence of a drug,
a system called GeneSwitch (gmr-GS). Unlike constant expression with gmr-Gal4, when
Hsp104 was turned on in the eye in the adult fly using gmr-GS, no Hsp104-induced
protein aggregation was observed (Fig I-4A).

However, we are unable to conclude

definitively that the lack of aggregation is because Hsp104 was not expressed during
development. Western immunoblot demonstrated that the expression level using gmrGS was much lower than by the other two eye-specific drivers (Fig I-4B), so we cannot
exclude the possibility that reduced protein levels may be responsible for the suppressed
phenotype.

In the course of our experiments, we also examined the adult-onset rhodopsin driver
rh1-Gal4, which is specific to photoreceptor cells. In this system, toxicity is measured
not by tissue loss but by degeneration of individual photoreceptor cells. By shining light
through the eye, the surviving photoreceptor cells are illuminated, and one can count the
number of photoreceptors in each ommatidium. In this assay, Hsp104 had no toxicity
and the pattern of seven photoreceptors per ommatidium was preserved (Fig 2-13).
Because rh1-Gal4 is adult-onset, this again points to a developmental process in the
initiation of Hsp104 toxicity, but does not exclude other possibilities, such as expression
level or another cellular factor in the tissue-specific environment.

To fully test if the Hsp104 defect is developmental, further experiments are needed.
Because protein levels are so different among the variants of the gmr-Gal4 driver, it is
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difficult to compare differences in toxicity between the drivers. Therefore, comparing a
strong Hsp104 line, such as 6.1, driven by gmr-GS to a weak line, such as 2.1, driven by
1xgr-Gal4, would result in similar expression levels. Thus, the contribution of expression
during development could be teased apart from differences in protein level. To confirm
the contribution of gene expression during development, raising gmr-GS larvae on the
activating drug would turn on the Hsp104 gene during developmental stages and
presumably resemble the toxicity of concomitant expression with gmr-Gal4.

Can Hsp104 toxicity be modulated?
Because we were not expecting to see any effect of Hsp104 expression, we wanted to
examine whether other molecules could suppress the observed toxicity. This would be
useful in development of Hsp104 as a disease treatment, but might also provide insight
into the processes by which Hsp104 exerts toxicity.

We observed two potential

modifiers:

1. The molecular chaperone Hsp70

The first molecule we wanted to co-express with Hsp104 was the chaperone Hsp70. It
is known to function as a coordinating chaperone with Hsp104, facilitating interactions
with substrates. Therefore, we reasoned that the entire chaperone network may be
unbalanced by Hsp104 expression and that raising Hsp70 levels would restore harmony.
In addition, Hsp70 is a strong suppressor of disease in multiple systems, and there are
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numerous examples of strong suppression of protein aggregation disease in Drosophila
provided by Hsp70 (see Fig 2-2, (Warrick et al., 1999, Chan et al., 2000, Auluck et al.,
2002)).

We were therefore extremely surprised that co-expression of Hsp70 and

Hsp104 is lethal (Fig I-5). With gmr-Gal4, we observed total lethality (Fig I-5A), and
reduced expression by 1xgr-Gal4 was
lethal in males but we did obtain
females
Evaluation

expressing
of

both

these

genes.
escapers

confirmed that Hsp104 and Hsp70
synergize to produce extreme toxicity,
with complete loss of eye pigmentation
and degeneration (Fig I-5B).
Figure I-5

Hsp104 and Hsp70 synergize to

The mechanism of toxicity resulting induce lethality
from the interaction between Hsp104
and Hsp70 remains unknown.

The

synergistic toxicity is undeniable, but
follow-up

experiments

would

be

A. With the gmr-Gal4 driver, eye images show that
Hsp70 has no effect on the eye. However, when coexpressed with Hsp104, animals are inviable and die
before emerging from the pupal case.
B. With the reduced 1xgr-Gal4, Hsp70 again has no
impact on the eye. Co-expression of Hsp104 is
lethal in males, but females survive although with
extreme degeneration of the eye. These escapers
demonstrate that the combination is toxic.

required to characterize how this arises. These proteins are co-expressed in eye tissue,
so the disruption must be extremely intolerable to cause death of the entire organism.
Our hypothesis is that Hsp104 is indiscriminately driving aggregation of endogenous
proteins and the addition of Hsp70 facilitates substrate interactions, thus worsening the
magnitude of the effect. If the introduced Hsp104 were itself misfolding, then it is likely
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that Hsp70 expression would chaperone the protein and prevent its misfolding.
Moreover, the Hsp104 toxicity was dependent on activity, as Hsp104 DPLDWB had no
negative impact on any tissue. Therefore, we interpret this finding to suggest that Hsp70
facilitates an activity-dependent Hsp104 process that disrupts normal cellular function.

2. The deubiquitylase MJD

In the course of evaluating Hsp104 as a disease-modulating agent, we noticed that nonpathogenic MJDnQ27 may show a capacity to suppress the Hsp104 effect. We were
investigating the effect of Hsp104 on suppressing degeneration associated with
expanded PolyQ in the MJD protein (Ataxin-3/ Machado-Joseph Disease protein), and
examined non-expanded MJDnQ27 as a control. The physiological role of MJD is as
deubiquitylase (DUB) that contributes to proteostasis through the ubiquitin-proteasome
system (UPS) (see Chapter 2). Therefore, expression of MJDnQ27 would provide the
physiological DUB activity without the accompanying PolyQ-initiated toxicity.

Even with the reduced 1xgr-Gal4 driver, a slight disruption caused by Hsp104 is
apparent, with some dark banding of the photoreceptor cells and a separation of the
basal level of the retina (Fig I-6A). Co-expression of Hsp104 with MJDnQ27 has no
such disruption (Fig I-6A), indicating that MJD corrects the process the Hsp104 disturbs.

To fully conclude that MJD is affecting the Hsp104 toxicity, we needed to look at
conditions in which Hsp104 had a much stronger effect. We therefore examined the
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gmr-Gal4 driver with every Hsp104 line (Fig I-6B), and retinal degeneration was
observable for each Hsp104 line.

For every Hsp104 line driven by gmr-Gal4, co-

expression of MJDnQ27 had no impact on severity of degeneration (Fig I-6B). As such,
we conclude that MJDnQ27 is able to correct mild disruptions caused by Hsp104
expressed by 1xgr-Gal4, but MJDnQ27 is unable to impact the severe degeneration
caused by Hsp104 expressed by gmr-Gal4.

Figure I-6
MJDnQ27 suppresses
Hsp104
A. Eye images and retinal sections
demonstrate that Hsp104 2.1 expression
by 1xgr-Gal4 causes a slight disruption to
the cellular organization within the retina.
MJDnQ27 has no toxicity on its own, and
further, serves to suppress the toxicity of
Hsp104. Co-expression of both proteins
prevents the eye impairment of Hsp104
alone.
B. Co-expression of MJDnQ27 has no
impact on eye degeneration caused by
Hsp104 expression by gmr-Gal4.

B

These findings suggest that the physiological function of MJD is able to suppress mild
disruptions caused by Hsp104.

This is consistent with our interpretation of Hsp104

causing errant protein aggregation; enhanced UPS function stimulated by MJD would
counteract the accumulation of aberrantly remodeled substrates. However, the lack of
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suppression for gmr-Gal4 driving Hsp104 suggests that the ability of MJDnQ27 to
modulate this toxicity is very limited.

Conclusions and Future Directions
Our finding that expression of Hsp104 alone had any effect on the fly eye was
unexpected.

We have characterized that increased Hsp104 expression level

corresponds to more severe toxicity, indicating that high doses are not well tolerated in
the fly.

Moreover, we discovered the toxic effect of Hsp104 coincided with the

development of protein aggregates. Further investigation will be required to determine
the nature of these aggregates and which proteins comprise them.

Since Hsp104

toxicity was enhanced rather than rescued by Hsp70, this implies a synergistic effect in
active remodeling of endogenous substrates. Consistent with this notion was the finding
that MJDnQ27, a facilitator of the UPS, suppressed limited examples of Hsp104-driven
degeneration.

However, the significance of the toxic effect of Hsp104 remains unconfirmed and many
details are lacking.

For example, the role of the observed Hsp104-driven protein

aggregates in causing toxicity is unclear. Our transgenic lines are poised to perform
further experiments to characterize the association between aggregation and toxicity, for
example, by detecting aggregate levels Hsp104 with Hsp70 (increased toxicity) or with
MJD (decreased toxicity). Moreover, we have some indication that Hsp104 may be
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causing problems specifically during development, so controlled experiments to separate
this contribution would greatly add to the characterization of Hsp104’s effect.

Many questions remain surrounding the specific mechanism of Hsp104 cytotoxicity as
well.

We have made the observation that Hsp104 expression results in protein

aggregation, but we have not characterized the accumulations further. We presume that
Hsp104 is driving aggregation by causing aberrant remodeling of endogenous
substrates, but this remains a hypothesis and requires further investigation.

In

particular, examining whether this aggregation is enhanced by the combination of Hsp70
with Hsp104 will be informative regarding our model of the chaperones’ synergistic offtarget effects. Moreover, our finding that MJD suppresses mild Hsp104 toxicity should
also be combined with an investigation into aggregation status, as enhanced UPS
activity might alleviate toxicity by combating protein accumulation. Use of MJD variants
that lack DUB activity would be required to confirm that physiological activity of MJD is
responsible for the suppression of Hsp104 toxicity.

It is also possible that controlled expression may be required for any inducible
chaperone. Hsp104 is tightly regulated in yeast, and is undetectable at basal levels
(Sanchez and Lindquist, 1990). Thus, the expression is highly controlled except when
specifically required to function during stress and recovery. Consistent with this idea,
even the inducible Hsp70 that is endogenous to Drosophila causes developmental
defects to fly cells when basal levels are highly over-expressed (Feder et al., 1992). As
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such, our use of GeneSwitch technology may be the most appropriate application of
Hsp104 induction.
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PART 2. Genetic screens: Does Hsp104 moduate toxicity of disease proteins?
To determine if Hsp104 could be harnessed as a therapeutic, a broad variety of
neurodegenerative disease-associated proteins were screened to see if Hsp104 could
mitigate protein toxicity in the fly eye.

Because of the deleterious effect of Hsp104

alone, we used the reduced eye driver 1xgr-Gal4 with the weak-expressing line Hsp104
2.1. We found interesting interactions between Hsp104 and different MJD isoforms, and
followed up with a more targeted screen of MJD variants.

We have defined the interaction between Hsp104 with MJD in detail in Chapter 2, but
wanted to document the complete results of our genetic screens. The full list of results
is presented below; the complete collection of eye images and paraffin sections are
available in the Bonini lab.

Screen 1: Does Hsp104 impact any protein aggregation disease?
We screened a panel of proteins known to be associated with neurodegenerative
disease to determine if Hsp104 had any capacity to modulate disease toxicity.
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Table I-3 Screen: Does Hsp104 modulate neurodegenerative disease?

Alzheimer’s Disease
Disease protein:
Aβ42 – WT
Aβ42 – Arctic
Aβ42 – artificial
Tau – WT
Tau – R406W

Line name:
#11c39/TM3,Ser
[K Iijima]
#4b1 (3)
[K Iijima]
#24c9/CyO
[K Iijima]
Box 26-1c
[M Feany]
Box 26-1e
[M Feany]

Interaction with Hsp104:
Aβ did not cause eye degeneration;
interaction not determined
Aβ did not cause eye degeneration;
interaction not determined
Aβ did not cause eye degeneration;
interaction not determined
No observable Tau toxicity;
interaction not determined
No observable Tau toxicity;
interaction not determined

Amyotrophic Lateral Sclerosis
Disease protein:
Line name:
(S) on 2
TDP-43–YFP
[Hyung-Jun Kim]
TDP-43 + hAtx2- TDP-43 (37M), hAtx232Q; gmr-Gal4
32Q (F26); gmr-YHIII
(YHIII)
[Hyung-Jun Kim]
PolyQ disorders
Disease protein:
Atx1-Q82
Htt-exon1-Q93
dAtx2

Line name:
M6 on 3
[P Taylor]
exon1[174]-httQ93 (2)
[L Thompson]
Drosophila Atx2.4
Box 12-1c

Machado-Joseph Disease (SCA3)
Disease protein:
Line name:

Interaction with Hsp104:
No interaction
No interaction (does not appear that
Hsp104 disruption is additive)

Interaction with Hsp104:
No interaction
No observable Htt toxicity;
Interaction not determined
No interaction

Interaction with Hsp104:

MJDnQ78

#24.1 (3)

Hsp104 enhanced toxicity

MJD-Q88.C14A

#5.2 CyO/Sco; w+/Sb

No interaction (severe degeneration)

MJD-Q79Δexon2

#6.1 (2)

Hsp104 suppressed toxicity

MJDtrQ46

nos> c19.1 L15

MJDtrQ54

nos> c19.1 L16

No observable toxicity;
interaction not determined
No observable toxicity;
interaction not determined
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No observable toxicity;
interaction not determined
No observable toxicity;
interaction not determined
No observable toxicity;
interaction not determined

MJDtrQ64

nos> c19.1 L17

MJDtrQ70

nos> c19.1 W631

MJDtrQ78

nos> c19.1 L18

MJDtrQ92

nos> c19.1 L19

Hsp104 suppressed toxicity

MJDtrQ78

c11.2 E11 /CyO

Hsp104 suppressed toxicity

The disease proteins caused minimal degeneration in this screen because of the use of
the reduced expression driver 1xgr-Gal4.

Therefore, it was difficult to determine if

Hsp104 suppressed toxicity or interacted in any way with a number of these proteins.

Of the various disease models tested, Hsp104 interactions with different variants of MJD
looked the most interesting. We looked at truncated fragments of the MJD protein that
are comprised mainly of the expanded PolyQ tract and saw that Hsp104 suppressed the
severity of truncated MJD toxicity.

We also looked at non-truncated MJD, which in

addition to its PolyQ-dependent role in disease, the full-length MJD protein has a
physiological role in proteostasis as a ubiquitin chain editing enzyme. The MJD protein
has deubiquitylase (DUB) activity carried out by the N-terminal Josephin domain, with
residue C14 acting as the catalytic amino acid. The interaction between Hsp104 and
full-length MJD is more complex.

We examined three variants the full-length MJD protein: the intact protein with functional
DUB domain (MJDnQ78), a variant with a point mutation to inactivate the catalytic amino
acid (MJD-Q88.C14A), and another non-functional variant that lacks a large portion of
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the Josephin domain (amino acids 9-63) that includes the active site (MJD-Q79Δexon2). We found striking distinctions among the variants of the same MJD protein.
The pathogenic MJDnQ78 had moderately severe toxicity when expressed by 1xgrGal4, and Hsp104 had a very strong interaction, causing much stronger degeneration,
including early lethality.

Due to loss of physiological DUB activity, MJD-Q88.C14A was more toxic than
MJDnQ78 and showed much stronger degeneration. Co-expression of Hsp104 had little
effect on this extreme toxicity, with both genotypes showing high lethality. MJD-Q79Δexon2 also had increased toxicity due to loss of the catalytic activity. However, we
observed that Hsp104 had a strong interaction with MJD-Q79-Δexon2, and completely
unlike the interaction with the other full-length MJD variants, provided strong
suppression of disease-associated toxicity.

These dramatically distinct interactions of Hsp104 with different forms of the same MJD
protein warrant further investigation, which were examined in the next genetic screen in
Screen 2.

Screen 2: Defining the interaction between MJD and Hsp104
We saw surprising interactions between Hsp104 and different isoforms of the MJD
protein (Screen I). Hsp104 effectively suppressed the toxicity of truncated forms of MJD
that are comprised mainly of an expanded PolyQ tract. However, Hsp104 dramatically
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enhanced the toxicity of full-length MJD despite the aggregation domain being an
identical PolyQ expansion. We also observed a surprising disparity between two MJD
variants lacking deubiquitylase (DUB) activity, which were originally constructed to be
redundant examples of inactive MJD. However, the variants were demonstrated to be
distinct, as Hsp104 strongly suppressed the variant lacking a portion of the Josephin
domain that contains the active site but did not affect the variant with a point mutation to
the active site.

In order to probe which portions of full-length MJD hinder the suppression of toxicity that
is observed for truncated MJD, we used a collection of MJD variants with various
functional deficiencies. In addition to variants lacking DUB activity, we also examined
interaction mutants unable to coordinate with known functional partners in the cellular
environment.

Our conclusions and a detailed model of the interactions between Hsp104 and MJD are
explored in depth in Chapter 2 (Fig 2-7), but the full results of the entire MJD screen are
presented here for reference.

In addition to MJD variants, we tested Huntingtin protein isoforms, as it was another
PolyQ protein that may or may not have an interaction with Hsp104. Additionally, we
also examined the interaction between Hsp104 and other molecular chaperones. The
AAA+ chaperone p97 was of particular interest because of its structural homology to
Hsp104 (Wendler et al., 2007) and its known ability to interact with MJD in its role as part
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of the UPS (Kuhlbrodt et al., 2011). Moreover, we were eager to test for an interaction
between Hsp104 and Hsp70. Hsp70 collaborates with Hsp104 during its disaggregation
activity and Hsp70 is a known suppressor of degenerative phenotypes, so we wanted to
see if co-expression of Hsp70 with Hsp104 would mitigate the deleterious effect of
Hsp104 on its own.

Table I-4 Screen: Defining the interaction between Hsp104 and MJD

Expanded MJD screen
Truncated MJD, non-expanded Q
Disease protein:
Line name:
Interaction with Hsp104:
MJDtrQ27

N18.3-d

No interaction

MJDtrQ46

nos> c19.1 L15

No interaction

Truncated MJD, expanded Q
Disease protein:
Line name:

Interaction with Hsp104:

MJDtrQ92

nos> c19.1 L19

Hsp104 suppressed toxicity

MJDtrQ78

c11.2 E11 /CyO

Hsp104 suppressed toxicity

Q71tr-257

#3.13

Hsp104 suppressed toxicity

Truncated MJD with location tags
Disease protein:
Line name:

Interaction with Hsp104:

MJDtrQ27–NES

A50.2

No interaction

MJDtrQ77–NES

#13.1

Hsp104 suppressed toxicity

MJDtrQ27–NLS

#28.1

No interaction

MJDtrQ65-NLS

#52a

Hsp104 suppressed toxicity

Full-length functional MJD, non-expanded Q
Disease protein:
Line name:
Interaction with Hsp104:
MJDnQ27 suppressed the mild Hsp104
MJDnQ27
#46.2
disruption
MJDnQ27p

#30.2

No visible interaction
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Full-length functional MJD, expanded Q
Disease protein:
Line name:

Interaction with Hsp104:

MJDnQ78

#24.1

Hsp104 enhanced toxicity

MJDnQ84p

#7.2

(29ºC) Hsp104 enhanced toxicity

Atx3-Q83-6M

#3.1

Hsp104 enhanced toxicity

Full-length non-functional MJD
Disease protein:
Line name:

Interaction with Hsp104:

MJD-Q27Δ

#25

No interaction

MJD-Q79Δ

#6.1

Hsp104 suppressed toxicity

MJD-Q27.C14A

P1467

No interaction

MJD-Q88.C14A

#5.2

No interaction (severe degeneration)

MJD interaction mutants
Disease protein:
Line name:

Interaction with Hsp104:

MJD-Q27-UIM*

#11.1

No interaction

MJD-Q80-UIM*

#31.1

(29ºC) No interaction (mild degeneration)

MJD-Q80-DM

#1.2

Hsp104 suppressed toxicity

MJD-Q71-HNHH
(p97*)

#3.11A

No interaction

MJD lacking RNA toxicity
Disease protein:
Line name:

Interaction with Hsp104:

MJDnQ81 CAA/G

#69.1 (II)

Hsp104 slightly enhanced toxicity

MJDnQ82.C14A
CAA/G

#4.17B /CyO

Hsp104 enhanced toxicity

Josephin domain; MJD lacking PolyQ
Disease protein:
Line name:

Interaction with Hsp104:

MJD-ΔQ

MJDΔ2 #44.2 /Tb

No interaction

Josephin – IR

#3.3 /CyO

No visible interaction

dJosephin

#2.3A (3)

No interaction
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Other interactions
Huntingtin
Disease protein:
Exon1-htt-Q20
Exon1-htt-Q93
Htt[1-676]-Q0
Htt[1-676]-Q138
Chaperone p97
Protein:

Line name:
exon1[174]-httQ20 (II)
[L Thompson]
exon1[174]-httQ93 (2)
[L Thompson]
htt676-Q0#B
[T Littleton]
htt676-Q138#C
[T Littleton]

Interaction with Hsp104:
No interaction
No toxicity; no interaction
No interaction
Hsp104 enhanced toxicity

Line name:
ter94 [26.8] #42B
[D Ruben]
Box 31-1d
[D Ruben]

Interaction with Hsp104:

p97

#6.1/Tb

No interaction

Chaperone Hsp70
Protein:

Line name:

hHsp70

#53.1 /CyO

Interaction with Hsp104:
Lethal in males; some females survived
but with severe degeneration

gmr-Gal4 +
hHsp70

P1055-R4 /CyO

ter94 FRT
ter94

No interaction
No interaction

Completely lethal

Our screen yielded important insight into the portions of full-length MJD that hinder
productive interactions with Hsp104. These results are well summarized in Chapter 2.
Additionally, we highlight three interesting findings:

1. Hsp104 is not modulating MJD toxicity by suppressing RNA toxicity

In addition to protein-driven toxicity, full-length MJD is known to have a component of
RNA toxicity (Li et al., 2008). In PolyQ disease, the repeat of the CAG codon within the
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RNA strand forms a hairpin structure and contributes toxicity to the PolyQ protein
phenotype (de Mezer et al., 2011). Previous work from our lab has demonstrated that
mutating the sequence such that the pure CAG repeat is interrupted by alternating CAA
and CAG (CAA/G) eliminates the toxic RNA structure while maintaining the same PolyQ
protein sequence (Li et al., 2008). Thus, examining CAA/G forms of MJD will define
protein-only interactions. Therefore, if we find that the Hsp104-driven enhancement of
full-length MJD is no longer evident with the CAA/G mutations, then it may be that the
negative interaction with Hsp104 is due to RNA toxicity rather than protein.

Full-length MJD with CAA/G did not have strong eye toxicity and co-expression of
Hsp104 slightly worsened retinal structure, but ultimately had little effect. In order to
evaluate the interaction more thoroughly, full-length MJD with CAA/G plus the Josephininactivating C14A point mutation was used to confer more severe degeneration. With
this more severe phenotype, it was apparent that co-expression with Hsp104 enhanced
degeneration. This is consistent with previous full-length MJD results containing a pure
CAG repeat, so these results indicate that Hsp104 is worsening toxicity through protein
interactions rather than by affecting RNA toxicity.

Further experiments would be

required to fully eliminate the possibility of an interaction between Hsp104 and RNA, but
the observed effect on MJD is due to protein-protein interactions, which is consistent
with our protein aggregation results (Fig 2-3B and D) and our model (Fig 2-7).

2. Subcellular location of MJD does not affect accessibility to Hsp104
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Location variants of truncated MJD were examined to determine if subcellular
localization affected Hsp104 performance.

We had found that Hsp104 suppressed

toxicity of truncated MJD with expanded Q, and we wished to examine whether Hsp104
could still access the protein when localized to either the nucleus or the cytoplasm.

Truncated MJD with an added nuclear export signal (NES) was directed to the cytosol; it
caused severe toxicity, which was suppressed by co-expression of Hsp104. Similarly,
nuclear-directed truncated MJD, by means of an added nuclear localization signal (NLS),
caused more moderate toxicity, and this was also mitigated by co-expression of Hsp104.
Thus, Hsp104 is able to localize to, and function within, either the cytosol or the nucleus,
suggesting that it is promising to treat protein aggregates regardless of subcellular
localization.

3. The Hsp104 interaction with PolyQ protein Huntingtin may mirror MJD

Huntingtin (Htt) is the PolyQ protein implicated in development of Huntington’s Disease
(Norremolle et al., 1993). Like MJD, expanded PolyQ in Htt leads to the formation of
inclusions and development of disease pathology (Davies et al., 1997).

The PolyQ

domain is found in the N-terminus of the protein, and because Htt is very large (>3000
amino acids), smaller fragments of Htt that contain the N-terminal aggregation domain
are often examined to facilitate aggregation (Thakur et al., 2009). We investigated Exon
1, which contains 67 amino acids plus the variable-length PolyQ repeat, and also a
larger fragment containing amino acids 1-676 plus PolyQ.
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Htt, like MJD, required expanded PolyQ in order to cause toxicity.

Thus, no

degeneration was observed for Exon1 Htt-Q20 or Htt[1-676]-Q0, and Hsp104 had no
effect (Fig I-7). Exon1 Htt-Q93 did not have visible toxicity when expressed by the
reduced 1xgr-gal4 driver, and Hsp104 had
minimal effect when co-expressed, appearing
identical to the mild effect of Hsp104 alone
(Fig

I-7A).

Therefore,

any

interaction

between the Exon1 Htt fragment and Hsp104
cannot be determined.
676]-Q138

did

not

Like Exon1, Htt[1cause

obvious

degeneration with the 1xgr-Gal4 driver, but in
marked

contrast,

Hsp104

co-expression Figure I-7 Hsp104 may have a negative
interaction with Huntingtin

caused strong toxicity with visible retinal Fragmented variants of Htt with non-

expanded Q demonstrated no toxicity.
degeneration (Fig I-7B). Thus, Htt[1-676] Because of the reduced expression by the
1xgr-Gal4 driver, the expanded Q variants
does have an interaction with Hsp104, and also displayed no degeneration. However,
we observed that while co-expression of
Hsp104 with Exon1 Htt-Q93 did not
this resulted in increased toxicity of the synergistically induce degeneration (A), the
combination of Hsp104 with Htt[1-676]disease protein.
Q138 caused enhanced toxicity (B).

Thus, we observed an Hsp104-driven worsening of toxicity for the longer fragment Htt[1676] but no such interaction with Exon1 Htt. Superficially, this resembles our findings for
MJD:

PolyQ domains with more protein flanking sequence are subject to negative

interactions with Hsp104 but a more accessible PolyQ domain is effectively remodeled
by Hsp104. However, the mechanism of the Hsp104 interaction with Htt requires much
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further characterization to draw any conclusions. For example, the expression levels of
the two proteins may be very different and while Hsp104 is able to manage Exon1, Htt[1676] passes a critical level that Hsp104 cannot tackle.

Alternatively, because the

difference between the PolyQ repeats in these two Htt variants is fairly substantial, it
could be that Hsp104 is able to remodel PolyQ regions up to a certain point but the
enzymatic activity is overwhelmed when the Q exceeds a threshold. A panel of variants,
such as those examined for MJD, would be required to fully understand the observed
interaction.
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PART 3. Examining Hsp104 mutants

Background
In addition to developing wild-type (WT) Hsp104 to investigate its capacity in modulating
protein-aggregation disease, we also sought to create Drosophila lines expressing
Hsp104 mutants. In addition to highlighting the deficiencies or enhancements of each
mutant, these may also offer mechanistic insight into how WT Hsp104 functions.

We were particularly interested to test an inactive mutant because this important control
has never been performed in vivo. We chose the inactive Double Pore Loop Double
Walker B (DPLDWB) Hsp104 mutant, which has four mutations (Y257A: E285Q: Y662A:
E687Q) to prevent ATP hydrolysis and substrate binding (DeSantis et al., 2012). Thus,
the Hsp104 molecule will be inactive in remodeling (Walker B mutations) but will also be
unable to serve as a trap to substrates (pore loop mutations) (Bosl et al., 2005). It is
critical to compare DPLDWB to WT Hsp104 because it will truly distinguish active
remodeling effects from passive effects that may occur as a result of novel protein
expression.

Additionally, we created an Hsp104 variant with a mutation to the middle domain,
A503V.

Previous research in the Shorter lab has shown that A503V Hsp104 has

enhanced anti-amyloid activity in vitro (unpublished data), so we were eager to test
whether it may have improved efficacy when introduced in vivo. Again, it is critical to
compare A503V to WT Hsp104 to determine what effect the mutation has on activity.
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ATPase Dead Hsp104
To create the ATPase Dead Hsp104, we used site-directed mutagenesis to introduce the
inactivating mutations (Y257A: E285Q: Y662A: E687Q) into our codon-optimized WT
Hsp104 plasmid. Multiple independent DPLDWB Hsp104 lines were obtained. The
transgenes were mapped and balanced:

Table I-5 DPLDWB Hsp104 lines

Line:
2.1
5.4
9.1
19.1

Chromosome:
3
X
2
3

Description
Moderate
Moderate
Moderate
Moderate

To characterize expression level, the Hsp104 gene was expressed in the eye by the
1xgr-Gal4 driver. We compared to levels of WT Hsp104 because it is critical to know
whether the proteins are at similar levels to make accurate comparisons. We found that
all DPLDWB lines had very similar expression levels, and that these fell between the
weak WT Hsp104 line 2.1 and the strong WT Hsp104 line 6.1 (Fig I-8B). Therefore,
these lines were determined to be appropriate for comparison to WT Hsp104.

Because we had observed that WT Hsp104 negatively impacted the eye, we chose to
characterize two DPLDWB lines for any potential toxic effect. We found that with either
the strong gmr-Gal4 driver or weak 1xgr-Gal4 driver, two separate lines of DPLDWB had
no effect on eye morphology (Fig I-8A). This finding implies that substrate binding and
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ATP hydrolysis are required for the toxic effect of WT Hsp104. This strengthens our
proposed toxicity mechanism of aberrant Hsp104-driven protein remodeling.

We also tested DPLDWB Hsp104
for

ability

to

modulate

MJD

disease. WT Hsp104 was able to
suppress the toxicity of MJDtrQ78
but

exacerbated

degeneration

associated with MJDnQ78 (Fig 22).

We therefore wanted to

confirm that these effects are
dependent on active remodeling Figure I-8 DPLDWB Hsp104 is non-toxic
A. Eye images and retinal sections demonstrate that
two DPLDWB Hsp104 lines, 2.1 and 9.1, had no impact
on eye morphology with either strong gmr-Gal4 or weak
1xgr-Gal4 drivers. This is in contrast to the toxic effect
of comparable expression levels of WT Hsp104, which
produced eye degeneration and retinal disorganization
We
first
performed
these (see Fig 2-1).
B. Western immunoblots demonstrate relative protein
experiments using the 1xgr-Gal4 levels for each DPLDWB Hsp104 line. All lines had
similar expression levels, which were between the levels
driver to match the conditions of weak WT Hsp104 line 2.1 and strong WT Hsp104 line
6.1.

by Hsp104.

used for WT Hsp104. We found
that DPLDWB Hsp104 had a mild mitigating effect on the degeneration associated with
both MJDtrQ78 and MJDnQ78 (Fig I-9A). The finding that DPLDWB Hsp104 does not
display the differential activities on the two disease proteins indicates that this feature of
WT Hsp104 is indeed activity-dependent.
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The effect of DPLDWB was also examined with the stronger gmr-Gal4 driver. In this
condition, neither DPLDWB line had any effect on severity of toxicity of either disease
protein (Fig I-9B). We were therefore reassured that the inactive DPLDWB Hsp104 is
indeed inactive, and confirmed that modulation of disease is dependent on the active
substrate binding and ATP hydrolysis of WT Hsp104.
Figure I-9 DPLDWB Hsp104 is
inactive
A. Using the 1xgr-Gal4 driver,
MJDtrQ78 and MJDnQ78 have
mild toxicity and co-expression
of DPLDWB Hsp104 has a mildly
mitigating effect.
Unlike WT
Hsp104, DPLDWB Hsp104 does
not show differential effects on
the two disease proteins.
B. Eye images and paraffin
sections confirm that DPLDWB
Hsp104 is unable to modulate
disease using the gmr-Gal4
driver. Both DPLDWB Hsp104
lines have no effect on the
severity of degeneration or
retinal impairment caused by
MJDtrQ78 or MJDnQ78. Again,
DPLDWB Hsp104 does not
show differential effects on the
two disease proteins. (Note that
Control and DPLDWB 2.1 lines
are duplicated from Fig 2-8.)

A503V

Previous research in the Shorter lab has indicated that A503V Hsp104 exhibits
enhanced anti-amyloid capacity compared to WT Hsp104.

However, it has been

documented that the A503V mutant is difficult to purify because of some initial toxicity
during bacterial expression. Because this Hsp104 variant has a mutation in the middle
domain, we have hypothesized that this mutation destabilizes the protein such that it is
difficult to express high levels of the protein.
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However, the A503V Hsp104 mutant

recovers from this initial difficulty and is obtainable with a longer growth time. Once it
has been purified, the A503V mutant has generally enhanced activity (antagonizing
amyloidogenesis, ATP hydrolysis, etc.), so we wanted to test its efficacy in vivo. We
were prepared for the possibility of toxicity on its own due to this observation from the
bacterial system, and therefore thought that the GeneSwitch system might be an ideal
setting for this Hsp104 mutant.

Multiple independent A503V Hsp104 lines were obtained. The transgenes were mapped
and balanced:

Table I-6 A503V Hsp104 lines

Line:
17.1
18.2
20.2

Chromosome:
2
2
X

Description
Lethal; dead larvae and dead pupae
Lethal; dead larvae and dead pupae
Unknown; no offspring from cross

To characterize expression level, the Hsp104 gene was expressed in the eye by the
1xgr-Gal4 driver. All lines proved to be lethal in this system, with flies dying in either the
larval or pupal stage. More lines were created in addition to those listed above, but the
lines were not robust and have been lost. One slightly milder line had viable larvae and
lethality was only seen in pupae, and from this, one female fly eclosed. This fly had a
decimated eye that was very small and lacked pigment entirely (Fig I-11), thus
confirming the extreme toxicity of A503V Hsp104. If this is due to an enhancemet of
activity compared to WT Hsp104 or a separate effect (e.g., due to protein instability) is
still unknown.
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Figure I-10 A503V Hsp104 is highly toxic
Only one female fly eclosed from the mildest A503V Hsp104 line driven by
1xgr-Gal4. The eye was severely compromised, displaying a very reduced
size, no pigment, and development of necrotic patches on the external eye.
This confirms that even when lethality is escaped, the A503V Hsp104
protein is damaging.

We had anticipated that A503V Hsp104 might be damaging on its own, so we used it in
the GeneSwitch setting to control expression by drug application.

We constitutively

expressed MJDtrQ78 by direct activation by gmr and used the gmr-GS driver to control
expression of UAS-transgenes. We found that WT Hsp104 was effective at suppressing
progressive degeneration, but DPLDWB Hsp104 and Hsp70 had no protective effect in
this sequential expression system (Fig 2-10).

We were hoping that the toxicity observed for A503V Hsp104 would be avoided by the
controlled expression of gmr-GS, and addionally that the enhanced activity of A503V
Hsp104 would result in a stronger rescue than that observed for WT Hsp104. However,
we found that the burst of A503V Hsp104 appeared to make MJDtrQ78 degeneration
worse when turned on early (Fig I-11A) or late (Fig I-11B). This is an initial observation
that requires more replicates and quantification, but we noticed a disruption to the retinal
shape as well as the tissue loss and wispy appearance of surviving retinal cells in the
A503V Hsp104-treated retinas. We cannot rule out the possibility that this toxicity is due
to A503V Hsp104 expression on its own. The expression levels of this mutant might be
tweaked to minimize disruption (akin to using the 1xgr-Gal4 driver for WT Hsp104), but
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our results in this experiment have led us to eliminate the A503V Hsp104 mutant from
further experiments.

Figure I-11 A503V Hsp104
worsens MJD toxicity
A.
gmr-MJDtrQ78
caused
degeneration of the retina; gmrGS expression of the indicated
Hsp104
transgene
was
activated at d1 and severity of
MJDtrQ78-induced
degeneration was evaluated at d7.
WT Hsp104 prevented tissue
loss, but expression of A503V
Hsp104 did not.
In fact, it
appears that MJDtrQ78 toxicity
may be enhanced by A503V
Hsp104.
B. Results were nearly identical
when the Hsp104 transgenes were turned on later, at d3. Again, MJDtrQ78 toxicity seems to be
enhanced by A503V Hsp104 co-expression, but more replicates are need for quantification.
Note that Control and WT Hsp104 images duplicated from Fig 2-10.

Conclusions and Future Directions
Our inactive mutant, DPLDWB Hsp104, was indeed found to be inactive. The mutant
Hsp104 had no negative impact on the eye, unlike equivalent levels of WT Hsp104.
DPLDWB Hsp104 was also unable to modulate MJD-associated degeneration.

Other inactive Hsp104 mutants might be used to probe the mechanism of WT Hsp104
further. For example, the mutation of the two Walker B sites (DWB) creates the Hsp104
“trap mutant”, which is known to bind substrate but not release it (Bosl et al., 2005).
Therefore, comparing DWB and DPLDWB Hsp104 might distinguish any off-target
negative interactions with substrate that are due to incomplete or partial translocation.
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The A503V Hsp104 mutant was extremely toxic on its own, and may be enhancing MJD
degeneration when temporally controlled by the gmr-GS system.

This mutant may

improve following further optimization, but we will not pursue it.

We may need to

develop other activity-enhanced mutants that do not show the negative effect. Screens
are ongoing in the Shorter lab to identify optimized Hsp104 variants.
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Overall conclusions: Expressing Hsp104 in the fly
There is still a lot to understand about Hsp104 expression in an animal system, and
therapeutic application of Hsp104 for protein aggregation disease is not yet feasible. We
observed unanticipated toxicity when WT Hsp104 was expressed in multiple Drosophila
systems.

Loss of Hsp104 activity through the inactivating DPLDWB mutations

eliminates this negative outcome, indicating that the mechanism of toxicity is dependent
on activity, possibly because Hsp104 drives indiscriminate aggregation of endogenous
proteins.

Exploration of further Hsp104 mutants may yield further insight into this

undesirable side effect of Hsp104 expression and may suggest ways to minimize the
damaging effects. Moreover, development of substrate-optimized Hsp104 mutants may
eliminate off-target interactions altogether. Our results also indicate that Hsp104 may be
most toxic during a sensitive developmental stage.

Taken together, the use of

GeneSwitch technology to selectively activate a controlled burst of Hsp104 expression is
probably the best paradigm to study Hsp104, as it eliminates the negative effect of
Hsp104 alone, and it most accurately replicates a disease-relevant application.
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APPENDIX II : BIOCHEMICAL STUDIES

DEVELOPING NOVEL ANTAGONISTS OF Aβ42 AMYLOIDOGENESIS
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Background
Alzheimer’s Disease (AD) is a devastating disorder that robs individuals of their cognitive
abilities by impairing memory, thinking, and behavior through the progressive
development of dementia (ADI, 2009, Thies and Bleiler, 2011). It places an enormous
burden on patients and families, as well as on economic and social resources, and is
increasing in prevalence as our population ages (Thies and Bleiler, 2011). AD patients
have striking neuropathology in their central nervous system upon autopsy, with large
neuritic plaques comprised of the Aβ42 peptide are observed in the extracellular space
of the brain (ADI, 2009, Thies and Bleiler, 2011).

Aβ42 is a short peptide of 42 amino acids that is released by proteolytic cleavage from
the membrane-bound Amyloid Precursor Protein.

The Aβ42 peptide is extremely

hydrophobic, and as such, is extremely aggregation-prone (Forman et al., 2004).
Specifically, the peptide forms linear fibrils that adopt the stereotypical amyloid fold.
Many proteins are known to access the amyloid conformation, which is defined as a
cross-β structure in which β-sheets form perpendicular to the fiber axis (Jimenez et al.,
2002, Luhrs et al., 2005). It is an extremely stable conformation that is resistant to heat
denaturation, detergents, and proteases (Westermark et al., 2005, Chiti and Dobson,
2006). Aβ42 fibrils then form lateral interactions to create the large amyloid plaques
observed in AD. Because of the strength of the intermolecular contacts of the cross-β
conformation, these plaques are thought to be intractable.
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Moreover, prior to amyloid fibril formation, monomers first access soluble oligomeric
assemblies (Kayed et al., 2003). These may be even more toxic than fibrils, and some
have proposed that fibrils are a protective mechanism to sequester the toxic soluble
species (Dobson, 2003, Kayed et al., 2003, Douglas et al., 2008, Wolfe and Cyr, 2011).
In fact, symptoms of neurodegenerative disease often appear before the accumulation of
high amyloid load (Hardy and Selkoe, 2002, Caughey and Lansbury, 2003). Further,
plaques may serve as a reservoir for release of toxic oligomers (Koffie et al., 2009).
Therefore, elimination of both mature amyloid fibrils and pre-amyloid oligomers would be
ideal, as both protein accumulations are associated with disease development.

As such, a treatment is needed to directly combat amyloidogenesis of Aβ42.

The

development of an anti-amyloid treatment may have farther-reaching implications, as AD
is also characterized by formation of amyloid inclusions of the tau protein in intracellular
neurofibrillary tangles (Forman et al., 2004). Moreover, many other neurodegenerative
diseases are characterized by underlying protein pathology, and despite vastly different
primary sequences, the proteins implicated often access the amyloid conformation
(Forman et al., 2004). Our hope is that agents to directly target amyloid fibrils will have
widespread application to the varied collection of devastating neurodegenerative
diseases.

Here, we present three novel therapies to combat Aβ42 amyloidogenesis: in Part 1, the
yeast disaggregase Hsp104; in Part 2, small molecule analogs of DAPH-1; and in Part 3,
arylamide foldamers.
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PART 1. Tailoring Hsp104 for Aβ42
Despite the remarkable stability of the cross-β fold, a yeast chaperone called Hsp104
actively disassembles amyloid fibrils (Shorter and Lindquist, 2004, 2006, 2008, DeSantis
et al., 2012). Hsp104 is a heat shock protein that greatly improves survival following
environmental stress by resolubilizing the proteins that become denatured and
aggregate during stress (Sanchez and Lindquist, 1990, Sanchez et al., 1992, Parsell et
al., 1994, Glover and Lindquist, 1998).

But in addition to reversing disordered

aggregates, Hsp104 also controls the disassembly and dissemination of amyloid fibrils
critical to beneficial yeast prion states (Chernoff et al., 1995, Shorter and Lindquist,
2008).

In yeast, certain proteins act as prions; they are regulated by sequestration

within self-replicating amyloid fibrils, thus reducing the available population of soluble
protein without affecting transcription or translation. Hsp104 is essential for restoring the
sequestered protein monomers to their soluble and active state (Chernoff et al., 1995,
Shorter and Lindquist, 2004, 2006, 2008).

But how does Hsp104 tackle the extremely stable intermolecular connections found
within amyloid fibrils? The active Hsp104 protein is a ring-type hexamer made of six 104
kDa monomers, each containing two substrate binding loops that project into the central
channel within two nucleotide binding domains (NBDs) (Fig II-1A) (Wendler et al., 2007,
Wendler et al., 2009). The disaggregase acts as a molecular machine that couples ATP
hydrolysis in each NBD to large structural shifts that ratchet the substrate binding loops
and thus pull the substrate through the central channel (Lum et al., 2004, Lum et al.,
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2008). Thus, Hsp104 pries protein monomers away from the protein aggregate, and
after passing through the Hsp104 channel, the substrate is released and the
resolubilized protein may adopt its native fold and resume normal physiological function
(Fig II-1A).

Because of this unparalleled
ability to dismantle amyloid,
Hsp104 is very promising in
attacking amyloids associated
with

human

disease.

Preliminary results from our lab
suggest

that

Hsp104

does Figure II-1 Hsp104 structure and function
A. Representation of Hsp104. The Hsp104 protein (green)

indeed have strong efficacy in assembles into a three-tiered ring-shaped hexamer. Each

monomer contains two conserved substrate-binding loops
antagonizing various disease- that project tyrosines into the central channel (yellow Y) and
two ATP hydrolysis sites (yellow star), one in each NBD.
Hsp104 remodels disordered aggregates, in collaboration
associated
amyloid
fibrils with Hsp70/40, and amyloid fibrils by prying monomers from
the aggregate and translocating through the central channel.
(DeSantis et al., 2012), but B. Amino acids Tyrosine and Phenylalanine.

Aβ42 was particularly resistant to Hsp104 remodeling.

My first aim was to isolate

conditions that would improve Hsp104 interactions with Aβ42 to allow evaluation of
Hsp104 as a potential therapeutic. In these experiments, it was critical to compare wildtype (WT) Hsp104 to an ATPase Dead Hsp104 variant (K218T:K620T) that has a
mutation in the conserved Walker A motif in each NBD and thus cannot bind or
hydrolyze ATP. This variant will therefore not be able to actively remodel substrates and
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will separate true activity-dependent interactions with Aβ42 from non-specific effects of
incubating fibrils with a foreign protein.

Additionally, Aβ42 fibrils may be so difficult to reverse because of the extremely
hydrophobic nature of the Aβ42 peptide. Thus, my second aim was to test Hsp104
variants with mutations to the substrate-contacting residues of Hsp104 to make them
more hydrophobic. Thus, the substrate-binding loops may be more similar to Aβ42 and
may have improved efficacy in contacting and subsequently dismantling Aβ42 fibrils.
The conserved substrate-interacting motif GYVG is found in WT Hsp104 (KYKG in
NBD1), and the tyrosine residue (Y) has previously been determined to make contact
with the substrate (Lum et al., 2004, Lum et al., 2008). One can envision that Y has
resulted from evolutionary pressures because the phenyl ring is able to strengthen
protein interactions and the polar hydroxyl group has the widest ability to interact with
diverse substrate residues. Therefore, by replacing the Y with phenylalanine (F), we
would maintain the phenyl ring but would eliminate the polar group and increase
hydrophobicity (Fig II-1B). We examined the Y→F mutation in each NBD to determine if
this did indeed increase efficacy of Hsp104.

Aβ42 fibrils are reversed by Hsp104
Previous results from our lab demonstrated that Hsp104 had minimal interaction with
Aβ42 fibrils, so we needed to optimize reaction conditions. We found that addition of the
organic solvent dimethyl sulfoxide (DMSO) to the reaction actually uncovered the anti-
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Aβ42 activity of Hsp104. To quantify these interactions, we incubated pre-formed Aβ42
amyloid fibrils with Hsp104 overnight (16 h) and then measured how much amyloid
material remained by using the amyloid-binding dye Thioflavin-T (ThT) (10 µM; excitation
450 nm, emission 482 nm).

In buffer alone (KHMD: 150 mM KCl, 40 mM Hepes-KOH pH 7.4, 20 mM MgCl2, 1mM
DTT; 5 mM ATP; and ATP Regenerating System: 10 mM creatine phosphate, 0.02
mg/ml creatine kinase), incubation with WT Hsp104 did seem to reduce the presence of
pre-formed Aβ42 amyloid fibrils to about 80%, but the inactive ATPase Dead Hsp104
actually reduced amyloid presence to a greater extent (Fig II-2A, left).

In the presence of 10% DMSO, the same reaction yielded vastly different results.
Addition of 10% DMSO to the reaction did not change the overall levels of untreated
Aβ42 fibrils, suggesting that DMSO is not altering the beginning fibril population. Rather,
DMSO unmasks the activity of WT Hsp104, showing amyloid levels being reduced to
about 10% of the starting amount (Fig II-2A, right). Further, the presence of DMSO does
not affect ATPase Dead Hsp104, and in fact, the inactive Hsp104 has less effect on
Aβ42 fibrils than in buffer alone (Fig II-2A, right). Thus, we conclude that DMSO is
allowing us to distinguish active remodeling of Aβ42 amyloid fibrils by WT Hsp104.

We wanted to determine the concentration DMSO concentration required to observe this
effect, so the reactions were repeated with increasing concentrations of DMSO (0 – 10%
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total volume). We observed that at least 7% DMSO was required to uncover Aβ42 fibril
disassembly by Hsp104 (Fig II-2B).
Figure II-2
WT Hsp104
reverses pre-formed Aβ42
fibrils
A. DMSO uncovers the
active remodeling of Aβ42
fibrils by Hsp104.
Preformed Aβ42 fibrils (0.5 µM)
were incubated with WT or
ATPase Dead Hsp104 (2
µM) for 16 h at 37ºC and
evaluated
by
amyloidbinding dye ThT.
The
reaction was performed in
either buffer alone (KHMD)
or in buffer with the addition
of 10% DMSO. In buffer
alone, WT Hsp104 did not
resolubilize Aβ42 from fibrils
when compared to the
inactive
ATPase
Dead
Hsp104. In the presence of
10% DMSO, WT Hsp104
activity was apparent when
compared to ATPase Dead
Hsp104. n≥2, Mean±SEM
B. At least 6% DMSO is
required to observe Hsp104 remodeling of Aβ42 fibrils. Pre-formed Aβ42 fibrils (0.5 µM) were
incubated with WT or ATPase Dead Hsp104 (2 µM) for 16 h at 37ºC and evaluated by amyloidbinding dye ThT. The reaction was performed in buffer with the addition of 0–10% DMSO. As
DMSO concentration increases, WT Hsp104 activity was uncovered while the passive effect of
ATPase Dead Hsp104 is minimized. n≥2, Mean±SEM

Our interpretation of these results is that DMSO is not affecting the nature of fibrils on
their own, but rather is allowing us to observe the true remodeling potential of Hsp104.
Because Aβ42 is so hydrophobic, we hypothesize that the peptides that are freed from
the fibrils by Hsp104 are immediately re-joining a fibril structure, which is why we do not
observe strong disaggregation by WT Hsp104 in buffer alone. Our hypothesis is that
with > 7% DMSO present, the released Aβ42 peptides remain solubilized after Hsp104
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release, thus allowing us to gauge Hsp104 activity. However, other interpretations are
possible, such as the possibility that DMSO increases the ATPase rate or solubility of
Hsp104.

Moreover, this experiment highlights the importance of having a negative

control. An ATPase Dead Hsp104 is crucial to distinguish active Hsp104 remodeling
from non-specific bulk protein effects.

We alternatively found that increasing Hsp104 concentration in strong excess to Aβ42
fibrils also allowed distinction between WT and ATPase Dead Hsp104. As the molar
excess of WT Hsp104 increased from 4× to 36×, WT Hsp104 activity improved but the
effect of ATPase Dead Hsp104 was unchanged (Figure II-3). The EC50 of WT Hsp104
was 5.7 µM with the maximal effect at 17.6 µM (57% fibrils remaining). Thus, achieving
higher concentrations of Hsp104 uncovers WT Hsp104 activity just as addition of DMSO
does, perhaps because increased availability allows Hsp104 to tackle the Aβ42 fibrils
before remodeled monomers rejoin the aggregate.
Figure II-3 High levels of
Hsp104 are required to
disassemble Aβ42 fibrils
Pre-formed Aβ42 fibrils (0.5
µM) were incubated for 16 h
at 37ºC with increasing
concentrations of either WT
or ATPase Dead Hsp104 (2–
18 µM).
As WT Hsp104
concentration increased, so
did the elimination of amyloid
content of the Aβ42 fibrils. In
contrast,
the
effect
of
ATPase Dead Hsp104 did not change with increasing concentration. The line of best fit for WT
2
2
Hsp104 was y = 0.0032x – 0.0988x + 1.318 (R = 0.99726) (EC50 = 5.744 µM; Maximal activity =
17.626 µM; Maximal disassembly = 0.5707) and the line of best fit for ATPase Dead Hsp104 was
y = -0.0032x + 0.8708. n≥3, Mean±SEM
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Hsp104 can be optimized for Aβ42
Once we had established that Hsp104 was able to reverse Aβ42 fibrils, we sought to
enhance its efficacy by introducing mutations to the substrate-binding loops of Hsp104.
We mutated the substrate-contacting residues Y257 and Y662 to F in order to make
them more hydrophobic and encourage interaction with the very hydrophobic Aβ42
peptide.

Again, overnight incubation of Aβ42 fibrils with WT Hsp104, but not ATPase Dead
Hsp104, reduced amyloid content as measured by ThT.

Mutation of the substrate-

binding loop in NBD1 (Y257F) or NBD2 (Y662F) alone did not enhance activity of
Hsp104 in dismantling Aβ42 amyloid fibrils (Fig II-4). However, when these mutations
were combined (Y257F:Y662F) such that every substrate-contacting residue was the
hydrophobic amino acid F, Hsp104 reversed amyloid fibrils completely, such that there
was no amyloid present (Fig II-4).
Figure II-4 An Hsp104 variant has
enhanced activity against Aβ42
fibrils
Y257F:Y662F Hsp104 has enhanced
disaggregation activity of Aβ42 fibrils.
Pre-formed Aβ42 fibrils (0.5 µM) were
incubated for 16 h at 37ºC with the
indicated Hsp104 variant (2 µM) in
KHMD with 10% DMSO. Mutation of
the substrate-contacting residues in
each NBD had little effect on their
own,
but
combined
increased
disaggregation activity to completely
eliminate amyloid fibril content. n≥2,
Mean±SEM
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We also examined Y257F:Y662F Hsp104 for activity against another substrate to
determine whether enhanced activity was specific to Aβ42. We examined the ability of
Hsp104 variants to reactivate chemically denatured firefly luciferase.

Because this

substrate forms a non-amyloid (disordered) aggregate, coordinating chaperones Hsp70
and Hsp40 were required for Hsp104 function. WT Hsp104 reactivated about 12% of
the denatured luciferase, Y257F:Y662F had less activity, reactivating about 8%, and
ATPase Dead Hsp104 was completely inactive (Fig II-5).
Y257F:Y662F

Hsp104

This suggests that

is

indeed specialized for activity
against Aβ42 as a substrate
and is not simply exhibiting
increased

remodeling

activity.
Figure II-5 The Aβ42-optimized Hsp104 variant is less effective against aggregated
luciferase
Y257F:Y662F Hsp104 does not have enhanced disaggregation activity of aggregated luciferase.
Chemically denatured firefly luciferase aggregates (500 nM) were incubated for 1.5 h at 25ºC
with Hsp70/Hsp40 (1 µM) and an Hsp104 variant (6 µM). The resulting products were tested for
ability to catalyze a luminescence reaction, indicating reactivated luciferase, and compared to
non-denatured luciferase to estimate the percentage of proteins reactivated from the aggregate.
WT Hsp104 was more effective at restoring luciferase function than Y257F:Y662F Hsp104, and
the ATPase Dead variant was completely inactive. n=2, Mean±SEM

Conclusions and Future Directions
Despite initial indications that Hsp104 was unable to interact with Aβ42, we were able to
identify two separate conditions to unmask its unique disaggregase activity. We found
that addition of 10% DMSO facilitated striking elimination of Aβ42 fibrils by WT Hsp104
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and minimized the apparent bulk protein effect of ATPase Dead Hsp104. Alternatively,
we found that very high levels of WT Hsp104 compared to Aβ42 (36-fold excess)
allowed Hsp104 to reverse fibrils. The effect of ATPase Dead Hsp104 does not change
with increased concentration, but does appear to reduce ThT reactivity consistently, to
about 80% of untreated fibrils.

Therefore, we used the DMSO condition to pursue

analysis of substrate-optimized Hsp104 variants.

Because of the extreme hydrophobic character of Aβ42, we mutated the substratecontacting residues on the binding loops of Hsp104 from Y to F.

We found that

Y257F:Y662F Hsp104 did indeed have enhanced ability to eliminate Aβ42 fibrils, and in
fact completely eliminated amyloid content. This enhancement of activity was specific
for Aβ42 as a substrate. Testing this variant in a biological system (e.g., Drosophila)
would ultimately determine if Y257F:Y662F Hsp104 is more promising against Aβ42
therapeutically.

The ThT results obtained here are promising, but more experiments are needed to fully
characterize the effect of Hsp104 on Aβ42 fibrils.

Sedimentation analysis would

determine whether Aβ42 is being truly resolubilized or redirected into non-amyloid
aggregates, and electron microscopy (EM) images would also be helpful in determining
the nature of remodeled Aβ42. To add physiological relevance, the toxicity of untreated
Aβ42 to cultured neuroblastoma cells (e.g., SH-SY5Y) could be compared to the Aβ42
fibrils treated with Hsp104 to establish whether Hsp104 treatment is reducing the toxicity
of these fibrils.
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The Aβ42 peptide is a cleavage product that has no known normal function. Thus,
elimination of Aβ42 following disassembly of fibrils would be ideal for this substrate.
Therefore, it would be useful to also test the HAP mutant of Hsp104, which has three
mutations (G739–K741 to IGF) that allow it to associate with the bacterial proteolytic
chamber ClpP (Tessarz et al., 2008). Thus, when HAP remodels a substrate, it feeds
the protein into ClpP for proteolysis rather than releasing the protein into a soluble state.
The HAP/ClpP system would be a useful tool for evaluating the improved efficacy of the
Y257F:Y662F mutations since the successfully remodeled substrates would be
eliminated from the reaction and cannot reform into fibrils with time. Examination of
Aβ42 elimination rates would give quantifiable data regarding relative potency of Hsp104
variants.
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PART 2. Developing small molecules for Aβ42

Background
Small molecules are appealing as a potential treatment for Aβ42 because of the relative
size in comparison to an amyloid fibril, allowing the molecule to intercalate within the
tight intermolecular contacts and break apart the associations.

Additionally, a small

molecule can be optimized for a specific substrate to enhance potency.

A screen of bioactive small molecules previously uncovered 4,5-dianilinopthalimide
(DAPH-1) as a potent inhibitor of Aβ42 amyloidogenesis (Blanchard et al., 2004). Our
lab has developed analogs based on this structure, with organic synthesis performed by
Professor Stephen Buchwald (MIT Chemistry). We designed molecules to probe the
necessity of each component group (aniline rings vs pthalimide) in anti-Aβ42 function as
well as exploring the parameters required of small constituents added to the aniline rings
(Fig II-6).

We employed these molecules in various assays to understand how DAPH molecules
interfere with various steps of the Aβ42 amyloidogenesis pathway. We were interested
in probing the role of these molecules in preventing and reversing fibril formation, ability
to affect oligomerization, and the effect of DAPH treatment on toxicity of the Aβ42
conformers.
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Figure II-6 Structures of DAPH analogs
The DAPH-1 structure was modified in this series of analogs. The collection includes molecules
deficient in aniline rings, either lacking rings (DAPH-6) or tethered to the scaffold (SA), and a
molecule with a bulky group added to pthalimide (DAPH-2) to determine which component
groups are critical in the observed anti-amyloid function of DAPH-1. A water-soluble analog
(DAPH-14) was also created. Small functional groups were added to the aniline rings to
determine what properties might enhance efficacy of the rings in interfering with Aβ42 amyloid
formation. Groups examined were fluorine (DAPH-7) and NO2 (DAPH-10), as well as methoxy
(DAPH-12) and a methyl group (DAPH-22). DAPH-12 was further probed by examination of
modifications to this molecule: replacing methoxy with ethoxy (DAPH-12a), a methyl group
added onto the pthalimide (DAPH-12b), or the creation of CF3 on the aniline rings (DAPH-12c).
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Initial results: DAPHs antagonize Aβ42 fibrils
Initial DAPH experiments were conducted in our lab by Huan Wang. First, a small
screen was performed to determine which component groups with the DAPH molecule
contributed to the inhibitory property observed for Aβ42 amyloid formation.

As with

previous studies, DAPH-1 suppressed Aβ42 fibril formation by ThT and this effect was
more pronounced as the concentration of the small molecule was increased (Fig II-7A).
DAPH analogs lacking aniline rings (DAPH-6) and with tethered rings (SA) were
ineffective at inhibiting fibrillization, suggesting that the aniline rings are critical for a
productive interaction with Aβ42, and these rings must be mobile.

Moreover, Huan

Figure II-7
Prevention of Aβ42
fibrillization by DAPHs
A. DAPH analogs require flexible
aniline rings to prevent Aβ42 fibril
formation. DAPH molecules (10 µM
or 40 µM, or equivalent volume
DMSO as a vehicle control) were
added prior to fibrillization of Aβ42
(10 µM), shaking at 700 rpm at 37ºC
for 24 h. Analogs deficient in aniline
rings (DAPH-6 and SA) do not
suppress Aβ42 fibrillization, but the
addition of small hydrocarbon groups
to the aniline rings (DAPH-12 and
DAPH-22) improve inhibitory potency
compared to that of DAPH-1. n=4,
Mean±SEM
B. Successful DAPHs eliminate the
appearance
of
Aβ42
fibrils.
Fibrillization reactions in the presence
of each small molecule as in A were
negatively stained and viewed by EM.
Aβ42 alone forms a dense network of
fibrils, and DAPH analogs showing
efficacy
in
suppressing
amyloidogenesis by ThT (A) also
prevented the visual development of
fibrils. Scale bar = 0.5 µm

Experiments by Huan Wang.
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found that addition of small hydrocarbon groups onto the aniline rings (DAPH-12 and
DAPH-22) enhanced the efficacy in preventing Aβ42 fibril formation, with lower
concentration of these analogs showing as much potency as the higher concentration of
DAPH-1 (Fig II-7A).

EM images confirmed that the analogs suppressing amyloid

formation by ThT indeed prevented fibril development (Fig II-7B).
Figure II-8
Reversal of Aβ42
fibrils by DAPHs
A. DAPH analogs require flexible
aniline rings to reverse Aβ42 fibril
formation. DAPH molecules (10 µM
or 40 µM, or equivalent volume
DMSO as a vehicle control) were
added to preformed fibrils of Aβ42
(10 µM) and incubated at 37ºC for 1
h. Analogs deficient in aniline rings
(DAPH-6 and SA) do not reverse
Aβ42 amyloid fibrils, but the
addition of small hydrocarbon
groups to the aniline rings (DAPH12 and DAPH-22) improve potency
compared to that of DAPH-1. n≥3,
Mean±SEM
B. Successful DAPHs eliminate the
presence of Aβ42 fibrils.
Preformed fibrils were incubated each
small molecule as in A, and were
negatively stained and viewed by
EM. Aβ42 alone maintained fibril
integrity, and DAPH analogs
showing efficacy in eliminating
Aβ42 fibrils by ThT (A) also
reversed the visual appearance of
fibrils. Scale bar = 0.5 µm

Experiments by Huan Wang.

Huan also examined the ability of the panel of DAPH analogs to antagonize pre-formed
Aβ42 fibrils.

Results were consistent with those seen in prevention of fibrillization.

DAPH molecules required flexible aniline rings to exhibit potency in reversing Aβ42
fibrils, and again, DAPH-12 and DAPH-22 showed enhanced activity (Fig II-8A and 8B).
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In addition to preventing and reversing Aβ42 fibrils, successful DAPH analogs also
affected the templating property of amyloid, as measured by the ability to seed
fibrillization of Aβ42 monomers. Huan observed that Aβ42 assemblies formed in the
presence of DAPH do not seed fibrillization of monomers, indicating that these
conformers formed in the presence of DAPHs are non-amyloid. She also found that
Aβ42 fibrils disassembled by DAPHs no longer serve as a template in seeding reactions,
indicating large structural reorganizations by the small molecules.

Therefore, it is

obvious that DAPH molecules are dramatically interfering with the highly stable amyloid
contacts and remodel the structures to eliminate the pernicious conformation.

After probing the mechanism of which components of the DAPH molecules interact with
Aβ42 fibrils, we sought to examine the interaction between DAPH-1 and oligomers, and
further, to examine if treatment with DAPH analogs eliminates the cytotoxicity associated
with Aβ42 fibrils.

DAPH-1 redirects Aβ42 oligomerization
We have established that DAPH-1 can prevent and reverse Aβ42 fibrils by remodeling
the structure of these assemblies. We next wanted to probe how DAPH-1 might affect
the pre-amyloid oligomerization of Aβ42.
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Jake Lazarus developed a protocol to promote Aβ42 oligomerization over fibril formation.
He found that an intermediate agitation speed served to encourage the formation of
oligomers and delay the conversion to fibrils (Fig II-9). We therefore used this procedure
for all oligomer studies.
Figure II-9
Aβ42 oligomer
preparation
Aβ42 amyloid formation was
monitored ThT.
Aβ42 was
dissolved
in
HFIP,
speedvacuumed
to
dryness,
and
resuspended in buffer. Agitation of
Aβ42 at 300 rpm or 1000 rpm at
37ºC promotes the rapid formation
of fibrils, but agitation at 500 rpm
favors the formation of oligomers.
The reactivity with amyloid-binding
dye ThT begins to increase after 2
h, suggesting the enrichment of
pre-amyloid oligomeric forms at
earlier time points.
Experiment by Jake Lazarus.

In order to evaluate the effect of DAPH-1 on Aβ42 oligomer formation, we sought to
visualize the appearance of discrete oligomeric species on a semi-native gel.

We

formed oligomers either alone or in equimolar DAPH-1 and then examined consecutive
time points of the soluble populations to visualize the time course of oligomerization.
Untreated Aβ42 started as low molecular weight (MW) oligomers but quickly
accumulated into high MW oligomers before forming large insoluble amyloid fibrils that
were unable to enter the gel (Fig II-10, vehicle). We found that DAPH-1 accelerated the
loss of soluble populations of Aβ42, redirecting oligomers into insoluble non-amyloid
accumulations (Fig II-10). Note that the formation of high MW oligomers was completely
prevented by DAPH-1 treatment.
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Figure II-10 DAPH-1 intereferes
with Aβ42 oligomerization
Equimolar DAPH-1 prevents Aβ42
oligomer
formation.
The
oligomerization
reaction
was
performed by agitating Aβ42 (100
µM) in the presence of DAPH-1
(100 µM) or equivalent volume
DMSO (vehicle) at 500 rpm. The
reaction products were filtered
through a 0.22 µm filter to collect
the soluble species at indicated
time points and then the oligomers
were exposed to 2% SDS, and,
without boiling the samples, were
resolved on a 10–20% Tris-tricine
gel at 4ºC. The peptides were detected by Western blot using the α-Aβ 6E10 antibody. The
progression of Aβ42 alone shows the transition from low MW oligomers to high MW oligomers to
insoluble fibrils unable to enter the gel. The presence of DAPH-1 prevents the formation of high
MW oligomers and redirects Aβ42 into insoluble aggregates that are non-amyloid in nature.

We next examined the time course of Aβ42 oligomerization by dot blot using
conformation-specific antibodies.

The oligomerization reaction was performed either

alone or in equimolar DAPH-1 and then spotted unfiltered to view the total population or
0.22 µm filtered to view only the soluble species. Each reaction was spotted in serial
dilutions to highlight subtle differences between treatments. The α-Aβ 6E10 antibody
showed that total levels of Aβ42 were consistent among the treatments, but highlighted
that DAPH-1 accelerated the loss of soluble Aβ42 (Fig II-11A). The A11 antibody that
recognizes a generic oligomer conformation did not have strong reactivity, but
differences were apparent in the highest concentration dilution, again showing that the
oligomeric structure was prevented by DAPH-1 (Fig II-11B).

Another conformation-

specific antibody, NAB61, which reacts with the structure of Aβ oligomers and some Aβ
fibrils that correspond to brain pathology, showed that DAPH-1 dramatically eliminated
the development of pathologic conformations by Aβ42 (Fig II-11C).
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These results

demonstrate that DAPH-1 accelerates the loss of soluble Aβ42 oligomeric populations
into less pathological forms.

Figure II-11 DAPHs redirect
Aβ42 oligomers
A–C. DAPH-1 redirects Aβ42
oligomers
into
insoluble
accumulations.
Aβ42
oligomerization was performed
as in Fig II-10 in the presence
of equimolar DAPH-1 (100 µM
each) and spotted in serial
dilutions on a nitrocellulose
membrane.
Samples were
passed through a 0.22 µm filter
to separate the soluble species
from
the
total
sample.
Antibodies used were: (A) AntiAβ 6E10 antibody to probe for
total Aβ levels; (B) Antioligomer A11 antibody to probe
for oligomeric structure; and (C)
Anti-Aβ
“pathologic
conformation” NAB61 antibody
(specific to oligomers and
certain fibril strains) to probe for
structures associated with brain
pathology.
DAPH-1
accelerates the loss of soluble
Aβ42 samples (6E10) and
reduces the presence of
oligomers (A11) and structures
associated with brain pathology
(NAB61).

Aβ42 oligomers, which are strongly associated with cytotoxicity, are structurally altered
by DAPH-1 treatment. Semi-native gel allowed visualization of distinct oligomeric bands,
and DAPH-1 dramatically reduced the amount of soluble oligomers formed and
completely eliminated the formation of high MW oligomers.

143

Therefore, DAPH-1

redirected oligomers from the amyloid pathway into alternate, insoluble structures. Dot
blot confirmed this accelerated formation of insoluble material and further demonstrated
that this corresponded to a loss of pathological material. Therefore, although DAPH-1 is
driving off-pathway aggregation, this conformation may be more tolerable in a biological
system than amyloid inclusions.

We have established that DAPH molecules structurally alter both Aβ42 fibrils and
oligomers, and next wanted to determine if these alterations reduce toxicity of these
conformers.

DAPH treatment reduces toxicity of Aβ42 fibrils
Again, we sought to use a panel of DAPH analog molecules to probe the efficacy of
DAPHs to disassemble Aβ42 fibrils, but the purpose of these experiments was to
examine whether remodeling by DAPHs corresponded to reduced cytotoxicity of the
fibrils. We tested DAPH-1, known Aβ42-optimized structures DAPH-12 and DAPH-22,
as well as an array of other analogs for potentially enhanced activity in disassembling
pre-formed Aβ42 fibrils. Immediately following the disassembly reaction, the moleculetreated reaction products were applied to cultured SH-SY5Y neuroblastoma cells to
monitor cell survival and therefore gauge toxicity.

Again, we observed that DAPH-1 had the ability to reverse pre-formed Aβ42 fibrils by
reducing amyloid content to 54% by ThT, and that DAPH-12 and DAPH-22 showed
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enhanced disaggregation activity (47% and 36%, respectively) (Fig 12A). The other
molecules tested had various degrees of success in antagonizing fibrils, with DAPH-12c
showing the most potent effect, reducing amyloid presence more than DAPH-1, to 35%
(Fig II-12A). It is interesting to note that while DAPH-12, containing the added methoxy
groups, showed improved efficacy against Aβ42 fibrils, the expansion to ethoxy in
DAPH-12a eliminated function altogether (88% fibrils remaining) (Fig II-12A).

Thus,

addition of a small hydrocarbon chain to the aniline rings of DAPH is beneficial, but the
chain must not exceed a certain length.

The Aβ42 fibrils treated by DAPHs were added extracellularly to cultured SH-SY5Y
neuroblastoma cells to mimic the toxic extracellular plaques that occur in AD. Untreated
Aβ42 fibrils (buffer) did cause toxicity, resulting in the death of 35% of the cultured cells,
as measured by MTT assay to assess mitochondrial viability (Fig II-12B). The DAPH
molecules showing greatest ability to reduce toxicity were DAPH-1 (24%), DAPH-12
(21%), DAPH-22 (13%), and DAPH-12c (15%) (Fig II-12B). Because the efficiency of
each DAPH to eliminate amyloid content of the fibrils corresponded so well to conferring
protection against toxicity, we performed a correlation to compare these two measures.
Indeed, reversal of cross-β structure by a DAPH molecule correlated well with
elimination of fiber toxicity, with a correlation coefficient of 0.889 (Fig II-12C).
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Figure II-12
DAPH
remodeling
corresponds to reduced
toxicity
A.
Certain DAPHs
reduce fibrillar content
of Aβ42 fibrils, as
measured by ThT. Preformed Aβ42 fibrils (10
µM) were treated with
the indicated DAPH
molecule (40 µM) for 2 h
at 37ºC.
As before,
DAPH-1 eliminated 46%
of
the
cross-β
conformation of the
fibrils, and DAPH-12,
DAPH-22, and DAPH12c showed enhanced
anti-amyloid
activity.
n≥5, Mean±SEM
B.
Fibrils treated by
certain DAPHs have
reduced toxicity. The
reaction products from
A were applied to
cultured
SH-SY5Y
neuroblastoma
cells
(10,000
cells/well,
undifferentiated)
such
that half the media was
replaced (5 µM final
concentration of Aβ42).
After 4 h treatment, cell
survival was measured
by the MTT assay,
which uses a dye to
measure mitochondrial
viability.
Treatments
were
normalized
to
treatment
by
small
molecule alone and
then compared to Triton
X-100
detergent
to
determine relative toxicity. Untreated Aβ42 fibrils were toxic to 35% of cells, but this was reduced
by pre-treatment with DAPH-1 or successful DAPH analogs (-12, -22, and -12c). n≥4,
Mean±SEM
C. Correlation between efficacy in eliminating amyloid and impact on toxicity for each DAPH
molecule. The correlation coefficient was 0.889, indicating a strong association between DAPHdriven elimination of cross-β conformation and resulting cytotoxicity of the treated Aβ42 fibrils.
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We have shown that DAPH analogs showing success in combating the amyloid structure
of Aβ42 fibrils also reduces the toxicity of those fibrils. We were also able to draw some
conclusions about structural alterations that improve the anti-Aβ42 activity of DAPH-1.
Previous results have demonstrated that the aniline rings are critical for function, and
further, we found that addition of small hydrophobic groups to these rings may enhance
the ability of DAPH to interact productively with Aβ42. Addition of methyl groups (DAPH22) improves efficacy, as does methoxy (DAPH-12), but interestingly, addition of ethoxy
groups (DAPH-12a) abolishes all functionality. Therefore, there is a size limitation of the
groups or the constituent may block activity.

It was unexpected that addition of a group to the pthalimide had an effect on the potency
of the DAPH molecule, as we have shown that the aniline rings are the critical
component in Aβ42 interactions. We observed that the addition of a bulky group on the
pthalimide did impair activity (DAPH-2, compared to DAPH-1) and that even a small
addition of a methyl chain had an effect (DAPH-12b, compared to DAPH-12). Therefore,
the pthalimide may be influencing the potency of the rest of the molecule.

It is harder to draw definitive conclusions about other constituent groups. We found that
NO2 groups on the aniline rings (DAPH-10) had strongly decreased activity compared to
DAPH-1.

The water-soluble analog DAPH-14 also showed impaired function.

Interestingly, while addition of fluorine alone had a slightly inhibitory effect (DAPH-7), we
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observed that CF3 (DAPH-12c) greatly potentiated anti-Aβ42 activity. More molecules
may be needed to clarify the contribution of these groups.

Speculation on the mechanism of DAPH molecules
The intermolecular contacts of the Aβ42 fibril have been well characterized, and many of
the critical residues involved in fibrillization have been identified. The adjacent amino
acids F19 and F20 are part of the protofibril core that is critical for amyloidogenesis
(Luhrs et al., 2005), and the repetition of the aromatic rings of the side chains was
reminiscent of the arrangement of the aniline rings in the DAPH-1 molecule (Fig II-13A
and II-13B). Because of our findings that the aniline rings are critical to the anti-Aβ42
function of DAPH molecules, we hypothesized that the aniline rings might be interfering
with the Aβ42 fibril by disrupting interactions between the aromatic rings (Fig II-13B). In
this model, DAPH-1 intercalates the Aβ42 fibril and, through π - π stacking, disrupts the
existing intermolecular contacts.
Figure II-13 Model of DAPH
with Aβ42
A. The DAPH-1 molecule has
aromatic rings (circled in pink).
B.
The Aβ42 peptide has
adjacent aromatic amino acids
(F19 and F20, circled in pink)
that are critical to fibrillization,
based on the structure from
Luhrs et al., 2005.
Our
hypothesis is that the DAPH-1
molecule interacts with the
Aβ42 fibril at these residues,
and by π - π stacking, disrupts
the existing fibril contacts.
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To test the feasibility of this model, we collaborated with Professor Kim Sharp to create a
motile representation of these molecules. Dr. Sharp created movies showing the natural
3-dimensional fluctuations of each molecule (Fig II-14A), and was then able to measure
the pseudo-torsion angles adopted by the bonds at the base of the aromatic rings of
interest (Fig II-14B). Superficially, it does seem that the aniline rings of DAPH-1 are able
to adopt angles that are complementary to the phenylalanines of the Aβ42 fibril, thus
supporting our model that aromatic interactions between these molecules may interfere
with the existing phenylalanine contacts within the fibril.

A

Figure II-14 Motion
models of DAPH
and Aβ42
A.
Modeling the
motion
of
the
aromatic rings in
DAPH-1 and in Aβ42
fibrils. The molecular
structures
were
animated to simulate
the range of motion
of each molecular
bond in solution.
B. The frequency of
time throughout the
simulations that the
aromatic rings spent
at specific torsion
angles was plotted in
a histogram.
Movies and analysis
by Professor Kim
Sharp

To experimentally test this interaction, we sought to use an Aβ42 fibril that did not have
the adjacent FF motif.

Previous research had determined that replacement of both

phenylalanines with isoleucines, F19I:F20I (FF→II Aβ42) still resulted in fibril formation
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(Hilbich et al., 1992). Additionally, the exchange of F19 for its binding partner across
fibril strands G38, F19G:G38F (F↔G Aβ42) also maintained the capacity to form fibrils
(Luhrs et al., 2005).

We had these two peptides synthesized in order to examine

whether DAPH-1 could interfere with the intermolecular contacts formed by these fibrils
lacking the FF motif.

We found that FF→II Aβ42 was able to form fibrils with similar kinetics to WT Aβ42, but
that under our conditions, F↔G Aβ42 did not (Fig II-15). Rather than optimizing the
reaction for both Aβ42 variants, we proceeded with experiments to determine if DAPH-1
maintained anti-amyloid properties for the FF→II Aβ42 peptide that lacks the aromatic
rings critical to our model.

Figure II-15
Aβ42 variant
fibrillization
Each variant of Aβ42 (10 µM)
was agitated in the plate reader
at 12.7 Hz at 37ºC for 20 h,
and resulting fibril formation
was monitored by ThT. FF→II
Aβ42 formed fibrils with similar
kinetics and to a similar extent
as WT Aβ42. Our conditions
did not result in F↔G Aβ42
fibrillization. n=3, Mean (SEM
not included for simplicity)

To determine if DAPH-1 interfered with FF→II Aβ42 fibrillization, we looked at amyloid
assembly in the presence of increasing concentrations of DAPH-1. DAPH-1 inhibited
amyloid formation of FF→II Aβ42, at levels almost identical to WT Aβ42 (Fig II-16A).
Moreover, DAPH-1 was as effective at disassembling pre-formed FF→II Aβ42 fibrils as
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pre-formed WT Aβ42 fibrils (Fig II-16B). Taken together, these data suggest that DAPH1 activity does not depend on the adjacent aromatic residues at F19 and F20; it must
antagonize Aβ42 amyloidogenesis in another manner.
Figure
II-16
DAPH-1
prevents fibrillization of an
Aβ42 variant
A.
DAPH-1
prevents
fibrillization of WT and FF→II
Aβ42 fibrils as measured by
ThT.
Aβ42 (10 µM) was
incubated with increasing
concentrations of DAPH-1 (0–
50 µM) with agitation of 700
rpm at 37ºC for 16 h. DAPH1 suppressed fibril formation
for both forms of Aβ42, with
similar
sensitivity
to
increasing small molecule
ratios. n=3, Mean±SEM
B. DAPH-1 reverses WT and
FF→II Aβ42 fibrils. Preformed Aβ42 fibrils (10 µM)
were incubated with DAPH-1
(10 µM or 40 µM) at 37ºC for
2 h and the amyloid content
remaining was examined by
ThT. Treatment with DAPH-1
eliminated fibrils for both
forms of Aβ42 to a similar
extent. n=3, Mean±SEM

In conclusion, the interaction between DAPH-1 and Aβ42 does not depend on aromatic
rings at F19 and F20. Therefore, it is unlikely that DAPH-1 is breaking fibers apart at
that location by means of aromatic ring interactions. The exact mechanism remains
under investigation in the Shorter lab.
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Conclusions and Future Directions
Our results have characterized DAPH-1 as a molecule that interferes with the
development of Aβ42 fibrils and oligomers, and even possesses the ability to reverse
pre-formed fibrils. Further, we have identified modifications to the DAPH-1 structure that
improve its activity as an Aβ42 antagonist. We found that short hydrocarbon chains
added to aniline rings are most effective but that the size of these groups must be within
a size limitation.

We also established that successful remodeling of Aβ42 fibrils by

DAPHs correlated with a reduction in the cytotoxicity of the fibril.

The interaction between DAPHs and oligomers requires further characterization. It will
be of interest to determine if the DAPH analogs with improved efficacy against Aβ42
fibrils will also have enhanced activity against oligomers. Additionally, the toxicity of
these forms is of great interest.

Previous studies have indicated that pre-amyloid

oligomers are more cytotoxic than fully assembled fibrils (Kayed et al., 2003). However,
our initial experiments to evaluate oligomer toxicity in SH-SY5Y neuroblastoma cells
indicated only minimal toxicity of oligomers. The structures of our oligomers may be
distinct from the oligomers from these studies, or an experimental parameter might need
to optimized (such as differentiating the neuroblastoma cells).

We examined a limited selection of DAPH analogs, so development of additional
molecules may allow even further optimization against Aβ42. We have developed some
guidelines for successful additions to the aniline rings, the short hydrocarbons of DAPH12 and DAPH-22, but additional investigation into the CF3 group of DAPH-12c is
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warranted. Other issues must be considered if DAPHs are to be developed as an AD
treatment, such as ensuring the molecule can cross the blood-brain barrier.

Because DAPH-1 potently interfered with FF→II Aβ42 amyloidogenesis, our model of
aromatic ring association between the aniline rings of DAPH-1 and the FF motif of Aβ42
was determined to be incorrect. Therefore, the mechanism of the interaction is still
unknown. The hairpin turn occurring at amino acids 26–30 is facilitated by a salt bridge
between D23 and K28 may be point of entry for small molecules because it may be
accessible to water molecules.

Mechanistic studies will be required to identify the

point(s) of interaction between DAPH-1 and Aβ42 fibrils.
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PART 3. Using foldamers to antagonize Aβ42 amyloidogenesis

Background
Foldamers are protein mimics that do not have a canonical peptide backbone but are
able to form secondary structures such as α-helices and β-sheets. These molecules are
critical for understanding the parameters of protein folding in terms of purely molecular
features (e.g., hydrogen bonding and hydrophobic interactions) rather than features that
may be peptide-specific (Goodman et al.,
2007, Zhang et al., 2012). There are distinct
classes of foldamers.

While the aliphatic

foldamers have carbon chains that have
variations to the natural α-peptide framework,
there is also a class of aromatic foldamers,
which include the arylamide foldamers, that
contain aromatic rings within the repeating
backbone motif (Fig II-17A) (Goodman et al.,
2007).

Despite having such a distinct Figure II-17 Foldamer framework

(A) The α-peptide is the canonical backbone
The arylamide
foldamers employ aromatic rings as spacers
aromatic foldamers are also able to adopt within the backbone.
(B) The polymeric arylamide chain is able to
secondary folds such as the α-helix or β-sheet adopt folds as an aliphatic chain would.
Shown is a crude example of an arylamide
foldamer
stacking
in
the
α-helix
(Fig II-17B) (Gellman, 1998). Additionally, conformation.

configuration from the canonical α-peptide, used in natural peptides.
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foldamers are able to oligomerize to form even more complicated quaternary structures
(Goodman et al., 2007).

Because these foldamers are able to mimic protein structures, but are not susceptible to
cellular proteolytic degradation pathways (Horne et al., 2009), these molecules may be
an ideal treatment for interrupting protein aggregation associated with disease.

Certain foldamers inhibit Aβ42 fibrillization
The aim of these experiments was to establish the potential application of aromatic
foldamers in combating Aβ42 amyloid formation.

We collaborated with Professor

William DeGrado, who selected and supplied the panel of arylamide foldamers used
here (Fig II-18). The collection of molecules includes carbon side chain additions with
various amine arrangements as well as intermittent addition of an ether group to the
aromatic rings within the backbone.
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Figure II-18 Collection of arylamide foldamers
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We performed the
Aβ42

fibrillization

experiment
presence

in

the
of

equimolar foldamer
and

monitored

amyloid

formation

by

Figure II-19 Certain foldamers prevent Aβ42 fibrillization

ThT.

The Foldamers have varying degrees of success in preventing Aβ42

foldamers

had µM) were agitated at 12.7 Hz at 37ºC for 4 h, with ThT monitoring fibril

fibrillization. Monomeric Aβ42 (10 µM) and the indicated foldamer (10

formation over time. Certain foldamers had a strong inhibitory effect

varying degrees of while other had no impact on amyloidogenesis. n=6, Mean±SEM

success in preventing Aβ42 fibril formation, with the impact ranging from no effect to
almost complete inhibition (Fig II-19).

From this collection, we have pulled out three foldamers to highlight the distinct
interactions that these molecules may have with Aβ42 (Fig II-20). Foldamer 344 (Fig II20, top panel) had no effect on Aβ42 fibrillization kinetics. Foldamer 615 is particularly
interesting because it did not suppress fibril formation and the final amyloid load is
equivalent to untreated Aβ42, but the foldamer delayed the lag phase preceding fibril
formation (Fig II-20, middle panel). The precise mechanism of this interaction requires
further characterization, but this finding may indicate that 615 is suppressing the
oligomer formation that is required to initiate amyloid formation, but once an elongationcompetent structure is formed, the foldamer has no effect on rapid fibril polymerization.
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Additionally, we identified Foldamer 334
as a potent suppressor of Aβ42 fibril
formation, which seems to completely
inhibit amyloidogenesis (Fig II-20, bottom
panel).
Figure II-20
Foldamers have distinct
effects on Aβ42
Foldamers may interact with Aβ42 at different
stages of amyloidogenesis. Graphs taken
directly from Fig II-19. Foldamer 344 had no
effect on Aβ42 fibril formation. 615 extended
the lag phase that precedes rapid elongation,
suggesting an interaction with obligate preamyloid oligomers. 334 was a very strong
suppressor of amyloid formation.

While certain foldamers were capable of preventing Aβ42 fibrillization, all molecules
tested were unable to reverse pre-formed fibrils (Fig II-21). Even the potent inhibitor of
amyloid formation, 334, had no effect on eliminating existing Aβ42 fibrils. Therefore,
foldamers must be interacting with Aβ42 along the amyloidogenesis pathway (e.g.,
capping fibril-templating structures) and have no ability to break apart the existing stable
contacts common to the amyloid cross-β fold.
Figure II-21 Foldamers do not
disassemble Aβ42 fibrils
No foldamer was able to
eliminate existing amyloid fibrils.
Pre-formed Aβ42 fibrils (10 µM)
were treated with the indicated
foldamer (10 µM) at 37ºC for 16
h, with ThT monitoring changes in
amyloid level. Each treatment
mirrored the untreated Aβ42
group, with amyloid level slightly
decreasing over time, but none
demonstrating
dramatic
disassembly. The Aβ42 alone condition did have a slight initial increase in amyloid levels, and all
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of the foldamers prevented this, again consistent with previous results that the foldamers interfere
with amyloid formation but are incapable of reversing the stable amyloid contacts once they exist.

Conclusions and Future Directions
These preliminary results suggest that foldamers are indeed a promising avenue to
prevent Aβ42 fibril formation.

Further experiments are needed to characterize the

inhibitory effect and determine how the foldamers interfere with amyloidogenesis. The
mechanism will be distinct from a small molecule, such as DAPH-1, which is able to
break apart existing contacts in addition to preventing contact formation. This is another
caveat of developing foldamers as a therapeutic; it must be administered prior to
development of amyloid load.

However, the idea that sequestration of toxic soluble

species into fibrils is beneficial suggests that foldamers may be ideal to prevent growth
of existing plaques without releasing toxic components by disassembling existing
aggregates.

Further collections of foldamers might be tested for potency in preventing Aβ42 fibril
formation, with the successful structures determined here guiding selection of new
molecules.

Moreover, a greater understanding of the foldamer state is needed to

understand the interaction and predict successful analogs. Some of these foldamers
associate into oligomeric complexes, and this may be critical to anti-Aβ42 function.
These issues, as well as determining ideal stoichiometry, are currently being
investigated in the Shorter lab.
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Overall conclusions: Developing novel antagonists of Aβ42 amyloidogenesis
The novel treatments presented here introduce potential disease therapies that might be
further developed to combat Aβ42 amyloid conformers. Hsp104, DAPH analongs, and
arylamide foldamers each present a separate mode of action, which, in turn, may each
be well suited for a specific disease environment. For example, our biochemical assays
indicate that Hsp104 and successful DAPH analogs physically dismantle pre-formed
Aβ42 fibrils, while successful foldamers could only prevent de novo amyloid formation.
As such, foldamer application to an existing amyloid fibril population would be
completely ineffective. However, one caveat of reversing Aβ42 fibrils is the potential
release of toxic species from sequestration within these aggregates (Hardy and Selkoe,
2002, Koffie et al., 2009). Therefore, a combinatorial therapy might allow synergistic
synthesis of these distinct activities. One can imagine that Hsp104 applied alongside
small molecules or foldamers might be more effective at eliminating amyloid fibrils that
Hsp104 alone because the Hsp104-remodeled Aβ42 monomers can be kept soluble by
the other treatment molecules.

Moreover, it has been reported that amyloid fibrils

formed in the presence of an inhibitory small molecule alter their intermolecular contacts
such that the molecule’s target site is altered, creating drug-resistant strains (Roberts et
al., 2009). A combination of small molecules was able to overcome this imposed strain
selection, but our hope is that even more diverse molecules may synergize further.

The results presented here are mostly preliminary in nature, and further investigations
will ultimately determine the potential of each of these treatment molecules in combating
Aβ42 amyloidogenesis.
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APPENDIX III : DETAILED METHODS
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Fly Phenotype Analysis and Protein Techniques
Eye Images
1. Anaesthetize flies on CO2 pad. To kill the fly, hold the fly still with a pair of
forceps with your left hand, and with your right hand, jab the sharp end of another
pair of forceps into the thorax. It is especially effective to slightly open the
forceps once inside the thorax.
2. Place a drop of clear nail polish onto a slide. Use the forceps to lift the fly by
holding onto its legs and then gently place the fly into the drop. It is best to put
the legs and abdomen in the nail polish but leave the head outside of the drop;
sometimes the drop will envelop the head if it is too close to the head or if it is
watery nail polish.
3. Wait for the nail polish to dry. Use your forceps to arrange or tilt the head so that
you have a flat view of the eye from above. (The fly might move or you may
need to readjust later, but arranging things now really saves time.)
4. Take your slide to the Leica Z-16 apo zoom microscope. Turn on the acquisition
software LAS V3.8 (you can skip the motorfocus drive initialization step by
selecting “cancel” and then “no”) and turn on the light source. In the Process tab,
select Z and then change setting to Transmitted Light Method 2.
5. Go to the Browse Tab and add a new folder within your data folder. [The icon
has a folder with a subfolder and a plus sign to indicate addition of a new
subfolder.] Use the rename button at the bottom to name the new folder with the
current date. Then, select the new folder as the capture location in which new
files will save. [This icon has a red dot on top of the subfolder and a white check
mark next to it.]
6. In the Acquire Tab, make sure you are in the Z window and view the image of the
fly. It is easier to adjust the fly’s position and head angle by looking through the
microscope lens and not by watching on the screen. Center the fly so its eye is
in the middle of the image.
7. Using the outer wheel on the attachment console, make sure the zoom is set to
maximum (114X) so all the images you take are equivalent.
8. Use the inner wheel to control focal plane.
a. In the image of the Z stack plane, click the left orange arrow so it turns
black. Move the wheel to adjust the focus to the lowest level (outer edge)
of the eye. Make sure the eye is positioned so that the whole outer edge
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is close to being in focus; this will ensure a nice angle in your picture.
Click the arrow so it turns orange again to lock in your setting.
b. In the Z stack image, click the right orange arrow so it turns black. Move
the wheel to adjust the focus to the highest level of the eye (usually the
top of the curve somewhere in the middle of the eye). Click the arrow so
it turns orange again to lock in your setting.
9. Set the Z Step size to 15. Your eye image should end up being around 10 steps
to accommodate the entire eye. You should adjust these settings if you’re taking
pictures of something larger than a fly eye.
10. Rename the image file name in Options. I also make sure that “Create stack”
and that “Align images before combining” are both checked.
11. Hit the Acquire button and watch as the scope takes images at each Z step. It
usually takes a while for the software to create the Multi-Focus image.
12. The software displays your image in the Browse tab when it is finished. If you
need to rename your file, you must do that within the data folder, as it will not let
you within the Leica software.

163

Paraffin Sections
Fixing heads
1. Fill an eppendorf tube with about 1 ml of Bouin’s fixative solution (Sigma HT10-132). Label the tubes ahead of time with an experiment number to keep track of
the genotype within that tube.
2. Anaesthetize flies on CO2 pad. Gently squeeze the thorax of the fly with forceps
in your left hand. The fly will extend its neck. Use a razor blade with your right
hand to sever the neck connection.
a. Some people remove the proboscis, but I do not. It is better to handle the
heads as little as possible if there is a degenerative eye phenotype.
3. Move the severed head into the eppendorf tube with your forceps.
4. Repeat until you have at least three heads per genotype (but you probably want
more if it is an important experimental condition!).
5. Once you have all the heads floating in the Bouin’s solution, add a small square
of KimWipe to hold the heads submerged under the surface of the liquid. This is
difficult and takes finesse. Your square should be just thinner than the width of
the opening of the eppendorf tube. Hold it with your forceps and lower it
perpendicularly to the surface of the liquid so that it enters in the middle of the
tube. Slide the KimWipe toward the tube wall and try to trap the heads between
the KimWipe and the wall. It may take several KimWipes to trap and hold all the
heads beneath the surface.
6. Put the eppendorf tubes in a rack on the Orbital Shaker and let them shake for 3
days to 1 week. (I have gone over a week’s incubation and the samples seemed
fine, but I try not to make it a habit. Usually, I monitor the tubes daily and wait
until the heads sink to the bottom.)
7. Make Leaching Buffer
50 mM Tris
150 mM NaCl
water

Stock
1 M Tris, pH 8.0
powder

For 1 L
50 ml
8.7g
to 1 L

8. Cut lens paper into sixths: Make two vertical cuts to divide it into thirds and then
a horizontal cut to separate each of those in half.
9. Set up a workspace in the hood. Place a pipette tip box lid on an angle by
putting one end on a tip grid insert and leaving the other on the flat surface. Fill a
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beaker with a level of Leaching Buffer that will cover your samples (usually
around 200 ml depending on the number). Gather embedding cassettes and
label them with your experiment number. Find a new plastic transfer pipette
(dropper).
10. Place a square of lens paper into the angled tip box lid and use the dropper to
dampen the square with Leaching Buffer.
11. Carefully remove the KimWipe bits from the eppendorf tube and make sure all
the heads stay behind in the Bouin’s solution. Suck the heads into the dropper
and then expel them onto the square of lens paper.
12. Use the dropper to carefully rinse the lens paper to remove a lot of the Bouin’s
solution. Let it flow down the angled surface and repeat until the paper is only a
faint yellow.
13. Make sure the heads are in the center of the lens paper square. Use forceps to
fold the lens paper into a C-fold in both directions, making a little packet to
contain the heads. Fold the right edge so it creates a crease about a third of the
width of the paper and so that it covers the heads in the center of the square.
Then, fold the left edge on top of that so the left flap overlaps the right flap. This
will create a fold ‘barrier’ on both sides to hold the heads into the middle. Then,
take the top edge and fold it down in the same manner so it creates a fold a third
of the way from the top, and fold the bottom up to overlap and complete the final
fold to hold the heads within the packet.
14. Once the packet is folded, you can use the dropper to squeeze streams of
Leaching Buffer onto it to clear the rest of the Bouin’s solution away.
15. Place the lens paper packet into the embedding cassette with the appropriate
label. Drop it into the beaker containing Leaching Buffer.
16. When all heads have been moved into cassettes, move the Leaching Buffer onto
the Orbital Shaker for 6 hours to overnight.
17. If you cannot proceed with the paraffin embedding procedure, you may store the
leached samples in 70% EtOH in the fridge. They should last indefinitely in this
condition, but try not to leave them for too long.
Embedding and Blocking Paraffin Sections
1. Prepare the embedding machine. All of the chemicals needed are stored in
bottles near the machine with the number for each bucket it should go in. Simply
pour the chemical into the indicated bucket. The solutions should be clear and
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you need about 1 L to fully submerge your samples, so you may need to refresh
the supplies occasionally.
1
2
3
4
5
6
7
8
9
10
11
12

Histoclear
(Empty)
70% EtOH
80% EtOH
95% EtOH (I)
95% EtOH (II)
100% EtOH (I)
100% EtOH (II)
Xylenes (I)
Xylenes (II)
Paraffin (I)
Paraffin (II)

Do not put samples in this!

Toxic! Use a mask or pour in a hood
Toxic! Use a mask or pour in a hood
Heated bucket, do not remove
Heated bucket, do not remove

You will need to rotate the machine by pressing the button on the keypad in order
for the openings to line up with each bucket.
Remember to turn on the exhaust fan above the machine once you have opened
the Xylenes container!
2. Lift the arm of the embedding machine out of its storage position in Histoclear.
Let the Histoclear drip back into the bucket.
3. After samples have been leached, put the cassettes into the appropriately sized
basket and place the basket into the embedding machine arm.
4. Run a program based on the length of time you want the process to take.
Overnight runs should be Program A (17 hrs) and daytime runs should be
Program D (6 hrs).
Program A:
3 hr
1 hr
1 hr
2 hr
2 hr
2 hr
1 hr
1 hr
2 hr
2 hr

Program D:
30 min 70% EtOH
30 min 80% EtOH
30 min 95% EtOH (I)
30 min 95% EtOH (II)
30 min 100% EtOH (I)
30 min 100% EtOH (II)
30 min Xylenes (I)
30 min Xylenes (II)
1 hr
Paraffin (I)
1 hr
Paraffin (II)

Note: I have started using Program D for daytime runs because I had an incident
in which the arm did not progress properly and my samples were left dry
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overnight and ruined. I frequently check the progress of the arm throughout the
daytime run.
5. The arm will stay submerged in the final step of hot paraffin until you use the
button on the keypad to raise the arm. When you retrieve your cassettes, let
them cool on a paper towel. You can store them indefinitely now that they are
paraffin-embedded.
6. To block the heads, take the cassettes to the Histology Prep Centre machine.
Turn on the cold plate (green switch on the left) and allow it start cooling down.
Collect a number of metal cup molds and make sure they are clear of old
paraffin, especially around the edges. Label the colored rings ahead of time.
7. Place your cassette onto the right portion of the hot plate and let the paraffin melt
enough that you can lift the lens paper packet out of the cassette without forcing
it. (I do this to the right side so the melted paraffin doesn’t get onto the molds I’m
using on the left side.)
8. Carefully unfold the C-folds of the packet. You may need to put it on the hot
plate to make it more pliable.
9. Use the foot petal to drip some paraffin into a metal cup mold. Don’t fill the cup
all the way. Let it sit on the hot plate in front of the drip spout.
10. Briefly heat up the lens paper at a point under the head you want to block in
order to loosen it. Use your forceps to scoop underneath the head to transfer it
into the metal cup mold. Do not lift the head by squeezing between the forceps.
11. Position the magnifying glass so you can see well. Position the head flat in the
middle of the cup and then bring the metal cup mold forward so it is resting just
off the hot plate. The paraffin will start to turn white and harden from the bottom
up, so you have limited time. Reach your forceps under the proboscis and gently
tilt the head upward so the proboscis moves from facing you to facing up, with
the back of the head at the base of the cup and the neck stump toward you.
Once it is in place, move the metal cup mold onto the cold plate to let it harden.
If you are not pleased with the head placement or angle, you can place the cup
back onto the hot plate and wait for the paraffin to melt to try again.
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12. Place your labeled colored ring onto the top of the metal cup mold so that the
tabs for the ring are perpendicular to the tabs on the cup. This will give you a
place to leverage when separating them later.
13. Use the foot pedal to fill the cup + ring with paraffin to the top of the ring.
14. Place the cup + ring on the cold plate and don’t move it while it hardens.
15. When the top of the paraffin looks opaque and the outside of the ring feels cool,
try separating the cup from the ring. It should come easily; if you have to force it,
you will often stretch or break the paraffin inside the ring and will have to redo it.
Now your sample is perfectly positioned in the paraffin bulb attached to the
colored ring and is ready to be cut.
Cutting Paraffin-Embedded Heads
1. Cool your paraffin-embedded samples attached to the colored ring by placing
them in ice for at least 30 min.
2. Turn on the microtome and check the settings are on 8 µm sections with
continuous transition. Turn on the water bath and heat to 38C.
3. Use a razor blade to trim the blocks to a trapezoid shape around your fly head.
This will allow the slices to form a ladder as they slices are cut. Make small
slices working from the outside in, or you might accidentally break off a chunk
that contains the head.

4. Put the block into the cutting stage and tighten the top screw as tight as you can.
Orient the trapezoid so the small edge is toward the top.
5. Unlock the hand wheel and rotate it so the sample moves toward the blade.
Bring the stage in or out with the arrow buttons so that the surface of the sample
just misses the blade.
6. Use the continuous cutting option by pressing start and adjacent button on the
console simultaneously. I like a speed around 9. The slices should start to
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accumulate as a ribbon on the blade surface, with the ladder shape mentioned
above. Watch as the ribbon goes and guide it go straight with a paintbrush.
a. If the sections have a cut or score through them, there may be something
on the edge of the blade. Use the large paintbrush to gently brush the
front and back edges as well as the surface of the sample to clear any
debris that might be damaging the sections.
7. When the specimen is finished, you will see the head starting to disappear from
your sections. Hit the stop button on the console. Carefully use two
paintbrushes to lift either end of the ribbon off the blade surface and move it onto
a napkin to the side. You may trim off the ends that do not contain useful layers
of the head: the length of the ribbon should fit onto a slide.
8. Repeat for two more samples of the same genotype. I usually put three samples
onto one slide.
9. When you have your three ribbons, get a paintbrush tip wet in the water bath and
use the droplet of water to adhere to the top of the ribbon. Lift the ribbon and
slowly move it over the water bath. Make sure it stays untwisted and that the
shiny side is facing down. Lower it so that the far end of the ribbon touches the
surface of the water, and then slowly lower the rest of the ribbon so it gradually
rests on the water.
10. Repeat for the other ribbons. When you have all three floating, use the
paintbrush to create currents between the ribbons to bring them closer together.
Arrange them so they are fairly close and will fit on a slide.
11. Take a pre-labeled Superfrost slide and put it perpendicularly into the water near
the top of the aligned ribbons. Angle the slide and slowly move it under the
samples. Lift the slide so the top of the ribbons stick to the top of the slide, and
then keep lifting the slide so it comes out of the water and the ribbons stay on.
You may need to adjust the angles of the ribbons with a wet paintbrush, but be
careful not to let the ribbon go over the edge of the slide, as it will twist
irretrievably.
12. Allow the slide to drip dry in a gray plastic slide holder.
13. After sectioning all the samples, dry the slides overnight by placing the slide
holder horizontally into the baking oven in the ablation room. Turn the oven on to
the 42C mark and leave the samples overnight.
14. In the morning, turn the oven up to 60C for 30 min.
15. Let the slides cool on the bench for 30 min.
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16. Dewax the samples by lowering the slide holder into a trough of Histoclear (I) for
5 min in the Room 307 hood. Move the holder into Histoclear (II) for another 5
min.
17. Clear the samples in Histoclear (III) to prepare the slides for mounting. Take the
slides out of the holder within the Histoclear (III) and let any excess Histoclear
drip back into the trough.
18. Squeeze a line of Cytoseal along the bottom edge of the slide. Place a long
cover slip at an angle along the bottom edge so it contacts the Cytoseal, and
then slowly lower the angle so the cover slip covers the whole slide.
19. Allow the slides to dry in the hood overnight.
20. Use the Leica fluorescence microscope to image the samples. Use the red
fluorescence channel to view the autofluorescence of the tissue. Find the
appropriate section to image.
a. Magnification: 20X objective with 1.6X
optovar
b. 16-shot acquisition with empirically
determined exposure time
c. Gain: 1.0X; Saturation: 100X; Levels:
0 – 1.1 – 255
d. Use the Focus tool [magnifying glass
icon] to select a region of interest and
use the hand wheel on the microscope
to adjust the focal plane until it is clear
on the screen.
e. Hit Acquire.
21. Process the image in Photoshop by changing to grayscale, inverting the colors,
and then adjusting the levels. Rotate and crop the image so the image is
highlighting the retinal structure.
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Western Blot
Running the gel
1. Collect heads by decapitating with a razor blade, and store them in an eppendorf
tube in the -80C freezer until ready to use. I take a minimum of 3 heads, but
usually 10–15 heads per genotype. Always be consistent within an experiment.
2. Add sample buffer to the eppendorf with your heads, usually 15–25 µl for ideal
coverage. I varied the volume depending on number of heads, just be consistent
within an experiment. I started by using NuPage 4X LDS Sample Buffer (Cat #
NP0007), but then switched to (and prefer!) Laemmli Sample Buffer (Cat # 1610737).
a. For NuPage 4X LDS Sample Buffer, add 12.5 µl β-ME to 112.5 µl sample
buffer, so final concentration is 10%. Note: This is 4X the concentration
that should be used when running your sample.
b. For Laemmli Sample Buffer, add 50 µl β-ME to 950 µl sample buffer, so
final concentration is 5%. Note: This is 1X and can be loaded directly
into the gel.
3. Use a blue pestle to grind the heads in the tube.
4. Boil samples at 99C for 3 min in heat block or Thermomixer. Pre-heat the heat
block so you don’t have to wait too long.
5. Spin samples at 15,000 rpm for 3 min.
6. Prepare a premade NuPage Novex 4-12% polyacrilimide bis-tris gel (Cat #
NP0322 for 12 wells; Cat # NP0323 for 15 wells) gel. Cut the gel out of its
sealed pouch over the sink. Remove the white sticker from the bottom of the gel
case to reveal an open line. Carefully remove the well dividers by gently pulling
straight out. Do not wiggle the divider or you may damage the wells! Rinse the
gel case and exposed wells with deionized water.
7. Place the gel against a white electrode insertion panel. Place either a second gel
or place a buffer dam on the other side of the insert. This should create a closed
reservoir. Lower the insert into a gel running box. Place an expander piece in
the back of the box and pull the handle so the expander presses tightly against
the insert. This creates a water-tight reservoir between the gel and the dam.
8. Dilute 20X NuPage MES SDS Running Buffer (Cat # NP0002) to 1X by
combining 100 ml with 1900 ml water.
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9. Pour 1X NuPage MES SDS Running Buffer into the reservoir between the gel
and the dam. Also add running buffer to the surrounding area so it covers the
open line on the gel case.
a. I use a plastic transfer pipette to squeeze running buffer into the wells.
You can see the preservative solution ripple out of the wells. This is
probably unnecessary, but I feel better about having clean wells.
b. At the very least, check that the well dividers are intact and vertical.
Move your head around to check the phase contrast of the gel with the
running buffer to make sure the little divider tab hasn’t folded over to
block one of the wells. Use a pipette tip to straighten dividers if
necessary.
10. Designate a lane for the molecular weight ladder SeeBlue Plus2 Prestained
Standard (1X) (Cat # LC5925). Load 10 µl of the molecular weight ladder.
11. Load 10 µl prepared sample into each well. You can change this volume
depending on your start volume. Note: It is better to load a designated amount
from each tube rather than to take whatever volume is present in the tube
because the volume can change during preparation of the sample. Also try to
load a full number of heads (for example, 8 µl of a 10 µl preparation made from 5
heads would be equal to loading 4 heads).
a. I like to put 1X Sample Buffer (e.g., Laemmli Buffer with β-ME but no
heads) into any unused wells. It helps the samples run straight without
spreading into neighboring lanes.
12. Run the samples for 15 min at 80 V.
13. Increase the voltage to 150 V and run until the blue front line reaches the bottom
of the gel (~45 min).
Semi-Dry Transfer
1. Make 2X transfer buffer with 10% MeOH. Combine 200 ml NuPage 20X
Transfer Buffer (Cat # NP0006-1) with 1600 ml water and 200 ml MeOH.
2. Soak 2 thick filter papers in 2X transfer buffer with 10% MeOH.
3. Cut a nitrocellulose membrane to the size of your gel. Soak the membrane in 2X
transfer buffer with 10% MeOH.
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4. Turn off the gel-running box and remove the gel case. Carefully crack the gel
case with the metal spatula until the connection points are severed and you can
lift one side of the case off the gel. Use the spatula to cut off the well lane
dividers and the thick part of the gel where it protrudes into the open line on the
case. Turn the gel upside down over a dish with 2X transfer buffer with 10%
MeOH and gently separate one edge of the gel from the case until the gel falls
into the transfer buffer.
5. Disassemble the semi-dry transfer apparatus and wet-wipe the metal plates with
2X transfer buffer with 10% MeOH.
6. Place one of the thick filter papers onto the apparatus base. I make sure the
Chinese character is away from me and the transfer paper’s long edge is
perpendicular to the long edge of the apparatus (vertical).
7. Use the roller tool or a 15 ml Falcon tube to gently roll out bubbles.
8. Place the nitrocellulose membrane onto the stack. Again, use the roller or a tube
to gently roll out bubbles.
9. Carefully tilt the dish with the gel in it and float the gel onto the spatula and
balance it so it doesn’t slide off. Take your time on this step.
10. Place the gel onto the nitrocellulose membrane and angle the spatula to allow
the gel to slide onto the membrane. Be careful to line it up well. Use the roller or
a tube to gently roll out bubbles (it will slide more than roll).
11. Place the remaining filter paper onto the stack. Roll out the bubbles.
12. Wipe the excess liquid from the surrounding plate. Place the spacer onto the
prongs and expand to lock into place. Put the lid firmly on top of that.
13. Turn on the power source. Run 20 V for 20 min (set for 400 mA).
Immunoblotting procedure
1. Place the membrane into a tip box containing PBS (Cat # P3813). Allow the
membrane to wash on an orbital shaker for 5 min.
2. Ponceau stain the membrane to make sure all the protein transferred correctly
and evenly. Pour Ponceau S solution (Cat # P7170) into the tip box and incubate
on the orbital shaker for 5 min.
3. Rinse the membrane in PBS for a short time. Monitor to make sure it doesn’t
completely remove the Ponceau stain. I usually shake a little in my hand just to
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remove the unbound Ponceau S solution. Place the membrane into a clear
sheet protector pouch.
a. Make a copy of the membrane with the black and white copy machine.
This is great for your lab notebook.
b. I used to scan a color photo of the staining, but I lost access to the
scanner computer. Now, I take a photo of the membrane with my camera
phone and email it to myself. You could use a regular camera, but I
found this to be easier.
4. Place the membrane back into the tip box and rinse with a fresh PBS wash for a
short time.
5. Remove the Ponceau stain with 0.1 M NaOH. Rinse quickly and watch the
Ponceau stream off the membrane; it is a lovely shade of lavender.
a. Make 1 M NaOH stock.
NaOH
water

Stock
powder

For 50 ml
2g
to 50 ml

b. Dilute to working concentration of 0.1 M NaOH. Add 5 ml 1 M NaOH
stock to 45 ml water.
6. Once there is no more Ponceau coming off the membrane and the membrane
looks white again (about 10-15 seconds), pour off the solution.
7. Rinse with 3 x 5 min PBS washes on the orbital shaker.
8. Block the membrane in 5% milk in PBS. I make this by weighing out 0.5 g milk
(Cat # 170-6404) in a 15 ml Falcon tube and then pouring PBS to the 10 ml line.
I am not overly cautious about exact amounts.
9. Cut a hybridization bag (#403) into fourths so that each is about the size of your
membrane. Cut the edges so only one edge is still connected, and then carefully
splay out the two sides of the bag. Place the membrane onto one face and then
fold the other face up so that it looks like a pouch around the membrane. Use
the Impulse Heat Sealer to seal two more edges (so only one edge remains
open). Pour in the 5% milk in PBS and then seal the final edge so it is enclosed
within the pouch.
10. Put the pouch face down the nutator and block for 30 min at RT.
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11. Cut a corner off the pouch and pipette your primary antibody into the liquid
through the opening. Massage the antibody into the milk and then reseal that
corner with the heat sealer.
a. Note: If you have a valuable antibody or a low dilution that would require
you use too much for this method, you can also make an antibody
solution in less volume (e.g., 2 µl antibody in 2 ml PBS). Cut the pouch
and put the membrane into a fresh pouch and add the antibody solution
before sealing the final edge.
12. Incubate with primary antibody overnight (unless otherwise noted) on the nutator
in the cold room.
13. Cut the pouch and put the membrane back into the tip box. Rinse 3 x 5 min in
PBS.
14. Block the membrane in 5% milk in PBS for 30 min on the nutator at RT.
15. Cut a corner off the pouch and pipette your HRP-conjugated secondary antibody
into the liquid through the opening. Massage the antibody into the milk and then
reseal that corner with the heat sealer.
16. Incubate with secondary overnight for 1 hr on the nutator at RT.
17. Cut the pouch and put the membrane back into the tip box. Rinse 3 x 5 min in
PBS.
18. Turn on the FujiFilm LAS3000 Imager and cool the camera.
19. Prepare the HRP substrate to develop the membrane. From the SuperSignal
West Dura Extended Duration Substrate kit (Cat # 34075), add 1 ml A and 1 ml B
to a 15 ml Falcon tube.
20. Carefully transfer the membrane into an uncut hybridization bag by lowering it
through the opening with forceps. Place it as close to the middle as you can.
Flatten the bag and squeeze any excess PBS off of the membrane so it is
pressed against the two faces of the bag.
21. Place the membrane into the machine and pour the HRP substrate solution into
the bag. Let it incubate a few minutes and allow the liquid to flow over the entire
surface of the membrane by gently tilting the bag. Squeeze the excess liquid
toward the bottom of the bag so it isn’t pooled on top of the membrane.
22. In the acquisition software, go to the Focusing tab to make sure the membrane is
in the viewing window and adjust the focus if necessary.
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23. In the Method/Tray Position tab, set the mode to Chemiluminescence. I usually
start by setting Exposure Type as Increment and the Exposure Time at 10 sec.
This will take an update the image every 10 sec while keeping the intermediate
images. I usually start with the Sensitivity set to Super, but then adjust down if
the signal is strong.
24. Allow the images to accumulate until it is definitely oversaturated. I save each
image because I don’t know what will be useful later; I like to have light
exposures all the way to really dark ones.
25. Set the Method/Tray Position to Digitize/Epi and then change the Exposure Type
from Increment to Precision and set the Exposure Time to 1/60 sec. Make sure
the Sensitivity is Standard or it will oversaturate.
26. Save the image, as it will allow you to know where the ladder is on your blot
when you look at the antibody placement.
27. To compile the two images, I first export each file in ImageGauge as a TIF 8 bit
file, and then open both with Photoshop. I drag the Epi image of the ladder into
the file containing the Chemiluminescent image, and hold shift when releasing.
This will line them up perfectly. Then I draw the ladder in a new layer and hide
the actual image of the ladder.
Table III-1 Antibodies used for Western immunoblot

Name
α-HA-HRP

1º/2º
Both (rat)

α-myc 9E10

Mouse

α-Hsp104

Rabbit

α-human-Hsp70 W27

Mouse

α-tubulin-HRP 11H10

Both (mouse)

α-actin

Rabbit

α-rhodopsin

Mouse

Goat α-Mouse-HRP

2º

Goat α-Rabbit-HRP

2º

Catalog Number
Roche
12013819001
Santa Cruz
sc40
Enzo Life Sciences
ADI-SPA-1040
abcam
ab3148
Cell Signaling
9099
abcam
ab8227
DSHB
4C5
Jackson ImmunoRes
115-035-146
Millipore
AP307P
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Dilution

Incubation

1:500

2h at 4ºC

1:500

O/N at 4ºC

1:2000

O/N at 4ºC

1:500

O/N at 4ºC

1:1000

O/N at 4ºC

1:2000

O/N at 4ºC

1:50

O/N at 4ºC

1:2000

1h at RT

1:5000

1h at RT

Cryosections and Immunohistochemistry
Blocking heads
1. Anaesthetize flies on CO2 pad. With your left hand, squeeze the abdomen of the
fly so its neck protrudes and with your right hand, use very sharp forceps to pull
the neck at the base of the head. The head should come off very cleanly with no
distortions (compression or extension).
2. Place a sheet of lab bench paper down to protect your bench. Squeeze a large
drop of Tissue Freezing Medium (TFM, red cap) into a round bottom well in a
glass dish.
3. Place the head into the well of TFM. Swirl the head under the surface and to the
bottom of the well. Remove any small air bubbles still attached the head. Be
careful! This is the longest step. Carefully lift the antennae and remove the
bubble from the divots below and stretch the proboscis to make sure no bubbles
lurk at the base.
4. Place more heads of the same genotype into the same well. I usually collect 6
heads per genotype.
5. Let the heads sit for 10-15 minutes in the TFM.
6. Prepare a strip of peel away plastic cup molds by placing a large drop of TFM
into each cup. Fill about halfway up the slanted surface, about to the notch on
the side.
7. Lift a head from the glass dish and place it into a cup (one head per cup). Do not
squeeze the head with your forceps; it is best to suspend the head in a droplet
between the forcep tips.
8. Swirl the head to the bottom of the cup and arrange it so the proboscis is facing
up and the neck stump is toward you (will produce coronal sections). Be certain
the head is flat as it may shift when you move the cup around.
9. Fill a plastic Tupperware dish with dry ice and pour ethanol on top. Let the
ethanol cool and bubble.
10. Smoothly place the strip of plastic cup molds into the ethanol. The edges of the
TFM will start to freeze from the bottom up. Once the TFM is completely hard
and white, use a Sharpie to draw a line on the edge of the TFM block to indicate
the bottom the sample (i.e., the edge toward which the neck stump points).
11. Label a 50 ml Falcon tube with the genotype information and let it chill in dry ice.
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12. Pull the strip of cups out of the ethanol and dab it onto the lab bench paper to
remove some of the excess cold ethanol. Squeeze the cup so the TFM block
pops out into the Falcon tube.
13. Store the Falcon tube in the -80C freezer indefinitely until you are ready to
section the heads.
a. You can also cut immediately! This is preferable because the tubes can
build up quickly and really crush your spirits.
b. There is also an option to prepare all your heads directly onto the cutting
stage chuck. I attempted this with poor results, but this would be ideal.
Basic idea: Place a large drop of TFM onto the chuck and lower it into
the ethanol/dry ice. As it begins to freeze upward, place a smaller drop
on top and put a head into it. Orient the head and let it freeze in the
ethanol. Add another drop and place another head and orient it. Let it
freeze, and keep building upward to create a totem pole of heads in a
vertical stack. You can cut these immediately and they are all already
aligned and positioned.

Cutting cryosections
1. Place the Falcon tube with your TFM blocks into the cryostat. Allow the blocks to
adjust to the temperature for about 30 minutes.
2. Line up the blocks in the cryostat so the marks are all facing you. Flip the blocks
over and draw a mark on the top side of the block so you can tell which way is
down when the block is facing up.
3. With your right hand, firmly grip the top of a block with forceps. (If you squeeze
too tightly, the block will pop out, so keep it a little loose.) With your left hand,
squeeze a dollop of OCT onto the chuck. Swiftly move the block onto the dollop
on the chuck and press down firmly so the dollop squeezes out on both sides.
Hold the block in place so the top is level; you have minimal time to adjust angles
so immediately level it out. The dollop will freeze pretty quickly and hold your
block in place.
4. Wait 20-30 minutes so the block is firmly frozen to the chuck. Label slides (one
slide per head) and leave them on the top of machine at room temperature.
5. Place the chuck into the holding stage. Position so the mark on the block is
facing down.
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6. Trim the specimen block into the trapezoid shape around the sample using a
razor blade.
7. Move the blade to the edge of the block using the in and out arrows ↑↓ on the
keypad. Also using the keypad, ensure that the section size is set to 12 µm.
8. Rotate the handle on the right side of the machine away from you (a clockwise
turn). This will move the blade the set sectioning size.
9. When a short ribbon strip lines up on the plate, press the room temperature slide
to the sample ribbon and it will stick. I put the ribbon perpendicular to the length
of the slide. Do not cut your ribbon long enough to reach from one edge to the
other, you want a clear border on all sides of the samples.
10. Check the sections in the ribbon in the microscope. Make sure the samples are
flat and don’t have bubbles on the tissue.
a. I have a hard time with samples rolling up on themselves. If you briefly
heat the front edge of the sample block with your fingernail, it will usually
cut smoother.
b. If your samples roll up or go wrong in any way, stop the ribbon you are
cutting, collect it, and start a new ribbon.
11. Store the slides in the machine until you are finished cutting all samples. You can
also store the slides in a slide box in the -80C freezer overnight.

Immunostaining cryosections
1. Warm up slides on slide warmer, set to 37C, for 30 min.
2. Make fresh 0.5% paraformaldehyde solution (PFA). Break a 20% stock
paraformaldehyde ampule in the hood. Add 1000 µl to 40 ml PBS.
3. Prepare the slide-holding humidity chamber. These are the shallow dishes
covered in aluminum foil with serological pipettes taped in the bottom. Rip paper
towels in half longways and place them in the bottom of the dish. Wet the paper
towels in the sink and pour off any excess water. You will place your slides on
the raised pipette platform.
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a. I find that 18 slides are about as much as I can handle (3 genotypes x 6
samples each). For this, I need one and a half humidity chambers, since
I can fit 6 slides in a pipette column.
4. Draw a circle around useful sections with the green pap pen. Be sure the circle
you draw will fit within your coverslip (I use the square ones). I find that three
ribbons gives about the right width.
5. Put the slides in the prepared humidity chamber.
6. Use a dropper to cover the circle area with 0.5% PFA. Let the sections fix for 30
min at RT.
7. Dump the PFA back into the Falcon tube and dispose of it properly.
8. Use a dropper to cover the circle area with PBS. After a 5 min incubation time,
dump the PBS into a waste container and dropper fresh PBS onto the circle. Do
a total of 3 washes, 5 min each.
9. Prepare PBSG blocking solution. 100X stock solutions of each component have
been made by Xiuyin.
PBSG solution:
0.2% BSA
0.01% saponin
1% goat serum
PBS

Stock
100X
100X
100X

For 40 ml
400 µl
400 µl
400 µl
40 ml

10. Cover the circle area with PBSG and block for 1 hr at RT. Store the PBSG at 4C
overnight.
11. Make 1º Ab solution in PBSG.
a. You can put in two antibodies at once, as long as the antibodies are from
different animals (e.g., one mouse, one rabbit).
b. The concentration is usually 1:100. For 18 slides, I put 13.5 µl primary
antibody in 1350 µl PBSG.
c. You usually have to preadsorb rabbit antibodies (see next section). In
this case, you are starting with a 1:25 dilution already, so I put 337.5 µl
1:25 preadsorbed antibody in 1350 µl PBSG.
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12. Spin the 1º Ab solution at 12,000 rpm for 5 min to settle any debris. This will
make the staining much cleaner.
13. Pick up the first slide and dump the PBSG block off the slides and then use a
kimwipe in the corner of the circle area to dry excess liquid off the sample. Add
70 µl of the 1º Ab to the circle and tilt to make sure the whole area is covered.
Place the slide back into the chamber and proceed to the next slide.
14. Incubate the antibody overnight in the cold room. Label the tray so no one
bumps it or moves it!
15. Do 3 PBSG washes (from PBSG stored in fridge overnight), 1 min each.
16. Make 2º Ab solution in PBSG.
a. If you used two primary antibodies from different animals, you must
choose secondary antibodies with different AlexaFluor attachment colors
(e.g., goat-anti-mouse-594 and goat-anti-rabbit-488).
b. Again, the concentration is usually 1:100, so I put 13.5 µl secondary
antibody in 1350 µl PBSG.
17. Spin the 2º Ab solution at 12,000 rpm for 5 min.
18. Dump off the PBSG rinse and use a kimwipe to dry the area, as before. Add 70
µl of the 2º Ab to the circle and tilt to make sure the whole area is covered.
19. Incubate the antibody for 1 hr at RT.
20. Do 3 PBS washes, 5 min each.
21. Make the Hoechst stain by diluting the stock solution 1:1000 in PBS (10 µl in 10
ml). The Hoechst 33342 stock (Cat# H3570) is in the fridge next to Xiuyin.
22. After the final PBS wash, dump off the solution and dry with a kimwipe. Dropper
the Hoechst onto the circle area and make sure the entire area is covered.
Incubate for 10 min.
23. Do 3 PBS washes, 5 min each.
24. Seal with a square coverslip. Place the coverslip on a small stack of paper
towels. Put a generous drop of Vecatashield (Cat # H-1000) onto the coverslip.
Lower the slide face-down onto the drop so the Vectashield spreads out to cover
all the specimen area. Use clear nail polish around the edges of the coverslip to
seal the entire area.
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25. Store the slides in a slidebox at 4C to preserve the signal.
Preadsorbing an antibody
1. Collect larvae from a vial or bottle. I use 5905 flies – you must use a line that
doesn’t have whatever your antibody will be detecting! I collect 20 wandering
larvae that seem large but not yet hardened. (I use 20 larvae to preadsorb 20 µl
of antibody, so you can adjust as needed.) I put the larvae in an eppendorf tube
as I collect.
2. I usually do a quick wash in PBS to remove residual fly food on the larvae. I use
a transfer pipette to add and remove liquid a few times and then spin the tube at
15,000 rpm for 3 min to settle the larvae. Use a pipette to remove all of the
liquid.
3. Make a 4% PFA solution by adding 2 ml of the 20% ampule stock to 8 ml PBS.
Use a transfer pipette to add about 1 ml to the eppendorf tube.
4. To fix the larvae, you need to physically tear apart the bodies. The best way to
do this is to use the transfer pipette to move the PFA and larvae into a round
bottom glass dish. Use two pairs of forceps to hold each larva with one forcep
and tear it apart with the other. It is hard for the forceps to reach into the bottom
of an eppendorf tube, so it is definitely worth the effort to move it to the glass
dish. After all larvae are torn apart, move the liquid and debris back into the
eppendorf tube.
5. Place the eppendorf tube on the nutator at room temperature and allow the
larvae to fix for 1 hr.
6. Spin the tube at 15,000 rpm for 3 min. Remove the liquid from the settled debris.
7. Wash 3 times in PBS. Add about 1 ml of PBS and nutate for 5 min, and then
spin again at 15,000 rpm for 3 min to remove the liquid.
8. Calculate how much antibody you want to preadsorb such that the final antibody
concentration is diluted 1:25. For 20 larvae, I add 20 µl antibody to 480 µl PBS.
Add this to the larvae debris and nutate at 4C overnight.
9. Spin the tube at 15,000 rpm for 3 min. Collect the supernatant containing the
antibody and save it in a fresh tube.
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Table III-2 Antibodies used for immunohistochemistry

Name

1º/2º

Catalog Number

Dilution

Incubation

1:100

1h at RT

1:100

1h at RT

1:100

1h at RT

1:100

1h at RT

1:100

1h at RT

1:100

1h at RT

1:100

1h at RT

1:100

1h at RT

1:100

1h at RT

1:100

1h at RT

1:100

1h at RT

1:100

1h at RT

1:1000

10m at RT

Main Antibodies:
α-HA 5B1D10

Mouse

α-myc 9E10

Mouse

α-Hsp104
α-Hsp70
α-Hsc70/Hsp70
AlexaFluor 594
Goat α-Mouse IgG
AlexaFluor 488
Goat α-Rabbit IgG
Confirmation Antibodies:
α-HA Y11
α-myc A14
α-human-Hsp70 W27
AlexaFluor 594
Goat α-Rabbit IgG
AlexaFluor 488
Goat α-Mouse IgG
Also used:
Hoechst dye

Rabbit
(preadsorbed)
Rabbit
(preadsorbed)
Mouse
2º
2º
Rabbit
(preadsorbed)
Rabbit
(preadsorbed)
Mouse
2º
2º

n/a

Invitrogen
32-6700
Santa Cruz
sc-40
Enzo Life Sciences
ADI-SPA-1040
Enzo Life Sciences
ADI-SPA-812
Enzo Life Sciences
ADI-SPA-822
Life Technologies
A-11032
Life Technologies
A-11008
Santa Cruz
sc-805
Santa Cruz
sc-789
Santa Cruz
sc-24
Life Technologies
A-11037
Life Technologies
A-11029
Molecular Probes
33342
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Pseudopupil
1. Anaesthetize flies on CO2 pad. Hold the fly body with forceps in your left hand
and use a razor blade to sever the neck.
2. Squeeze a line of Vaseline onto a microscope slide.
3. Hold the proboscis of the fly head to transfer the head onto the Vaseline line.
Lower the head at an angle so one eye is resting on the glass of the slide and the
other eye is propped on the line of Vaseline. This will allow the light to shine
directly through the raised eye. (Do not get Vaseline on the eye! It will blur the
image.)
4. I usually prepare 5 heads at a time on one line of Vaseline. Image the
pseudopupil within 10-15 min of preparation.

5. Go to the microscope. Place a drop of immersion oil onto each head.
6. Adjust the microscope settings:
a. 20X objective, 1.6X optical zoom
b. No fluorescent filter (C1)
c. Max voltage on lamp = 12V
d. Filters OFF, including GF switch
7. Looking through the eyepiece at a blank part of the slide, adjust the settings:
a. Focus the condenser so you get a small octagon of light
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b. Close aperture iris as much as possible
8. Using the microscope light bulb (you do not need the fluorescence light source!),
center a head within the field of view and adjust the plane so the pseudopupil is
in focus. It will look very small! It takes a long time to adjust to seeing and
distinguishing the small spots.
9. Count the number of photoreceptor cells per ommatidial cluster. This takes
practice, so start with control genotypes that should have 7 photoreceptors per
ommatidia to get used to what you’re looking for.
a. Photoreceptor cells undergoing degeneration can be very difficult to
quantify. The lighted spot may be missing altogether, in which case it is
easy to know it is missing. But most often, the light becomes very blurry
and is not exactly a discrete spot but is not exactly missing either. You
need to make a judgment call about how blurry the edges need to be to
quantify it as an intact cell. You must be consistent! I find it helpful to do
as many genotypes as you can at once so you are more consistent in
your designations.
b. If you are worried about bias in designating blurry photoreceptor spots
within an ommatidium, blind yourself to the genotype. Write the genotype
on the bottom of each vial when you put the flies in. Scramble the vials
around and then randomly number them. Collect data with reference to
the random number. After collecting the data, turn each vial over to see
which number corresponds to which genotype.
10. Count 10 ommatidia per eye, and examine 10 eyes per genotype. This will give
sufficient data points for the spreadsheet analysis.
11. Try to take pictures. This is exceedingly difficult as it is hard to get multiple
ommatidia into one plane of focus. You need 4-7 ommatidia in view, and the
ideal set up is as a daisy pattern (one in the middle with the others surrounding
that one in a circle; see below).
12. Camera settings must be adjusted:
a. Levels: 50 – 1.6 – 255
b. 36-shot resolution (may have to use 16-shot if the image looks wavy)
13. Crop the image and clean it up in Photoshop.
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Original:

Adjusted levels:

14. Analyze the data in the Excel spreadsheet template pseudopupil.xls
a. The spreadsheet was created by a previous lab member. It can be found
on the Bonini Lab Server, in the BONINI LAB – PROTOCOLS folder.
b. Each row indicates one eye. Enter the number of ommatidia that
displayed 7 photoreceptor cells, 6, etc. You should have 10 ommatidial
counts for each row, so the total will read 10 after you have entered your
data.
c. The spreadsheet will automatically calculate the mean and standard
deviation or standard error. Use Prism for statistics.
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SDD-AGE and Western Blot Aggregate Analysis
Preparation before starting
1. Collect heads and store in an eppendorf tube in the -80C freezer until ready to
process all genotypes. I use 5 heads per genotype.
2. Prepare all the solutions before beginning the protocol.
3. Make Lysis Buffer. I make a 100 ml stock containing Tris, NaCl, and water. I
store this indefinitely, and I make 10 ml batches fresh each time I use it, to which
I add the β-ME and a Roche Complete Mini EDTA-free Protease Inhibitor
Cocktail Tablet (Cat # 04693159001).
Stock
For 100 ml
100 mM Tris
1 M Tris, pH 7.5
10 ml
50 mM NaCl
5M
1 ml
10 mM β-ME (fresh)
14.3 M
add 7 µl to 10 ml
protease inhibitors (fresh)
tablet
add 1 tablet to 10 ml
water
89 ml
4. Make 4X Sample Buffer. It is difficult to get these components into solution, so
add ingredients in the order listed to the right.
2X TAE
20% glycerol
8% SDS
bromophenol blue
water

Stock
50X
100%
powder
powder

For 25 ml
1 ml
5 ml
2g
0.0125 g
17 ml

order:
3
4
2
5
1

a. Make sure each component is fully mixed in before adding the next. You
will need to nutate thoroughly after adding SDS. Additionally, once
complete, I leave it on the nutator overnight before using.
b. The SDS will fall out of solution if left for a long time. If there is any
precipitate, make fresh Sample Buffer. You can store the Sample Buffer
on the nutator instead of on the shelf to extend use.
5. Make TAE Buffers.
a. 1X TAE. [For making the agarose gel.]
1X TAE

Stock
50X
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For 1 L
20 ml

water

980 ml

b. 1X TAE with 10% SDS. [For making the agarose gel.]
1X TAE
10% SDS

Stock
(made above)
powder

For 50 ml
45 ml
5g

c. 1X TAE with 0.1% SDS. [For running the agarose gel.]
1X TAE
0.1% SDS
water

Stock
50X
powder

For 1 L
20 ml
1g
980 ml

Preparation of lysate
1. Collect some liquid nitrogen in a dewar.
2. Add 25 µl of Lysis Buffer (prepared fresh) for 5 heads. From this, I usually end
up collecting 20-21 µl of lysate at the end.
3. Grind the heads with a blue pestle. It is easier to do if you use the special
eppendorf tubes that fit the blue pestles. Thoroughly crush the heads, and then
take care to leave as much of the Lysis Buffer in the tube when you remove the
pestle. I usually rotate the pestle at the dry top part of the tube to remove all
residual liquid.
a. I grind the heads in all tubes before moving on to the next step.
4. Use long forceps to lower each eppendorf tube into the liquid nitrogen. Wait a
few seconds for the liquid to completely freeze.
5. Let the tubes thaw on ice.
a. I use the thawing time to label eppendorf tubes for the final lysate you
collect at the end.
6. Grind again with a new blue pestle. (This should release contents from the cells
that were broken open during the freezing process.) Again, take care to leave as
much liquid behind as possible.
7. Spin the lysates for 3 min at 15,000 rpm.
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8. Collect 20 µl supernatant into a new tube labeled lysate.
a. You can prepare a lot of lysates at once and store them in the -80C
freezer until ready for use.
b. If continuing with SDD-AGE/Western immediately, go ahead and divide
the lysate into two tubes: 10 µl for SDD-AGE and 5 µl for Western blot.
(Note: This is not the exact volume I used for all my experiments, but it is
what I would recommend going forward.)`

SDD-AGE and Western blot
1. This protocol is adapted from Halfmann and Lindquist, J Vis Exp, 2008.
http://www.ncbi.nlm.nih.gov/pubmed/19066511
2. Make 1.5% agarose gel containing 0.1% SDS.
Stock
powder
stock

1.5% agarose
1X TAE

For 70 ml
1.05 g
70 ml

Swirl. Microwave for 1 min, 30 sec. Swirl. To this, add:
0.1% SDS

1X TAE with 10% SDS (100X)

700 µl

3. Place in a mold and use the 8 well insert to clear the bubbles away. Insert one or
two 15 well inserts (I like to do two rows in one gel to speed up processing). Let
the agarose cool and harden on the benchtop.
4. Separate lysates: 5 µl aliquot for Western blot; 10 µl aliquot for SDD-AGE.
5. Add 3.33 µl of 4X homemade Sample Buffer to 10 µl SDD-AGE sample. Pipette
up and down to mix.
6. Remove agarose gel from the mold and insert it into the running apparatus.
Submerge the gel in 1X TAE with 0.1% SDS. Make sure the gel is positioned so
that the protein will run toward the red + pole.
7. Load SDD-AGE samples into the wells. Put 1X Sample Buffer (diluted in Lysis
Buffer) into the empty wells so it will run evenly. I also load the SeeBlue Plus2
protein ladder, but one with larger molecular weight markers might be more
appropriate.
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8. Run SDD-AGE samples in the agarose gel at 18 V for 4 hours. The published
protocol recommends 3 V per cm of agarose gel width, and the mini-gel mold is 6
cm across.
9. Prepare NuPage LDS Sample Buffer by adding 10% β-ME. Add 1.667 µl of 4X
NuPage Sample Buffer with β-ME to 5 µl Western sample.
10. Boil samples for 3 min, spin at 15,000 rpm for 3 min.
11. Load Western samples into the wells of a pre-cast 4-12% Bis-Tris gel. Run the
gel as described in the Western blot section.
12. Transfer protein from Bis-Tris gel onto a nitrocellulose membrane using semi-dry
transfer at 20 V for 20 min. You should be able to complete the Western blot
procedures before the SDD-AGE gel finishes the 4 h run.
13. Transfer protein from SDD-AGE agarose gel onto a nitrocellulose membrane
using downward capillary transfer overnight.
a. Make 1X TBS (Cat # T6664-10PAK).
b. Cut 5 square 3 MM CHR Whatman papers, 20 x 20 cm (Cat # 3030-861),
into fourths. Leave these squares dry.
c. Cut 1 square 3 MM CHR Whatman paper, 20 x 20 cm, into fourths. Prewet these squares in 1X TBS.
d. Cut 1 long 3 MM CHR Whatman paper, 18 x 34 cm (Cat # 3030-221), in
half long-ways. Pre-wet this “wick” in 1X TBS.
e. Stack the following components in a glass dish:
i.
ii.
iii.
iv.
v.
vi.

4 paper towels, folded in half
20 square sheets of dry Whatman paper
2 square sheets of wet Whatman paper
Nitrocellulose membrane
Agarose gel
Place two strips of parafilm on either side of the agarose gel to
prevent the TBS from flowing around instead of through the gel.
vii. 2 square sheets of wet Whatman paper
viii. 1 long “wick” sheet of wet Whatman paper
ix. Carefully place the gel casting tray directly on top of the agarose
gel.
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x. Carefully center a 1 L bottle full of liquid on top of the gel casting
tray to apply pressure to the gel. Check back to make sure things
are balanced evenly before leaving it overnight.
xi. Pour TBS into pipette tip boxes on either side of the stack and
lower the ends of the “wick” paper into the reservoirs.
f.

See schematic below:

14. After you have all the protein safely transferred onto nitrocellulose membranes
(SDD-AGE + capillary transfer; Western + semi-dry transfer), proceed with
Ponceau S staining and antibody probing, as described in the Western blot
section.
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DNA Techniques
PCR to genotype recombinant flies
Isolation of genomic DNA
1. Make Squash Buffer:
10 mM Tris-HCl
1 mM EDTA
25 mM NaCl
water

Stock
1 M, pH 8.0
0.5 M
5M

For 50 ml
500 µl
100 µl
250 µl
49 ml

Stock
(above)
20 mg/ml
5 mg/ml

For 2 ml
2 ml
40 µl
40 µl

On ice, make fresh:
Squash Buffer
20 µl/ml Proteinase K
0.1 mg/ml RNase

2. Anaesthetize flies on CO2 pad. Collect 10 flies of one genotype in an eppendorf
tube.
3. Add 300 µl Squash Buffer + PK + RNase. Grind flies with a blue pestle.
4. Transfer fly lysate to a pcr strip of small tubes. Run MCSQUASH program:
MCSQUASH
(Lid = 105.0ºC)
1
37.0ºC 40:00
2
95.0ºC 05:00
3
4.0ºC
hold

(transfer to ice when finished)

5. Transfer fly lysate back to an eppendorf tube. Add 300 µl phenol-chloroform pH
8.0-8.5 (Sigma P3803-100ML) to the tube. When drawing the 300 µl from the
stock bottle, be sure to put your tip at the bottom of the bottle to ensure you don’t
draw the top storage layer of Tris.
6. Spin the eppendorf tubes in a microcentrifuge at 8,000 rpm for 10 min. The
phase separation will be evident, with a thick liquid at the bottom, the fly bodies in
the middle, and a clear liquid supernatant at the top.
7. Collect 200 µl of the supernatant into a new tube. I do not risk getting more than
that volume for fear of accidentally collecting some liquid from the other layer.
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8. Add 1/10 volume (20 µl) of NaOAc 3 M, pH 5.2 to the tube.
9. Add 2X volume (440 µl) of 100% EtOh to the tube.
10. Mix with pipette or by flicking. Spin the tubes at 12,000 rpm for 10 min.
11. Carefully pipette away the supernatant. Wash the pellet with 1 ml 70% EtOH
(made with MilliQ water to maintain purity!). Spin the tubes at 12,000 rpm for 2
min.
12. Carefully pipette away the supernatant. Use a 2 µl pipette to fully remove all
residual liquid. Be thorough in this step. Once all liquid has been removed, let
the pellet air dry for 5 min.
13. Resuspend the pellet in 20 µl TE Buffer, pH 8.0-8.5.
Stock
1 M, pH 8.0
0.5 M

10 mM Tris-HCl
1 mM EDTA
water

For 50 ml
500 µl
100 µl
49 ml

14. Store in -20C freezer.

PCR amplification of genomic DNA
1. Use the Taq 2X Master Mix kit.
a. Know the features of your transgenic insert. The Hsp104 gene has 2727
bases (< 3 kb) with GC content of 61.97.
b. Use the Standard Buffer for 50-65% GC content.
2. Determine which primers to use. (See my “Protocols” binder for information
about where these primers align with the DNA.)
a. To amplify a UAS-transgene insert, use:
pUAST-5’b
pUAST-3’b

5’- AGCAACCAAGTAAATCAACTGC -3’
5’- TTCATCAGTTCCATAGGTTGG -3’

b. To amplify a Gal4 insert, use:
NB 1224

5’- GTCTTCTATCGAACAAGCATGCGA -3’
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NB 1225

5’- TGACCTTTGTTACTACTCTCTTCC -3’

3. Set up mix in a pcr strip tube:
Desired concentrations:
200 nM primer
< 1,000 ng DNA (1 µl)
1X Master Mix
MilliQ water to 25 µl

Volume added:
1 µl 1/10 primer mix
1 µl genomic DNA
12.5 µl 2X Master Mix
10.5 µl MilliQ water

a. Be sure to include positive and negative controls to know that your PCR
reaction is working properly.
4. Run the PCR amplification reaction in the thermocycler. Check your polymerase
enzyme for optimal running temperature and the size of your gene will inform the
time required at each step.
a. For a UAS-transgene insert:
MCPCRUAS
(Lid = 105.0ºC)
1
94.0ºC 02:00
2
94.0ºC 00:30
3
55.0ºC 00:30
4
68.0ºC 01:30
5
Repeat 2–4 x 30
6
68.0ºC 05:00
7
10.0ºC hold
b. For the Gal4 insert:
MCPCRGAL
(Lid = 105.0ºC)
1
94.0ºC 02:00
2
94.0ºC 00:15
3
56.0ºC 00:20
4
72.0ºC 00:30
5
Repeat 2–4 x 29
6
72.0ºC 05:00
7
10.0ºC hold
5. Collect the PCR reaction products and check the size of the amplified insert by
agarose gel. You can store the reaction products at -20C.
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Running DNA on an agarose gel
1. Run these things on a gel. Hsp104 product should run at 2.8 kbp and Gal4
product should be ~420 bp.
2. Make a 1.5% agarose gel in 1X TAE buffer.
Stock
powder
stock

1.5% agarose
1X TAE

For 70 ml
1g
70 ml

a. Microwave 1 min. Swirl. Microwave another 1 min.
b. Add 7 µl of 10,000X SYBR safe DNA stain to the flask.
c. Pour the liquid into the plastic mold. Insert a well-divider comb.
d. Let the gel polymerize on the benchtop.
3. Place the gel mold into the running apparatus. The DNA runs toward the red +
pole, so make sure the wells are toward the black – end (with plenty of space for
the DNA to resolve on its way to the + end).

4. Submerge the gel in the running apparatus in 1X TAE.
5. Prepare samples by adding 5X Blue Juice to samples:
8 µl PCR product
2 µl 5X Blue Juice
Note: I got Blue Juice from Alondra and don’t know what is
actually in it.
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6. Load 1 µl of 1 kb + Ladder into one of the lanes. Load 5 µl of the PCR product
sample into each other lane.
7. Run the gel at 100 V for 15+ min.
8. View DNA bands in the UV imager in the fly stock room. Alter the exposure time
with the +/- buttons on the screen and zoom by hand on top of the machine.
a. Print the photo on the attached paper roll.
b. Save the image to the Untitled Folder on the Desktop. You can retrieve
the images with a USB flash drive.

Purifying PCR products
1. Use the QIAquick PCR purification kit.
2. Add 5 volumes of Buffer PB to 1 volume of PCR sample and mix.
50 µl PCR sample
250 µl Buffer PB
3. Load sample onto a QIAquick column. Centrifuge at 13,000 rpm for 1 min.
Discard flow-through.
4. Wash the column with 750 µl Buffer PE. Centrifuge at 13,000 rpm for 1 min.
Discard flow-through. Centrifuge column for an additional 1 min.
5. Place column in a clean eppendorf tube. Add 30 µl Buffer EB to the center of the
membrane. Let stand for 1 min. Centrifuge at 13,000 rpm for 1 min.
6. Check concentration and purity on the NanoDrop.
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Site-directed mutagenesis
1. Select plasmid and design primers to introduce the desired mutation.
2. Use the QuikChange Lightning Kit to introduce mutations. See kit for details on
reaction preparation and cycle guidelines.
3. Set up reaction in a pcr strip tube:
5 µl
10X Reaction Buffer
1 µl
DNA template (1/10) 10-100 ng
1 µl
primer 1 125 ng
1 µl
primer 2 125 ng
1 µl
dNTP mix
1.5 µl
QuikSolution reagent
39.5 µl MilliQ water
Pipette up and down to mix.
+ 1 µl

QCL enzyme

Pipette up and down to mix.
4. Run the reaction in the thermocycler. Use MCQUIKCH program. The elongation
step (#4) requires 30 sec/kb of DNA. The Hsp104 plasmid is 12 kb, so I used 6
min.
MCQUIKCH
(Lid = 105.0ºC)
1
95.0ºC 02:00
2
95.0ºC 00:20
3
60.0ºC 00:10
4
68.0ºC 06:00
5
Repeat 2–4 x 17
6
68.0ºC 05:00
7
4.0ºC
hold
5. Digest the parental plasmid by adding 2 µl Dpn1 enzyme. Incubate the reaction
at 37C for 5 min.
6. Check concentration and purity on the NanoDrop.
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Mini-Prep and Midi-Prep
Transformation into bacteria
1. Select plasmid. Transform the plasmid into XL10-Gold cells (or another
appropriate cell type). Thaw the cells on ice.
2. Add 2 µl β-ME provided with the cells to a 45 µl aliquot of cells. Swirl and
incubate on ice for 10 min.
3. Add 2 µl plasmid to the cells. Swirl and incubate on ice for 30 min.
4. Heat the tubes in a 42C water bath for 30 sec. Incubate on ice for 2 min.
5. Add 500 µl warm LB. Shake cells in the thermocycler at 37C for 1 hr.
6. Plate the media onto an agar plate containing ampicillin (Cell Center). Spread
the liquid with an L-shaped spreader.
7. Invert the plate and incubate at 37C overnight.
a. You may store the plates in the refrigerator for up to a week. Wrap the
edges with parafilm and store inverted.
Mini-Prep
1. Select a single colony from the overnight plate by touching the plate with a nonfiltered pipette tip. Drop the tip into a 15 ml Falcon tube containing 5 ml of LB +
100 µg/ml ampicillin.
a. Shake the tubes at 37C overnight.
2. Spin the Falcon tubes in the large centrifuge at 3500 rpm for 5 min. Pour off the
supernatant. A small residual volume will remain; resuspend the pellet in this (~
1 ml). Transfer the resuspended cells to an eppendorf tube.
3. Spin the eppendorf tubes in the microcentrifuge at 8,000 rpm for 3 min.
4. Follow kit protocol:
a. Resuspend the pellet in 250 µl Buffer P1 (in the fridge).
b. Add 250 µl Buffer P2 and invert tube to mix.
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c. Add 350 µl Buffer N3 and invert tube to mix.
d. Spin the tube at 13,000 rpm for 10 min.
e. Load supernatant into the QIAprep spin column.
f.

Spin at 13,000 rpm for 1 min. Discard the flow-through.

g. Apply 500 µl Buffer PB to the column.
h. Spin at 13,000 rpm for 1 min. Discard the flow-through.
i.

Apply 750 µl Buffer PE to the column.

j.

Spin at 13,000 rpm for 1 min. Discard the flow-through. Spin again at
13,000 rpm for 1 min to dry the column.

k. Put the column into a clean eppendorf tube. Add 50 µl Buffer EB to the
center of the membrane and let it stand for 1 min. Spin at 13,000 rpm for
1 min to collect the DNA.
5. Check concentration and purity on the NanoDrop.
Midi-Prep
1. Select a single colony from the overnight plate by touching the plate with a nonfiltered pipette tip. Drop the tip into a 15 ml Falcon tube containing 5 ml of LB +
100 µg/ml ampicillin.
a. Shake the tubes at 37C for 8 h.
2. Dilute the culture 1/500 into LB + 100 µg/ml ampicillin. Add 50 µl culture to 25 ml
LB in a 50 ml Falcon tube.
a. Shake the tubes at 37C overnight.
3. Spin the Falcon tubes in the large centrifuge at 4,000 rpm for 20 min at 4C.
a. You can freeze the cell pellet at -20C at this step, but I don’t.
4. Follow the kit protocol:
a. Resuspend the pellet in 4 ml Buffer P1 (fridge).
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b. Add 4 ml Buffer P2. Invert to mix. Let sit for 5 min.
c. Add 4 ml chilled Buffer P3. Invert to mix. Incubate on ice for 15 min.
d. Centrifuge in a round-bottom tube at 13,000 rpm for 30 min at 4C in the
Beckman Coulter Avanti Centrifuge J-25I (rotor JA-25.50) near the
Pohlschröder lab. Collect the supernatant.
e. Centrifuge the supernatant in a fresh round-bottom tube at 13,000 rpm for
15 min at 4C.
f.

Equilibrate a QIAGEN-tip 100. Apply 4 ml Buffer QBT and allow to drip
through by gravity flow.

g. Apply the supernatant from the last spin to the QIAGEN-tip.
h. Wash the QIAGEN-tip with 10 ml Buffer QC. Repeat. (2 x 10 ml)
i.

Elute DNA with 5 ml Buffer QF.

j.

Precipitate DNA by adding 3.5 ml isopropanol. Mix well. Spin at 4,000
rpm for 75 min at 4C in the large centrifuge. Carefully remove and
discard the supernatant.

k. Wash the DNA pellet with 2 ml 70% EtOH. Spin at 4,000 rpm for 75 min
at 4C. Carefully remove and discard the supernatant.
l.

Let the pellet air dry for 10 min. Redissolve the DNA in 200 µl TE Buffer,
pH 8.0.

5. Check concentration and purity on the NanoDrop.
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Restriction Digest and Ligation
Restriction enzyme digestion of DNA plasmid
1. Select plasmid. Determine which restriction enzymes are needed. Look up
which buffer is ideal for those two enzymes.
a. Mine are XhoI and XbaI. For this, I could use either NEBuffer 4 or
Promega Buffer D. I located Promega Buffer D, so I used that one.
2. Set up reaction in an eppendorf tube, aiming for 10 µl.
1 µl
6 µl
2 µl
0.5 µl
0.5 µl
0.1 µl

10X Buffer – Promega Buffer D
MilliQ water
DNA plasmid (~1,000 ng)
enzyme XhoI
enzyme XbaI
100X BSA (supplement 100 µg/ml)

3. Incubate for 1 h at 37C.
4. Prepare the 1.5% agarose gel in 1X TAE Buffer. (see previous section)
5. Add 5X Blue Juice to each sample.
10 µl reaction product
2.5 µl 5X Blue Juice
6. Load samples and 1 µl ladder. Run at 100 V for 15+ min.
7. You should see two distinct bands representing the plasmid empty vector and the
excised gene insert.
a. If you start with 1,000 ng of pUAST-Hsp104 plasmid, you should be left
with ~ 800 ng backbone and ~200 ng gene insert.
DNA gel extraction
1. Wearing special UV goggles, view the gel containing your excited gene insert on
a UV light box. Use a sharp razor blade to carefully cut a rectangle out of the gel
containing your desired fragment.
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2. Weigh the gel slice in an eppendorf tube. Subtract the mass of an empty tube to
determine how much the gel slice weighs.
3. Use the QIAquick Gel Extraction Kit.
a. Add 3 volumes Buffer QG to 1 volume gel (100 mg ≈ 100 µl).
b. Incubate at 50C for 10 min, or until gel has dissolved completely. Vortex
every 2-3 min to help dissolve the gel.
c. Add 1 gel volume isopropanol. Mix.
d. Apply sample to QIAquick spin column. Spin at 13,000 rpm for 1 min.
Discard the flow-through.
e. To wash, add 750 µl Buffer PE to the column. Spin at 13,000 rpm for 1
min. Discard the flow-through. Spin again at 13,000 rpm for another 1
min.
f.

Place column into clean eppendorf tube. Add 30 µl Buffer EB to the
center of the membrane. Let stand for 1 min. Spin at 13,000 rpm for 1
min.

4. Check 1 µl of product on a DNA agarose gel.
DNA plasmid ligation
1. Use the NEB Quick Ligation Kit.
2. Collect the linearized DNA fragments you want to ligate. Set up the reaction:
a. Combine 50 ng of plasmid vector with 3-fold molar excess of gene insert.
b. Adjust volume to 10 µl with MilliQ water.
c. Add 10 µl 2X Quick Ligation Buffer. Mix.
d. Add 1 µl Quick T4 DNA Ligase. Mix.
e. Spin briefly to bring all liquid to the bottom.
f.

Incubate at room temperature for 5 min.

g. Chill on ice.
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3. Transform the ligated plasmid or store the reaction product at -20C.
4. Mini-prep several (~ 5) colonies that result from this transformation.
5. Run the DNA from these mini-preps on an agarose gel to ensure that each is the
correct size and is correctly ligated. Also check concentration and purity of each
on the NanoDrop.
6. Select a plasmid from this and mini/midi-prep it. Send this for sequence
confirmation.
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DNA Sequencing
1. Select plasmid and determine concentration.
2. Design sequencing primer oligos.
a. To sequence a UAS-transgene insert, use:
pUAST-5’a
pUAST-3’a

5’- GCAACTACTGAAATCTGCCAAG -3’
5’- TGTCCAATTATGTCACACCACA -3’

3. Fill out submission form for NAPCore at CHOP.
4. Prepare samples. 9 µl is required, but I always prepare 18 µl so they can re-run
the reaction if it doesn’t resolve well.
4 µl
6 µl
8 µl

Plasmid to be sequenced (1 µg; 4 x 250 ng/µl)
Primer oligo (3.2 pmol)
MilliQ water

5. Drop off samples in Room 906B in the Abramson Building at CHOP.
6. Use MacVector (program) or EMBOSS Needle (website)
http://www.ebi.ac.uk/Tools/psa/emboss_needle/ to align the sequences with the
plasmid.
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